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Abstract
The ubiquitin proteolysis pathway utilizes three enzymes, an E1 activating
enzyme, an E2 conjugating enzyme and an E3 ligating enzyme, to respectively activate,
transfer and ligate ubiquitin (Ub) onto a substrate protein. The creation of a K48-linked
poly-Ub chain on a substrate will target this protein to be degraded by the 26S
proteosome. E2 conjugating enzymes are central proteins in this pathway and interact
with the E1 and E3 enzymes to perform Ub transfer. The mechanism by which Ub
molecules are interconnected remains poorly understood. The E2 enzymes HIP2 and
Ubc1 have been shown to create poly-Ub chains in the absence of E3 enzymes and
substrates.

In this thesis, HIP2 and Ubc1 were investigated through physical and

structural methods to clarify their mechanism of poly-Ub chain assembly.
The study of HIP2 and Ubc1 was aided by the formation and purification of stable
HIP2-Ub and Ubc1-Ub disulphide linked complexes that closely resemble the HIP2~Ub
and Ubc1~Ub thiolester intermediates.

The physical techniques of sedimentation

equilibrium and SAXS determined that HIP2 and Ubc1 as well as their disulphide
complexes are predominantly monomeric. Activity assays were also performed on these
enzymes indicating that the E2~Ub thiolester is the sole species required to create polyUb chains.

Additionally, these assays determined that both free Ub and E2-Ub

complexes could act as Ub acceptors for poly-ubiquitin chain extension.

NMR

experiments were also performed through the use of isotopically labelled HIP2, HIP2-Ub
and HIP2-Ub2 complexes.

NMR chemical shift perturbation experiments identified

significant intramolecular interactions between HIP2 and Ub in both HIP2-Ub and HIP2iii

Ub2 complexes. The intramolecular interaction within HIP2-Ub2 utilizes a C-terminal
Ub-associated (UBA) domain and this domain is not present in other human E2 enzymes.
These intramolecular interactions indicate the HIP2-Ub and HIP2-Ub2 complexes behave
predominantly as Ub donors within poly-Ub chain formation. These results have allowed
the formulation of mechanisms to describe HIP2 and Ubc1 function. The determination
of these mechanisms is especially important for HIP2, as its function has been associated
with the progression of both Huntington’s and Alzheimer’s disease.

Keywords: ubiquitin, HIP2, Ubc1, E2 conjugating enzyme, poly-ubiquitination, UBA
domain, nuclear magnetic resonance, chemical shift perturbation, sedimentation
equilibrium, small angle X-ray scattering, Huntington’s disease, Alzheimer’s disease
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Chapter 1
Introduction

1.1 The Ubiquitination Pathway
The genetic code of all organisms is held within DNA used to synthesize proteins
that are responsible for carrying out virtually all cellular processes. These proteins exist
in a dynamic state where both protein synthesis and protein degradation are regulated to
maintain a state of homeostasis within the cell (1, 2). A major mechanism of protein
degradation has been attributed to the ubiquitin proteolysis pathway, which has been
found to be responsible for the degradation of short-lived, damaged, misfolded or
denatured proteins within the cell (3). The ubiquitin proteolysis pathway was primarily
discovered through the results of a single scientific study in 1978 that eventually lead to
the awarding of the 2004 Nobel prize in chemistry to Hershko, Ciechanover and Rose (4).
Further studies identified and characterized the primary enzymatic components and
function of this pathway (5-11).
The ubiquitination pathway focuses on the small, heat stable, 76-residue protein
named ubiquitin (Ub). Ubiquitin is highly conserved in eukaryotes as only four amino
acids differ among yeast, plant and animal sequences (12, 13).

The ubiquitination

pathway consists of three key enzymes that activate and transfer Ub onto a lysine residue
in a target protein (Fig 1.1). Ubiquitin first associates non-covalently with a ubiquitinactivating enzyme (E1) and the C-terminal glycine (G76) of Ub is adenylated through an
ATP-dependant reaction. This adenylated Ub molecule then reacts with the E1 enzyme’s
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Figure 1.1 A schematic representation of the ubiquitination pathway. The ubiquitination
pathway consists of three key enzymes, the E1 activating enzyme (green), the E2 conjugating
enzyme (blue) and the E3 ligating enzyme (yellow) that activate and transfer Ub (pink) onto a
lysine residue in a substrate (orange) protein. Chemical bonds are shown for the atoms
representing the C-terminus of Ub (COOH), enzyme cysteine side chains (SH), and substrate or
ubiquitin lysine side chains (NH2). Thiolester bonds are formed on E1, E2 and E3 enzymes.
Isopeptide bonds are created on Ub and substrate side chain lysines. Substrates undergo polyubiquitination through the interconnection of Ub lysine side chains with additional Ub molecules.

3
active site cysteine to covalently link Ub to the E1 enzyme through a reactive thiolester
bond (Fig 1.1). The Ub is then transferred from the E1 active site cysteine to a ubiquitinconjugating enzyme (E2) active site cysteine through a transthiolesterification reaction
(Fig 1.1). A ubiquitin-ligating enzyme (E3) then binds simultaneously to a substrate
protein and the E2 to transfer Ub to the ε-amino group of a lysine residue in a substrate.
There are two major types of E3 enzymes, a RING (really interesting new gene) E3 aids
in the transfer of Ub directly from the E2 enzyme onto the substrate, and a HECT
(homologous to E6AP carboxyl terminus) E3 first forms a thiolester with Ub and then
transfers Ub onto the substrate (Fig 1.1). The covalent linkage of Ub is converted from a
reactive thiolester to a more stable isopeptide bond on the target substrate.

1.1.1 Poly-Ub chains
The ubiquitination pathway can result in the attachment of either a single Ub or
multiple Ub molecules to a target protein (Fig 1.1). Multiple Ub molecules may be
attached to substrates on several different lysine residues or by the creation of a polyubiquitin (poly-Ub) chain attached to a single lysine. Poly-Ub chains are formed by the
connection of the C-terminus of one Ub to a lysine residue on another Ub creating an
isopeptide bond resulting in a stable chain of interconnected Ub molecules. Ub contains
seven lysine residues (K6, K11, K27, K29, K33, K48 and K63) and each lysine has been
shown to participate in poly-Ub chain linkages, although K48, K63 and K11-linked polyUb chains are the most prominent (14). The type of poly-Ub chain linkage determines
the biological function of the target substrate (15, 16). Proteins labelled with a single Ub
have been identified to play roles in several cellular functions including protein sorting,
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trafficking and processing, gene expression and silencing, and endocytosis (15-17).
Proteins labelled with K63-linked poly-Ub chains have been linked to other nonproteolytic functions including DNA repair, kinase activation, protein trafficking, protein
translation and endocytosis (15, 16). Proteins labeled with K11-linked poly-Ub chains
have been linked to degradative and non-degradative roles within the cell (18, 19).
Proteins labelled with K48-linked poly-Ub chains are the most prevalent form of
ubiquitination.

K48 poly-Ub chains composed of four or more Ub molecules are

recognized by the 26S proteosome whereby the attached proteins are degraded and
recycled by the cell (20). The poly-Ub chains are themselves are then dismantled back
into single Ub molecules by deubiquitinases for the purpose of recycling Ub for further
ubiquitination events (21, 22). The K48-linked poly-Ub degradation signal is the most
common fate of ubiquitinated proteins within the cell. This ubiquitin proteolysis pathway
will be the primary system studied in this work.

1.1.2 Substrate specificity
In humans, there are two known E1 enzymes, at least 35 E2 enzymes and over
1000 E3 ligases in the ubiquitination pathway (23, 24). Each E1 enzyme can interact
with multiple E2 enzymes, and each E2 enzyme interacts with many different E3
enzymes. Substrate specificity within this pathway is partially determined by specific
E2/E3 combinations but mostly by unique E3/substrate interactions (25).

Substrate

specificity is therefore driven by substrate-specific protein binding domains located in
each E3 ligase. These various E2/E3 combinations allows for the specific regulation of
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certain substrates during different cellular cycles and stresses to maintain cellular protein
homeostasis.

1.1.3 Ubiquitin-like proteins
Following the discovery of the ubiquitin proteolysis pathway, many ubiquitin-like
(Ubl) proteins have been identified. The Ubl proteins all contain a similar structure to
that of Ub and function by an analogous enzyme cascade of E1, E2, and E3 enzymes that
covalently attach Ubl proteins to lysine residues of specific substrate proteins (26, 27).
Ubl conjugations do not primarily result in degradation of substrates, but rather act by
regulating a wide variety of cellular functions (27).

The Ub and Ubl pathways

encompass a massive amount of regulatory control within the cell resulting in a large
amount of research in this area in the recent decade. The two most well studied Ubl
proteins are SUMO (small ubiquitin-like modifier) and NEDD8 (neural precursor cellexpressed developmentally downregulated-8). NEDD8 is the most similar Ubl to Ub
sharing 60% sequence identity (28). NEDD8 is activated by the heterodimeric E1 Uba3Ula1 and is conjugated by the E2 enzyme Ubc12 (29). SUMO is activated by the
heterodimeric E1 Uba2-Aos1 and is conjugated by the E2 enzyme Ubc9 (28). Many
other identified Ubl proteins include FAT10, ISG15, LC3, ATG12, UFM1, and URM1.
These Ubl proteins are just beginning to be understood and have been linked to many
highly divergent functions (27). Cross-talk between the Ub and Ubl pathways can be
performed in many ways including multiple modifications of a single substrate such as
tumor suppressor p53 that can be modified with Ub, NEDD8, SUMO and FAT10 (28).
Cross-talk is also observed for the SUMO modification of the E2 enzyme HIP2 that
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inhibits its function in the ubiquitination pathway (30). Due to the highly analogous
enzyme cascades in the Ub and Ubl pathways, structural studies of NEDD8 and SUMO
related enzymes have provided valuable insight into the function of Ub related enzymes.
The structural knowledge acquired from Ubl pathways has greatly advanced the
proposals for functional mechanisms utilized in the ubiquitin proteolysis pathway.

1.2 Diseases Related to Ubiquitination
Malfunction of the ubiquitination proteolysis pathway can result in many different
diseases. The unwanted accumulation and aggregation of ubiquitinated proteins into
inclusion bodies (large protein aggregates) is the hallmark of many neurodegenerative
diseases. Ubiquitination has also been linked to several forms of cancer as well as
muscle wasting disorders, and inflammatory diseases. Due to the wide variety of enzyme
functions related to the ubiquitination pathway, the list of diseases known to be affected
by ubiquitination is expected to rise significantly as more studies in this field are
performed.

1.2.1 Neurodegenerative Diseases
The most prominent diseases linked to ubiquitination are neurodegenerative
diseases including Alzheimer’s disease, Parkinson’s disease and polyglutamine disorders
such as Huntington’s disease and spinocerebellar ataxias (31). Alzheimer’s disease is
involved in progressive memory loss and is characterized by extracellular plaques that are
composed of misfolded and aggregated amyloid β peptides (Aβ). Alzheimer’s disease
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has been linked to ubiquitination through the incorporation of the ubiquitin variant
UBB+1 (32), reduced proteosomal activity (33), mutated ubiquitin hydrolyases (34), and
the effect of specific E3 ubiquitin ligases (35). The UBB+1 Ub variant contains a Cterminal extension that does not allow thiolester formation and is therefore a nonfunctional Ub molecule. However, the UBB+1 is recognized as a substrate and is polyubiquitinated itself. This UBB+1 capped poly-Ub chain is resistant to disassembly by
deubiquitinating enzymes and correspondingly inhibits the 26S proteosome (36).
Autosomal recessive juvenile parkinsonism (ARJP) is an early-onset form of Parkinson’s
disease and has been shown to be caused by mutations in the protein parkin (37). The
parkin protein was later identified to be a RING E3 ligase, and disease causing mutations
result in the accumulation of parkin’s substrate proteins (38, 39).
disorders

including

Huntington’s

disease

and

spinocerebellar

Polyglutamine
ataxias

are

neurodegenerative diseases that are biochemically identified by intracellular inclusion
bodies that contain ubiquitinated proteins (31). The polyglutamine region of the protein
huntingtin is expanded in Huntington’s disease and aggregates into these inclusion
bodies. The biological function of wild type huntingtin remains poorly defined, however,
huntingtin is associated with the ubiquitination pathway as mutant huntingtin is found to
be ubiquitinated in vivo and has been shown to interact with the E2 enzyme HIP2
presumably responsible for this ubiquitination (40). Mutant huntingtin overexpression
was also observed to inhibit proteosomal activity (41). All of these neurodegenerative
diseases result in lower 26S proteosome levels and activity indicating that aberration in
the proteolysis pathway is critical in all neurodegenerative diseases (42-44).

Large

protein aggregate formation in these diseases appears to be for the purpose of avoiding
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the toxic effect of the accumulation of soluble ubiquitinated proteins and the aggregation
is a way to handle these non-degradable proteins (45). The true nature of toxicity in these
diseases is still poorly understood.

1.2.2 Cancers
Human Papillomaviruses (HPV’s) exist in many different subtypes, some of
which produce oncoproteins E6 and E7 that interact with tumor suppressor protein p53
and the retinoblastoma susceptibility protein Rb respectively (31). Interaction of the
HPV oncoprotein E7 with Rb promotes the ubiquitination and degradation of Rb (46).
Rb normally interacts inhibits growth promoting E2F transcription factors, and thus
degradation of Rb promotes cell growth leading to cancer (47). The E6 protein binds to
the E3 ligase E6AP and this complex then interacts with p53 promoting its ubiquitination
and degradation (48). The p53 protein acts as a tumor suppressor by arresting cellular
proliferation, inducing repair mechanisms and in extreme stress induces apoptosis.
Regulation of p53 is normally achieved through ubiquitination by the E3 ligase Mdm2.
The design of a chemical inhibitor (nutlin) for Mdm2 can result in extended p53 function
by minimizing its degradation resulting in longer cell cycle arrest and increased apoptosis
of tumor cells in various cancers (49).
During oxygen shortage (hypoxia) a transcription factor called hypoxia inducible
factor (HIF-1α) promotes the synthesis of proteins important in red blood cell creation
and angiogenesis. HIF-1α is normally an unstable protein with a half life in cells of less
than 10 minutes and is ubiquitinated and degraded by the E3 ligase VCB-Cul2 complex
(31). A component of the VCB-cul2 complex, pVHL, is a tumor suppressor that is
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mutated in almost all renal cancers allowing HIF-1α to be constantly active promoting
tumor formation (50).

1.3 The E1, E2 and E3 Enzyme Cascade
1.3.1 E1 activating enzyme
The initial enzyme utilized in ubiquitination is the E1 activating enzyme. The E1
activating enzymes are large proteins (~110-120 kDa) that initially bind Ub noncovalently and adenylate the C-terminus of Ub through ATP hydrolysis.

The E1

activating enzyme uses a second domain that contains an active site cysteine to perform a
nucleophilic reaction with the adenylated Ub moiety to create a reactive thiolester bond
(51). After formation of an E1~Ub thiolester, the E1 activating enzyme binds to an E2
conjugating enzyme and through a transthiolesterification reaction transfers the Ub to a
cysteine residue at the active site on the E2.

There are two human E1 activation

enzymes, Uba1 and Uba6, that activate Ub molecules and both of these enzymes interact
with a different set of E2 conjugating enzymes allowing for increased specificity in the
ubiquitination pathway (23, 52). The crystal structure of the yeast Uba1 E1 activating
enzyme allows for further insights into how this enzyme functions (Fig 1.2A) (51). The
yeast Uba1 shares 50% sequence identity to the human Uba1, indicating these enzymes
are likely to function similarly (51). The E1 activating enzyme can be divided into
several functional domains (Fig 1.2A). The core of E1 houses the adenylation domain
(AD) that binds ATP and Ub and assists in the adenylation of the C-terminus of Ub. The
N-terminal region of E1 contains the first and second catalytic cysteine half
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Figure 1.2 Structures of E1 activating enzymes. (A) The crystal structure for the S. cerevisiae
Uba1 E1 activating enzyme (PDB: 3CMM). Different domains have been coloured differently to
show the division of functional units within the enzyme where the adenylation domain (AD purple) binds Ub (teal) non-covalently for adenylation, the first and second catalytic half domains
(FCCH - green, SCCH - blue) contain the active cysteine used for creation of the E1~Ub
thiolester, and the ubiquitin fold domain (UFD – red) is responsible for E2 binding. (B) The
crystal structure of the human NEDD8 E1 heterodimer APPBP1-Uba3 (PDB: 2NVU)
demonstrates how NEDD8 can be transferred onto the E2 enzyme. The E1 heterodimer
APPBP1-Uba3 (2 shades of green) interacts with two NEDD8 (orange) molecules, one on the
adenylation site and one through a thiolester linkage. The UFD (red) is rotated compared to (A)
showing that UFD movement occurs upon Ubc12 (blue) E2 enzyme binding. The active site
cysteine side chains (yellow) are the site of thiolester formation with Ub or Ubl proteins.
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domains (FCCH and SCCH) responsible for housing the E1 active site cysteine for Ub
thiolester bond formation. The C-terminal region of E1 contains the Ub fold domain
(UFD) that binds to E2 conjugating enzymes to assist a transthiolesterification reaction to
transfer Ub from an E1~Ub thiolester to an E2~Ub thiolester (51). The E1 enzyme can
bind 2 Ub molecules at the same time, one on the active site cysteine and another on the
adenylation domain. The method by which adenylated Ub is transferred onto the E1
active site cysteine is not obvious as there is a 36 Å separation between the cysteine side
chain and the adenylated Ub C-terminus in this structure (Fig 1.2A). Experimental
studies on the SUMO E1 activating enzyme have shown that adenylated SUMO is
transferred to the catalytic cysteine domain (equivalent to FCCH/SCCH in Uba1) through
allosteric changes and a rotation of this domain bringing the catalytic cysteine into close
contact with the SUMO C-terminus (53). These allosteric changes are also expected to
occur in the FCCH/SCCH domain of Uba1 to move adenylated Ub onto the catalytic site
(53). Insights into the position of the E2 conjugating enzyme in relation to the E1
enzyme were elucidated through experimentation on the NEDD8 heterodimeric E1
activating enzyme APPBP1-Uba3 in complex with the NEDD8 E2 Ubc12 (Fig 1.2B)
(54). In this E1/E2/NEDD8/NEDD8 quaternary structure, both thiolester linked and
adenylated NEDD8 protein are represented and a rotation of the UFD domain is required
to position the E2 enzyme’s catalytic cysteine into close proximity (23 Å) with the E1
enzyme’s catalytic cysteine. It is expected that a further rotation of the UFD domain will
position the active sites of the E1 and E2 enzymes to within 5 Å allowing for a
transthiolesterification transfer reaction to occur to form the E2~Ub thiolester (Fig 1.2B).
The importance of a rotation in the UFD domain of Uba1 was shown through proline
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mutations in the flexible linker that impaired thiolester transfer from E1 to E2 enzymes
indicating the Ub E1 functions similarly to the NEDD8 E1 (51). The Uba1 enzyme also
shows nanomolar affinity for E2 enzymes when it is dually loaded with Ub and has much
weaker affinity for the E2 in the absence of ATP and Ub (51). These affinity changes on
the E1 enzyme indicate that E2 enzymes bind to the E1 to accept Ub and then dissociate
from the E1 once the E2~Ub thiolester has formed. This bind and release action likely
allows the Ub E1 enzyme to efficiently charge a wide variety of Ub E2 conjugating
enzymes.

1.3.2 E2 conjugating enzymes
The E2 conjugating enzyme is the central enzyme in the ubiquitination pathway.
The E2 enzyme first interacts with the E1~Ub thiolester and Ub is transferred to the E2
enzyme to form the E2~Ub thiolester intermediate. The E2~Ub thiolester then interacts
with an E3 ligase and transfers Ub to the E3 enzyme and then onto the substrate or
directly onto a substrate. There are at least 35 E2 enzymes in the human proteome, 30 of
which are known to directly activate Ub in the ubiquitination pathway (24). These E2
conjugating enzymes all contain an ~150 residue structurally conserved catalytic core
domain (55). This catalytic core domain is found in all E2 enzymes and consists of 4 βstrands that make up an anti-parallel β-sheet, 4 α-helices, and a very short 310 helix
immediately following the active site cysteine (Fig 1.3A) (55). Many E2 enzymes also
contain a highly conserved HPN motif about 7-8 residues upstream of the conserved
catalytic cysteine at the active site (56). The conserved catalytic cysteine is utilized to
form a thiolester with the C-terminus of Ub. The asparagine within the HPN motif has
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Figure 1.3 General structure of E2 conjugating enzymes and E2~Ub thiolesters. (A) The crystal
structure for human UbcH5a (PDB: 2C4P) illustrates the general structure of all E2 enzymes. The
structurally conserved catalytic core domain of E2 enzymes consists of 4 β-strands that make up
an anti-parallel β-sheet, 4 α-helices, a very short 310 helix, and the active site is centered around
the conserved active site cysteine (yellow) and oxyanion hole stabilizing asparagine (green). (B)
The structural alignment and overlay of five E2~Ub thiolesters demonstrates the variation of
reported Ub positions in relation to the catalytic core domain. For clarity only the UbcH5b
(green) catalytic core is shown while the Ub is positioned and coloured differently for each
E2~Ub thiolester: Ubc1~Ub (PDB: 1FXT - red), UbcH5b~Ub (PDB: 3A33 - cyan), Ubc13~Ub
(PDB: 2GMI - blue), UbcH5b~Ub (PDB: 3JVZ - orange), and UbcH8~Ub (PDB: 2KJH magenta) are labelled Ub1, Ub2, Ub3, Ub4 and Ub5 respectively.
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been proposed to stabilize an oxyanion intermediate of the E2~Ub thiolester to aid in the
preceding nucleophilic attack of a lysine side chain on a substrate (56-58). The function
of the histidine in the HPN motif remains unknown, although it could be used to aid the
catalytic activity of the asparagine or be involved in protein stability (56, 59).
Although the structures of these E2 enzymes are highly conserved, there are very
few highly conserved residues within these proteins providing a large diversity between
E2 enzyme surface residues (59). The electrostatic properties of E2 enzymes have also
been shown to vary widely based on significantly different surface charges (60, 61).
These variations in residues and electrostatics may facilitate specific interactions for each
individual E2 enzyme. An added variation of E2 enzymes includes additional N-terminal
and C-terminal protein extensions to the catalytic core domain, and these can be subcategorized into 4 classes. Class I E2 enzymes contain only the catalytic core (Fig 1.3A)
(62). Class II, III and IV E2 enzymes contain a C-terminal extension, a N-terminal
extension, and both C-terminal and N-terminal extensions respectively (62).

These

extensions form unstructured and structured protein domains of various sizes and provide
additional protein interaction surfaces to modulate the specific functions of individual E2
enzymes.
The E2 enzyme must interact with both the E1 and E3 enzymes to carry out Ub
transfer. The E2 enzyme utilizes its N-terminal α1 helix and loop between β1 and β2 to
contact the E1 enzymes UFD domain (63). The E2 enzyme also utilizes its N-terminal
α1 helix, loop between β3 and β4, and loop between the 310 helix and α2 to contact E3
enzymes (64). These interaction regions on the E2 enzyme for E1 and E3 involve
overlapping surfaces. E2 enzymes have been shown to bind either the E1 or E3, but not
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both simultaneously, indicating that the E1-E2-E3 ubiquitination pathway is a stepwise
cascade reaction as opposed to a large protein complex (65). This fact also indicates that
the E2 enzyme is in a constant state of association and dissociation with its E1 and E3
interacting partners (65).

1.3.3 The E2~Ub thiolester and stable intermediate
The E2~Ub reactive intermediate represents an active ‘charged’ conjugating
enzyme. Most structural knowledge of E2 enzymes has been accumulated on free E2
enzymes as the E2~Ub thiolester is highly reactive and unstable, making its purification
and characterization difficult. Experimental study of the E2~Ub reactive intermediate is
vital towards advancing knowledge in this pathway as it is predicted that most E2
enzymes are usually found in the active E2~Ub state in vivo and therefore the E2~Ub
thiolesters are more likely to be recognized by interacting proteins than E2 enzymes
alone (66). Two different types of stable E2-Ub thiolester mimic complexes have been
produced to study the E2~Ub thiolester intermediate. The first E2-Ub complex can be
formed by an E2 active site cysteine to serine mutation that results in a longer lived ester
bond (67). The second E2-Ub complex can be formed by a Ub C-terminal glycine to
cysteine mutation that can be used to form a stable disulphide bond with the active site
cysteine of the E2 enzyme (68). There are currently 5 structures of E2-Ub intermediate
complexes including Ubc1~Ub (69), UbcH8-Ub (70), Ubc13-Ub (67), and two UbcH5bUb structures (71, 72). The alignment and overlay of these 5 structures illustrates the
varying reported positions of Ub in these different E2~Ub structures (Fig 1.3B). The
covalent attachment of Ub to the E2 enzyme does not result in any significant
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conformational changes in either protein, which indicates that the mere placement of Ub
onto the E2 enzyme is responsible for alterations in protein interactions (55). The
structure of the Ubc1~Ub thiolester (truncated Ubc1) was produced through NMR studies
where the unstable short lived Ubc1~Ub thiolester was produced in situ and the observed
interactions between Ubc1 and Ub allowed the structure of this thiolester to be modelled
(Fig 1.3B – Ub1/red) (69). The UbcH8-Ub disulphide complex was also solved using
NMR and the Ub position on the E2 enzyme was found to be much different to that of
Ubc1~Ub (Fig 1.3B – Ub5/magenta) (70). Additionally, crystal structures of Ubc13-Ub
and two UbcH5b-Ub ester complexes also place Ub in several different positions. These
crystal structures make some contact with neighbouring molecules within the crystal
lattice allowing for the possibility that the Ub position may be affected by these contacts
(Fig 1.3B – Ub2/cyan, Ub3/blue, Ub4/orange) (67, 71, 72).

Taken together these

structures all adopt significantly different positions for Ub in their E2~Ub thiolesters (Fig
1.3B). The various positions for Ub on different E2 enzymes can affect access to the
reactive thiolester and expose or block different surfaces of the E2~Ub, which may affect
reactivity in regards to interactions with E3 enzymes and substrates, although this has not
yet been well investigated (70, 73). The variation in Ub positioning between these
structures also supports recent experimental evidence that the E2-Ub intermediate may be
highly dynamic and mobile (74). This would indicate that the observed Ub positions in
these E2-Ub structures may be ‘snap shots’ or predominant species of a mobile Ub
molecule (Fig 1.3B). Further studies on E2-Ub intermediate complexes are required to
fully understand the dynamics and effects of Ub placement within E2~Ub thiolesters.

17
The E2~Ub thiolester also affects protein affinities to drive the E1-E2-E3 enzyme
cascade. This is observed as unconjugated E2 enzymes strongly bind E1 enzymes and
upon formation of the E2~Ub thiolester, these enzymes preferably dissociate (51).
Recent studies have shown that certain E2~Ub species have increased affinity for E3
enzymes over the free E2 enzyme (72, 75) (Dr Spratt personal communication). The
E2~Ub would then enhance interaction with E3 enzymes and after transfer the E2
enzyme may preferably dissociate to recharge on the E1 enzyme. A fixed or mobile
position of Ub in the E2~Ub thiolester may or may not affect these interactions. More
experimentation on affinity of E2~Ub versus free E2 enzymes is required to clarify
association and dissociation within the E1-E2-E3 enzyme cascade.

1.3.4 E3 ligating enzymes
The E3 ligases are the final enzyme in the ubiquitination pathway responsible for
the selective binding of substrates and E2 enzymes to assist transfer of the thiolester
linked Ub onto a substrate. The thiolester linked Ub is converted to a stable isopeptide
bond when the C-terminus of Ub is linked to the ε-amino group of a lysine residue in a
substrate. There are more than 1000 E3 ligases and substrate specificity is accomplished
by each E3 ligase having a different set of substrates allowing for differential regulation
of various proteins within the cell (24).

E3 ligases can be distinguished by their

enzymatic function and fall into two major categories, the HECT (homologous to E6AP
carboxyl terminus) E3 ligases and RING (really interesting new gene) E3 ligases. More
than 95% of all known human E3 enzymes are RING E3 ligases (76). HECT E3 ligases
contain a conserved active site cysteine used for the transfer of Ub from the E2~Ub
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thiolester to make an E3~Ub thiolester prior to reaction with an E3 bound substrate lysine
residue. The RING E3 ligase does not contain an active site cysteine, but rather works as
a scaffold in substrate ubiquitination by placing the E2~Ub thiolester in close proximity
to a substrate to aid Ub transfer.
Structural knowledge of E2 enzyme interactions with E3 ligases is aided by the
crystal structure of the E2 enzyme UbcH7 interacting with the E6AP (human
papillomavirus E6 associated protein) E3 ligase HECT domain (Fig 1.4A) (77). The
E6AP HECT domain contains an N-terminal region (N-lobe) that binds the E2 enzyme,
and a C-terminal region (C-lobe) that contains the conserved cysteine residue responsible
for thiolester formation (Fig 1.4A). This UbcH7/E6AP structure indicates that a 41 Å
distance exists between the E2 and HECT E3 active site cysteine residues (Fig 1.4A).
Additional structures of other HECT E3 ligases have shown that the C-lobe can adopt
alternative positions due to a flexible linker that can result in the reduction in this spatial
gap between cysteine residues (78).

This was confirmed with the structure of

UbcH5b~Ub with the Nedd4L HECT E3, which illustrates a significantly moved C-lobe
placing the E3 catalytic cysteine within 8 Å of the thiolester bound Ub C-terminus (Fig
1.4B) (72). This structure shows that movement of the C-lobe of the HECT domain is
required for Ub transfer from the E2 to the E3. Contacts between the E2 attached Ub
moiety and the C-lobe stabilize the movement of the C-lobe to aid in Ub transfer (72).
Structural knowledge of E2 enzyme interactions with RING E3 ligases is revealed
by the crystal structure of c-Cbl (casitas B-lineage lymphoma) RING E3 ligase in
complex with the E2 enzyme UbcH7 and a substrate peptide (Fig 1.4C) (64). The c-Cbl
RING E3 associates with the E2 enzyme UbcH7 through its zinc-stabilized RING domain
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Figure 1.4 Structures of a several E2/E3 enzyme complexes. (A) The crystal structure of
UbcH7-E6AP (PDB: 1C4Z) and (B) UbcH5b~Ub-Nedd4L (PDB: 3JVZ) illustrate the binding of
an E2 (UbcH7 - blue) and E2~Ub (UbcH5b~Ub – blue ~ teal) thiolester to the HECT E3 ligases
E6AP and Nedd4L respectively. The HECT domain is divided into 2 lobes, the N-lobe (orange)
and C-lobe (purple). Movement of the C-lobe details the allosteric changes required to position
the E2 and E3 active site cysteine residues (yellow) into close proximity. (C) The crystal
structure of ZAP-70/c-Cbl/UbcH7 (PDB: 1FBV) illustrates the interaction between the RING
domain (purple) of the E3 c-Cbl (orange) interacting with the E2 UbcH7 (blue). There is a large
distance between the E2 active site (yellow) and the substrate peptide ZAP-70. (D) The crystal
structure of UbcH5b (blue) and Cnot4 RING domain (purple) illustrates the common interface
between RING domains and the N-terminal region of the E2 enzyme (PDB: 1UR6). The RING
domains are structurally stabilized by two Zn2+ ions (teal spheres).
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(Fig 1.4C). RING domains contain a highly conserved C3HC4 motif that coordinates two
zinc ions to stabilize its structure (79). RING E3 ligases utilize the RING domain to bind
the E2 enzyme’s N-terminal α1 helix as well as several loops near the N-terminus (Fig
1.4C). The UbcH7/c-Cbl complex is one of very few solved E2/RING E3 structures.
Other solved E2/E3 RING structures include UbcH5b/Cnot4 RING E3 (Fig 1.4D),
Ubc13/TRAF6 RING E3, and UBE2D1/IDOL RING E3, which show very similar
protein interaction surfaces are utilized in all reported E2/RING E3 structures (80-82).
E3 ligases incorporate many other protein binding domains for the purpose of binding
substrates and recruiting other proteins required for larger functional E3 complexes (79).
The UbcH7/c-Cbl complex also includes a peptide from the ZAP-70 protein kinase, a
known ubiquitinated substrate of this E2/E3 complex (Fig 1.4C) (64). The distance from
the E2 enzyme active site’s bound Ub thiolester to the ZAP-70 substrate is 60 Å. A
similar large spatial gap has been observed between an E2~Ub thiolester and substrate in
the large E3 RING ligase containing SCF complexes (83). The mechanism utilized by
these enzymes for bridging this spatial gap is still under investigation, although it is likely
that some allosteric change in the E3 enzyme or protein interactors is required to allow
substrate ubiquitination. There are currently no structural details that show how Ub is
transferred from the E2~Ub thiolester directly to a substrate.

1.4 Formation of Poly-Ub Chains
Structural knowledge acquired from E1, E2 and E3 enzymes in various complexes
has illustrated the general mechanisms utilized to activate and transfer Ub onto the E2
and E3 enzymes.

Additional structures of E2~Ub/RING-E3/substrate or HECT-
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E3~Ub/substrate are required to clarify how the thiolester linked Ub is directly
transferred to an ε-amino group on a substrate lysine residue.

It is expected that

conformational changes in E3 enzymes are required to transfer Ub onto substrates. The
general mechanism of Ub activation and transfer onto substrates has been developed from
these various E1, E2 and E3 structures, however, the mechanism by which these enzymes
interconnect Ub molecules into poly-Ub chains remains very poorly understood.

1.4.1 Proposed Poly-Ub chain formation mechanisms
Several mechanisms have been proposed to explain how the ubiquitination
pathway enzymes position Ub molecules for the creation of various Ub-Ub linkages
found in poly-Ub chains (84, 85). The simplest proposed mechanism for poly-Ub chain
formation is the sequential addition model. In this model, the substrate lysine reacts with
the first Ub and subsequent Ub additions are attached to the lysine residues on Ub itself,
thus creating a chain sequentially (Fig 1.5A).

The logical complication with this

mechanism is that the site of attachment of each new ubiquitin molecule becomes more
remote as the chain extends, presumably making the required nucleophilic attack from
each Ub lysine’s ε-amino group less probable. Alternative methods for poly-Ub chain
formation are supported by experimentation on many E2 and E3 enzymes that show polyUb chains can be produced prior to interaction with substrates. These results suggest
poly-Ub chains may not be constructed on the substrate but rather preassembled
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Figure 1.5 Schematic representation of several proposed mechanisms for the formation of polyUb chains. Ub molecules (yellow, orange, red and green) are depicted by small coloured circles.
(A) The sequential addition model involves Ub added one at a time to first the substrate and then
lysine side chains of Ub itself. (B) Preassembly of chains on the HECT E3 enzyme is performed
like the sequential addition model only the chain is built on the E3 enzyme and then transferred
onto the substrate. (C) A thiolester attached juggling model suggests an E2/E2 dimer allows for
chains to be built on the E2 enzyme. In this model, both Ub molecules are thiolester bound and
proper Ub positioning would allow one Ub to act as an acceptor and the other to act as a donor.
In this manner chains extend on the proximal side of the growing chain. A similar juggling
model can be performed using an E2/E3 HECT pairing. (D) Preassembly of chains may also
require non-covalent binding of an acceptor Ub to be positioned so its lysine side chain can react
with a thiolester bound Ub donor. In this model, a HECT E3 is depicted to have both the active
site thiolester and non-covalent binding site for Ub. This model could also be replaced with any
combination of E2 monomer, E2/E2, or E2/E3 complex where a non-covalently connected Ub
acceptor can be positioned for reaction with an E2 or E3 thiolester bound Ub donor.
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prior to attachment to substrate. One mechanism to preassemble poly-Ub chains would
be similar to the sequential addition model except that poly-Ub chains would be built on
a HECT E3 ligase and then transferred in a single step onto the substrate (Fig 1.5B). This
mechanism would require an E2~Ub/E3~Ub interaction that would position the two
thiolester bound Ub molecules in an orientation such that a lysine side chain of the
E3~Ub could react with the E2~Ub reactive thiolester to yield E3~Ub2. In this process
the chain extends via multiple charging of the E2 enzyme. Another mechanism to
preassemble poly-Ub chains would require an E2-E2 dimer to positions two Ub
molecules such that one E2~Ub lysine can react with the thiolester of a second E2~Ub
(Fig 1.5C). In this process the chain extends via multiple charging of the E2 enzymes,
and a back and forth juggling of the thiolester attached proximally extending poly-Ub
chain. Alternative mechanisms of poly-Ub chain preassembly may also utilize noncovalent Ub interacting surfaces on either the E2 or E3 enzyme (Fig 1.5D). These
mechanisms would be driven by the positioning of a non-covalently bound Ub within
reactive distance to a thiolester bound Ub on either the E2 or E3 enzymes. The model
depicted in Figure 1.5D could also be replaced with any combination of E2 monomer,
E2/E2 complex, or E2/E3 complex where a non-covalently connected Ub acceptor can be
positioned for reaction with an E2 or E3 thiolester bound Ub donor. These preassembled
poly-Ub chain mechanisms all require the placement of two Ub molecules in close
proximity to allow one Ub’s lysine ε-amino side chain to react with the C-terminus of a
thiolester bound Ub to create a stable isopeptide bond. More detailed experimentation is
required to clarify how poly-Ub chains can be created in the ubiquitination pathway.
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1.4.2 K63 poly-Ub chain formation
The only well defined structural model showing poly-Ub chain formation
involves the Ubc13/Mms2 complex responsible for the production of K63-linked polyUb chains (73). Ubc13 is an ‘active’ E2 conjugating enzyme that contains an active site
cysteine utilized to form a Ubc13~Ub thiolester.

Mms2 is a ubiquitin conjugating

enzyme variant that is an ‘inactive’ E2 paralogue that shares significant sequence
similarity with E2 enzymes but does not contain an active site cysteine. The Mms2
protein does not form a thiolester bond with Ub, but rather forms a non-covalent bond
with free Ub in solution (86). Ubc13 interacts with Mms2 and the crystal structure of the
Ubc13/Mms2 can be combined with the NMR modelled non-covalent Mms2/Ub
structure and the Ubc1~Ub thiolester structure to place both Ub molecules on this E2
heterodimer such that the K63 side chain of the Mms2 bound Ub comes into close
proximity of the C-terminus of the Ubc13~Ub thiolester (Fig 1.6) (67, 69, 73, 87, 88).
This model constructed from three PDB files contains a 12 Å reaction distance between
one Ub’s K63 lysine and the thiolester Ub C-terminus, but another NMR modeled
version of this same structure indicates the reactive distance to be ~3 Å (73). This model
directly shows how one Ub can be reacted with a second Ub to create a K63-linked
diubiquitin (Ub2) molecule in the absence of an E3 enzyme or substrate. Cycles of this
reaction presumably explain how longer K63-linked poly-Ub chains are created by the
Ubc13/Mms2 E2 heterodimer (67).

The method utilized to build these chains is a

mixture of the mechanisms depicted in Figure 1.5C and 1.5D, where an E2 dimer is used
to position the non-covalently bound Ub to react with the thiolester bound Ub for poly-
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Figure 1.6 The human E2 heterodimer Ubc13/Mms2 structurally illustrates the mechanism for
K63-linked poly-Ub chain formation. This four protein complex is composed of the Ubc13
(purple) and Mms2 (orange) which were crystallized in complex (PDB: 1J7D), aligned with the
thiolester connected Ub (blue) positioned from Ubc1~Ub (PDB: 1FXT) and the non-covalent
interaction of Ub (red) on Mms2 (PDB: 1ZGU). The side chain Lys63 (green) of Ub (red) acts as
an acceptor for reaction with a thiolester bound Ub (blue) donor connected at the Ubc13 active
site (yellow). This model contains a roughly 12 Å reaction distance.
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Ub chain attachment. In this way the growing chain would be free in solution as opposed
to attached at the active site thiolester.

A highly detailed Ub-Ub positioning for

attachment has not yet been presented for any other poly-ubiquitination pathways.

1.4.3 Cdc34 experiments indicate Cdc34~Ub may directly dimerize for activity
Initial studies using chemical cross-linking reagents indicated possible
dimerization of the E2 enzymes Ubc1, Ubc4 and Cdc34 (Ubc3) (89-91).

Further

investigation of Cdc34 determined that this E2 produces both free K48-linked poly-Ub
chains and Cdc34 attached K48-linked chains in the presence of Ub, ATP, E1, Cdc34,
and its E3 RING protein complex (92). Fusion proteins that force Cdc34 to dimerize
were found to increase poly-Ub chain formation activity in the absence of the normally
required E3, suggesting that dimerization activates Cdc34 activity (92). Further studies
on Cdc34 showed that two differentially tagged E2 enzymes can coimmunoprecipitate in
vivo (yeast cells) (93).

Coimmunoprecipitations could still be performed on Cdc34

proteins absent E3 enzyme binding, and the active site cysteine was required for
coimmunoprecipitation, indicating that dimerization of Cdc34 appears to be dependant on
the presence of an activated thiolester (93). Previous sedimentation equilibrium studies
on free Cdc34 indicate the enzyme is monomeric, although the Cdc34~Ub thiolester was
not investigated (92).

Combining these results indicates either the E3 enzyme or

Cdc34~Ub thiolester may assist dimerization to drive the mechanism depicted in Figure
1.5C. Regardless of the exact mechanism used, the fact that poly-Ub chains can be
formed without substrate further supports the possibility that poly-Ub chains may be
preassembled prior to substrate attachment.
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1.4.4 K48-linked Poly-Ub chains can be built on Ube2g2 enzymes
Another example of poly-Ub chain formation activity prior to substrate addition
comes from the E2 enzyme Ube2g2 (Ubc7). Activity assays performed on Ube2g2 with
its RING E3 ligase gp78 resulted in K48-linked poly-Ub chain formation (94). In this
study, reactions of ATP, E1 and Ube2g2 with either wild type Ub or Flag tagged Ub with
a K48R substitution (UbK48R-Flag) were used to create two different Ube2g2 thiolesters,
Ube2g2~Ub and Ube2g2~UbK48R-Flag. The Ube2g2~Ub thiolester contains the reactive
K48 residue on Ub that can act as a Ub acceptor, while the Ube2g2~UbK48R-Flag
thiolester contains the unreactive K48R substitution and therefore can only act as a Ub
donor. The addition of the RING E3 ligase gp78 causes the reaction of these two
intermediates to yield a diubiquitin attached thiolester Ube2g2~Ub-UbK48R-Flag. These
results indicate a direct reaction between two Ube2g2 (E2) enzymes can occur causing
the attachment of one Ub to a second Ub while both are covalently linked to the E2. This
reaction required the gp78 RING E3 enzyme that has been shown to oligomerize (95).
Therefore, the requirement for E3 may be to allow oligomerization of Ube2g2 enzymes
in order to position Ub molecules in proximity for poly-ubiquitination activity. Further
supporting the biological significance of this in vitro activity is the fact that poly-Ub
chains linked to Ube2g2 can also be transferred onto a substrate, HERPc, indicating that
preassembled chains can be transferred from the E2 enzyme onto a substrate (94). This
evidence suggests a dimeric mechanism for Ube2g2 in which chains are preassembled
prior to their attachment to substrates by thiol juggling as depicted in Figure 1.5C.

28
1.4.5 HECT E3 enzymes in poly-Ub chain extension
A study of two HECT E3 ligases has shown poly-Ub chain activity in the absence
of substrates (85). In these studies the HECT E6AP E3 ligase was found to synthesize
poly-Ub chains using an E2/E3 heterodimer by reacting two covalently bound Ub
molecules, one connected to the UbcH5a (E2~Ub) and one connected to the E6AP
(E3~Ub), to yield E6AP~Ub2 (85). These results indicate that poly-Ub chains could form
on the E3 enzyme and the growing chain’s distal Ub would continually act as the Ub
acceptor during chain extension (Fig 1.5B).

This model of Ub chain extension is

presumably assisted by movement in the C-lobe of E6AP to allow positioning of a
growing chain attached to the E3 ligase (Fig 1.4A/B) (85).
An alternative mechanism for poly-Ub chain activity was observed for the HECT
E3 ligase KIAA10 and UbcH5a. In this mechanism KIAA10 was observed to bind Ub
non-covalently and this Ub acts as the acceptor by reacting with the KIAA10 thiolester
bound Ub donor to build unanchored poly-Ub chains (85). The non-covalent Ub binding
on KIAA10 must position the acceptor Ub lysine into reactive distance with the
KIAA10~Ub donor as is depicted in Figure 1.5D. Chain extension would occur on the
distal end of the growing chain where a K48 lysine is still available to be positioned by
the non-covalent binding site (Fig 1.5D).

1.4.6 Alternative poly-Ub chain mechanisms
Non-covalent Ub binding has been observed on the UbcH5c E2 enzyme on the
backside of the enzyme far removed from the active site cysteine (96, 97).

The

positioning of the non-covalently bound Ub is too far to interact with the active site
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linked UbcH5c~Ub thiolester. This result indicates UbcH5c can bind 2 Ub molecules
simultaneously, but does not position them for direct interaction in poly-Ub chain
activity.

The non-covalent binding of Ub on UbcH5c is however required for its

observed poly-Ub chain formation activity in the presence of several different E3
enzymes (97). This non-covalent binding also causes oligomerization of UbcH5c~Ub
thiolesters as the E2 bound Ub can associate with the non-covalent binding surface of a
neighbouring UbcH5c (97). The mechanism of poly-Ub chain formation in this enzyme
remains poorly understood but oligomerization may be a key requirement for function.
The Ubl proteins SUMO2 and SUMO3 have also been shown to interact non-covalently
with an equivalent region of the E2 enzyme Ubc9. The non-covalent binding in Ubc9 is
also required for SUMO chain formation, likely through a similar mechanism to UbcH5c
(98).
The process of dimerization is not solely limited to E2 enzymes, as many E3
ligases have been shown to dimerize including Brca1/Bard1 involved in breast cancer and
Ring1b/Bmi involved in histone mono-ubiquitination (99, 100). This E3 dimerization
was shown to be very important as mutations in the dimerization domain of Brca1
promotes cancer formation (99).

1.5 HIP2 and Ubc1 E2 conjugating enzymes
The mechanisms of poly-Ub chain formation become complicated as interactions
involve E2/E3, E3/E3, or more complex dimeric combinations of these enzymes to
position Ub molecules for reactivity.

The simpler function of the E2 heterodimer

Ubc13/Mms2 that does not require an E3 enzyme or substrate has provided very sound
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structural information towards the assembly of K63-linked poly-Ub chains. Similar
structural information is lacking for K48-linked poly-Ub chains.

Two well studied

enzymes that also have K48-linked poly-Ub chain formation activity in the absence of
both E3 ligases and substrates are the yeast E2 enzyme Ubc1, and its human homolog
HIP2. Since these E2 enzymes do not require E3 ligases, they should utilize a simpler
mechanism for poly-Ub chain assembly in comparison to other K48 poly-ubiquitination
pathways. How these two E2 enzymes function still remains poorly understood.

1.5.1 Ubc1
The E2 conjugating enzyme Ubc1 from yeast Saccharomyces cerevisiae was first
identified in 1990 (101). The primary function for Ubc1 in yeast was found to be the
selective degradation of short lived and abnormal proteins during early stages of growth
after spore germination (101). Ubc1 also appears to functionally overlap with the other
E2 enzymes Ubc4 and Ubc5 as single mutants of Ubc1 or Ubc4 have a slow growth
phenotype, while double mutants fail to sporulate (101). This result shows that Ubc4,
Ubc5, and Ubc1 have overlapping function. Ubc4 and Ubc5 are class I E2 enzymes
containing only the traditional ~150 residue catalytic core domain while Ubc1 is a longer
215 residue class II E2 conjugating enzyme that possesses an additional C-terminal
extension. The first experimental work on purified Ubc1 showed that K48-linked polyUb chains were formed on the Ubc1 enzyme itself in the presence of only E1, MgATP,
Ubc1 and Ub (102).

These poly-Ub chains were linked to the Ubc1 K93 residue

indicating that Ubc1 performs an auto-ubiquitination of itself reminiscent of substrate
ubiquitination. Auto-ubiquitination assays were also performed on a Ubc1 truncation
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(Ubc1Δ) that had the C-terminal domain removed. Comparison of activity in Ubc1 and
Ubc1Δ demonstrated that wild type Ubc1 could form poly-Ub chains up to four Ub
molecules in length, while Ubc1Δ resulted in much longer poly-Ub chains up to 12 Ub
molecules in length (102). This result indicates that the 65 residue C-terminal domain
may control the length of poly-Ub chains produced. Further investigation indicated Ubc1
may dimerize as it was shown to chemically crosslink and elute earlier than expected by
size exclusion column chromatography (89). The poly-Ub chain formation activity of
Ubc1 may therefore require a dimeric mechanism to function.
The structure of full length Ubc1 was solved using NMR spectroscopy and is
composed of the traditional catalytic core domain of 4 α-helices, 4 β-strands, and the
very short 310 helix immediately following the active site cysteine C88 residue (Fig
1.7A). The Ubc1 enzyme also contains a C-terminal Ub-associated (UBA) domain that is
composed of a small 3 helix bundle (α5-α7) (Fig 1.7A) (103). UBA domains are found
in several other proteins and have been shown to bind Ub non-covalently (104), in some
cases bind poly-Ub chains preferentially (105), and also been implicated as a
dimerization domain (106).

The Ubc1 UBA domain was shown to interact non-

covalently with free Ub (103). The full length Ubc1 NMR structure shows that the
catalytic core domain and the UBA domain are connected by a flexible linker (103). This
flexible linker allows a wide range of movement of the UBA domain in relation to the
catalytic core. Therefore, the structure of full length Ubc1 is elongated, which may
explain prior results in gel filtration experiments where Ubc1 eluted earlier than expected
(89). The Ubc1 structure also shows that the proximity of K93 in the 310 helix is very
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Figure 1.7 Structure of the E2 conjugating enzyme Ubc1 and Ubc1Δ~Ub thiolester. (A) The full
length Ubc1 was solved using NMR spectroscopy (PDB: 1TTE) showing the classic catalytic
core domain of 4 α-helices, a short 310 helix, and 4 β-strands that form an anti-parallel β-sheet
that wraps around the central α2 helix. Ubc1 also contains a C-terminal ubiquitin associated
(UBA) domain composed of a 3-helix bundle of α5-α7. The catalytic core domain is connected
to the UBA domain through an unstructured flexible linker. (B) Ubc1Δ (no UBA domain) was
modelled with a thiolester bound Ub (teal) to position this Ub on the surface of Ubc1Δ (PDB:
1FXT). In this structure the hydrophobic side of Ub (located on the β-sheet) faces and interacts
with the α2 helix in Ubc1. In this way the Ubc1~Ub thiolester bound Ub is held closely to the
Ubc1 enzyme. Ubc1 secondary structural elements include α-helices (blue), β-strands (red),
unstructured loops (grey) and the active site cysteine (yellow).
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close to the C88 active site indicating that auto-ubiquitination may occur as a result of an
intramolecular transfer of Ub directly from the active site to the K93 residue.
The structure of the Ubc1Δ~Ub thiolester was modelled using NMR spectroscopy
by creating the thiolester in situ (Fig 1.7B) (69). In this structure the hydrophobic surface
of Ub (located on the β-sheet) faces and interacts with the α2 helix in Ubc1Δ. This
results in Ub being tightly bound to the Ubc1 catalytic core domain.

Further

experimentation on Ubc1 was greatly aided by the creation of a stable thiolester mimic
formed with a disulphide bond between a substituted Ub (UbG76C) and the C88 of the
active site (68). This Ubc1-Ub disulphide complex was shown to accurately mimic the
Ubc1~Ub thiolester complex through NMR experiments (68). Experimentation on this
Ubc1-Ub complex indicates that the UBA domain does not interact non-covalently with
the thiolester bound Ub, but can interact with free Ub (68). The ability of the UBA
domain to bind Ub in the Ubc1-Ub complex shows that Ubc1 has the ability to bind two
Ub molecules simultaneously.

The binding of two Ub molecules may support a

monomeric mechanism of Ubc1 as the UBA domain could theoretically position the noncovalently bound Ub in proximity to a thiolester bound Ub. The Ubc1 protein was also
shown to be monomeric by sedimentation equilibrium (107), although the formation of
Ubc1~Ub thiolester may facilitate dimerization as was observed in Cdc34 (93).
Very recent work on Ubc1Δ has suggested a novel function of the E1 enzyme that
would be required for poly-Ub chain formation on the auto-ubiquitinated Ubc1Δ (108).
This implies that an E1/E2 complex is required to position 2 Ub molecules together for
poly-Ub attachment rather than an E2/E2 complex. This could imply the E1 enzyme
directly extends chains on E2 enzymes, or may assist E2 dimerization. Additional recent
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Ubc1 experimentation has shown that Ubc1 and Ubc4 E2 conjugating enzymes can polyubiquitinate Cyclin B involved in cell cycle progression with a large RING E3 complex
called APC (anaphase-promoting complex) (109). In this study Ubc4 and Ubc1 appear to
have different functions as Ubc4 is more active in initial Ub attachment to substrates and
Ubc1 is more active at extending chains on substrates that already have a single attached
Ub (109). This study also tested Ubc1Δ (UBA removal) and observed products with
shorter chain length (109). This result contrasts with the Ubc1Δ auto-ubiquitination
experiments where longer poly-Ub chains were produced (102). These results may
support a sequential addition model using combinations of E2 enzymes. Even with these
few activity results, the mechanism for poly-Ub chain formation of Ubc1 remains very
poorly understood.

1.5.2 E2 conjugating enzyme HIP2 (E2-25K)
The E2 conjugating enzyme E2-25K was shown to interact with the protein
huntingtin and is suspected to poly-ubiquitinate huntingtin for degradation resulting in
E2-25K being renamed HIP2 (huntingtin interacting protein 2) (40, 110). HIP2 is a 200
residue E2 conjugating enzyme that is highly conserved as human HIP2 has 100%
sequence identity with bovine HIP2, and 66% sequence similarity with its yeast homolog
Ubc1 (40, 111). The active site of HIP2 contains even greater conservation having 90%
identity with Ubc1 within 20 residues around the active site (111). HIP2 has been shown
to be widely expressed in many tissues but is highly expressed in brain tissue (40). The
HIP2 structure was solved as a dimer by X-ray crystallography and is classified as a class
II E2 indicating it possesses the traditional catalytic core domain and a C-terminal UBA
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domain (Fig 1.8A) (PDB: 1YLA - unpublished). HIP2 was not observed to crosslink
(112), and its dimerization capacity is not well investigated. Therefore the relevance of
this dimeric crystal structure remains unknown.

The monomer of this structure is

depicted in Figure 1.8B. The HIP2 structure is again composed of the classic 4 α-helices,
4 β-strands, a 310 helix, and a C-terminal UBA domain (Fig 1.8B). Compared to the
similar Ubc1, HIP2 has a shorter linker connecting the catalytic core to the UBA domain,
and it is unknown if this linker is also flexible (Fig 1.7A versus Fig 1.8B). The C92
catalytic active site is used to create a thiolester with Ub, and the UBA domain has
recently been shown to bind free Ub non-covalently, giving HIP2 the ability to bind 2 Ub
molecules simultaneously, just like Ubc1 (113, 114). These structural similarities to
Ubc1 indicate that HIP2 should function by a similar mechanism to Ubc1.
Very recently the crystal structure of HIP2 with non-covalently bound Ub was
solved showing the nature of Ub binding to the HIP2 UBA domain (Fig 1.8C) (113).
UBA domains are characterized by a conserved hydrophobic MGF patch between α1 and
α2 in the 3 helix bundle used for protein interactions (115). It is this MGF region of the
HIP2 UBA domain that was seen to bind free Ub (113). Ubc1 also utilizes its similar
QGF residues in UBA/Ub binding (103). This general UBA/Ub binding surface has been
observed for several other UBA domains and is shown in more detail on an example
UBA domain (Ede1) in Figure 1.8D (104). The major binding interface between these
two proteins is composed of the MGF and α3 of the UBA domain and the C-terminal end
and hydrophobic residues in the β-sheet portion of Ub. The HIP2 UBA domain has also
been shown to bind poly-Ub chains (Ub4) with higher strength than single Ub
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Figure 1.8 Structure insight into the human HIP2 E2 conjugating enzyme. (A) The full length
HIP2 enzyme was solved using X-ray crystallography (PDB: 1YLA) as a dimer where the β-sheet
side of HIP2 opposite the active sites contact each other. (B) Half of the structure shown in (A)
leaves a monomeric HIP2 showing the classic catalytic core domain and a C-terminal UBA
domain. The unstructured linker between the catalytic core and UBA domain is shorter than that
observed for Ubc1. (C) A recent structure of HIP2 has shown the non-covalent binding of Ub
with the UBA domain (PDB: 3K9P). In this structure the hydrophobic face of Ub interacts with a
highly conserved MGF sequence in the UBA domain of HIP2. (D) Many other UBA domains
show a similar interaction with Ub. An example from the protein Ede1 depicts a similar UBA/Ub
non-covalent interaction (PDB: 2G3Q). Most UBA domains contain this MGF motif and use a
large portion of the third α-helix in this 3-helix bundle to contact the hydrophobic face of Ub.
HIP2 secondary structural elements include α-helices (blue), β-strands (red), unstructured loops
(grey) and the active site cysteine (yellow) and oxyanion stabilizing asparagine (green) while Ub
(teal) is coloured uniformly.
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molecules (105). NMR experiments on a similar UBA domain (UBA2 from hHR23A)
have shown a K48-linked Ub2 used both Ub hydrophobic surfaces to contact the UBA
domain (116). These results are consistent with stronger binding to poly-Ub chains
indicating that HIP2 may bind poly-Ub chains in a similar manner.
HIP2 activity was initially found to create unanchored K48-linked poly-Ub chains
with only E1, MgATP, and Ub (117). The function of HIP2 is similar to Ubc1 only the
K48-linked poly-Ub chains are free in solution as opposed to connected to the K93
residue in Ubc1.

HIP2 was also found to be able to use non-thiolester linked Ub

molecules as Ub acceptors indicating Ub acceptors may be thiolester linked or bound
non-covalently (117). Diubiquitin (Ub2) was also found to be a better Ub acceptor than
Ub alone indicating the kinetics of poly-Ub chain formation become more favourable as
the chain grows (117). Since the HIP2 UBA domain has also been shown to bind polyUb chains (Ub4) with higher strength than single Ub molecules, the UBA domain may
account for the use of longer poly-Ub chains as more efficient Ub acceptors (105). These
results imply that the UBA domain is required for chain extension. Further experimental
studies on HIP2 were performed with a truncated HIP2Δ155 (UBA removed at residue
155) or HIP2Δ159 and these truncations still retained poly-Ub chain activity although
they were not as efficient (30, 114). These results indicate that UBA aids in activity but
may not be essential. Very recent experiments have shown the UBA domain is required
for full activity of HIP2 (114), and its yeast homolog Ubc1 (109). The presence of even
partial activity with UBA removal indicates HIP2 dimerization may be required to place
two Ub molecules in close proximity. The purpose of the UBA domain therefore remains

38
poorly understood but its known affinity for Ub and poly-Ub chains allows for many
possible interactions with E2, E3 or substrate linked Ub or poly-Ub molecules.
The purpose of HIP2 building unanchored poly-Ub chains remains unknown,
although the E1 enzyme can form thiolesters with both Ub and Ub2 and transfer these
thiolesters onto HIP2 with similar kinetics (117). This indicates that preassembled Ub2
can be utilized to form HIP2~Ub2 that could act as a Ub donor in further chain extension
or substrate labelling (117). This is supported by the discovery that unanchored poly-Ub
chains are found in vivo and can be loaded onto substrates using Ubc4 with similar
kinetics to a single Ub (118). These results show HIP2 may function by preassembling
poly-Ub chains prior to substrate attachment.
Very little is known about HIP2’s cognate E3 enzymes or substrates.

The

biological activity of HIP2 remains widely unknown. Only a small number of RING E3
enzymes were implicated to interact with HIP2 through yeast two-hybrid studies (119).
HIP2 ubiquitinates the substrate p105 a precursor for p50, involved in NF-kB signaling,
through an unknown E3 ligase (120). Very recent work has identified HIP2 to bind the
RING E3 NARF (Nemo-like Kinase (NLK)-associated Ring finger) to ubiquitinate
transcription factors TCF/LEF, and their corresponding degradation suppresses Wnt-βcatenin signaling involved in embryonic development and tumorigenesis (121). HIP2 has
also been linked to Cyclin B1 degradation and DIABLO degradation but no E3 ligase has
been identified (122, 123).

HIP2 may also be involved in the degradation of Rb

(retinoblastoma tumor suppressor protein) involved with HPV oncoprotein E7 resulting
in the promotion of cancer (124). The lack of many identified E3 ligases for HIP2 has
limited the study of HIP2 activity on specific substrates.
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The most interesting HIP2 function is in both Alzheimer’s and Huntingtin’s
disease. Alzheimer’s disease has been characterized by extracellular plaques that are
composed of misfolded and aggregated amyloid β peptides (Aβ). HIP2 was shown to be
upregulated in neurons exposed to Aβ peptides (125). Alzheimer’s disease has been
linked to ubiquitination through the incorporation of the ubiquitin variant UBB+1 (32) and
reduced proteosomal activity (33). The UBB+1 variant contains a C-terminal extension
that when added to the end of a K48-linked poly-Ub chain is resistant to deubiquitinating
enzymes and correspondingly inhibits the 26S proteosome (36). HIP2 may largely affect
these functions by incorporating UBB+1 into poly-Ub chains as HIP2 has recently been
found to bind both Ub and UBB+1 by the UBA with equivalent affinity (113). HIP2 is
expressed in many tissue types (126) and is highly expressed in the brain (40), the site of
polyglutamine and Alzheimer’s diseases. Huntington’s disease is characterized by the
expansion of the polyglutamine portion of the protein huntingtin that results in their
aggregation into inclusion bodies.

HIP2 interacts with the huntingtin protein and

presumably is responsible for its ubiquitination (40). HIP2 was also found to exist in
Huntington’s disease inclusions also containing huntingtin, Ub and UBB+1 (127).
Additionally, HIP2 is suspected to play a role in aggregate formation and cell death (127,
128). HIP2 involvement in both Huntington’s and Alzheimer’s disease may be related by
a similar mechanism of pathogenesis.

1.6 Scope of Thesis
The ubiquitination pathway is an important regulatory pathway within the cell and
its disruption has been linked to many neurodegenerative diseases and cancer.

A

40
significant amount of work over the last two decades has expanded the understanding of
the E1-E2-E3 enzyme cascade used to poly-ubiquitinate substrates for degradation.
However, the mechanism by which most these enzymes build poly-Ub chains on their
substrates remains poorly understood. An improved understanding of the mechanisms of
poly-Ub chain assembly will aid in determining how these pathways are disrupted in
many diseases.
HIP2 and Ubc1 do not require E3 enzymes and substrates to create poly-Ub chain
linkages. HIP2 and Ubc1 employ a simple functional mechanism that only requires the
addition of Ub, ATP and the E1 enzyme. Investigating these enzyme structures and
protein interactions is crucial to fully comprehending their function in the ubiquitination
pathway.

The work in this thesis is based on the following hypotheses:
•

The E2 conjugating enzymes HIP2 and Ubc1 dimerize upon formation of E2~Ub
thiolesters. (investigated in Chapter 2)

•

The E1 enzyme does not directly extend a poly-Ub chain on the HIP2~Ub and
Ubc1~Ub thiolesters. (investigated in Chapter 2)

•

Unique intramolecular interactions exist for HIP2~Ub and HIP2~Ub2 thiolesters
that will provide a rationale for poly-Ub assembly. (investigated in Chapter 3 and
4)

These hypotheses were studied through the creation of disulphide complexes to mimic
Ubc1~Ub, HIP2~Ub and HIP2~Ub2 thiolesters. Investigation of these complexes was
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performed using sedimentation equilibrium, small angle X-ray scattering (SAXS), and
activity assays using unlabelled and fluorescently labelled proteins. NMR spectroscopy
chemical shift mapping was utilized to determine protein interactions within HIP2-Ub
and HIP2-Ub2 through isotopic labelling (15N and 13C) of individual proteins within these
complexes. These investigations have led to the clarification of possible mechanisms that
HIP2 and Ubc1 utilize to assemble poly-Ub chains.
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Chapter 2
Determination of the Dimerization Capacity and Enzymatic
Component Requirements for Poly-ubiquitin Chain Assembly
in the E2 Conjugating Enzymes HIP2 and Ubc1

2.1 Introduction
The ubiquitin proteolysis pathway utilizes three enzymes, E1, E2 and E3 to
respectively activate, transfer and ligate ubiquitin (Ub) onto a target protein (Fig 2.1A).
These enzymes work together to build K48-linked poly-Ub chains that are formed on
substrate proteins, targeting them to be degraded by the 26S proteosome.

The

mechanism of Ub-Ub covalent attachment in poly-Ub chain formation remains poorly
understood.
There are various competing hypotheses describing the formation of poly-Ub
chains, and it is possible that different E2 enzymes use different mechanisms to link Ub
molecules (1). The sequential addition model, suggests one ubiquitin at a time is added
to a substrate eventually forming a poly-Ub chain. Other models involve the preassembly
of poly-Ub chains that are then transferred as a block onto a substrate. There is growing
evidence that preassembly of poly-Ub chains may require the dimerization of E2
enzymes to position two Ub molecules to be connected together prior to attachment to
substrate (2-9).
The E2 conjugating enzymes Ubc1 and HIP2 have poly-ubiquitination chain
activity in the absence of E3 enzymes and substrates, and thus these E2 enzymes may
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Figure 2.1 A schematic representation of the ubiquitin proteolysis pathway and a method by
which poly-Ub chains may be constructed. (A) Ubiquitin is attached to a ubiquitin activating
enzyme (E1) through an ATP dependant process that creates a highly reactive thiolester linkage.
The Ub is then transferred to a ubiquitin conjugating enzyme (E2), and through the use of a
ubiquitin ligating enzyme (E3) reacts with a lysine residue on a substrate. Proteins destined for
degradation are labelled with a poly-Ub chain of four or more Ub molecules targeting the
substrate to the 26S proteosome. (B) A model of E2 dimerization driven by interaction between
the E2 enzymes whereby Kd1 defines the dissociation constant of this interaction. (C) A model of
E2~Ub thiolester dimerization driven by interactions between Ub and the E2 enzymes whereby
Kd2 defines the dissociation constant of this interaction. (D) A possible mechanism showing how
poly-Ub chain formation can be performed using an E2 dimer to position Ub molecules
(numbered 1-3) for attachment. Each arrow between Ub molecules represents the K48 side chain
nucleophilic attack to the reactive thiolester of a second Ub. For simplicity these models do not
depict the UBA domain of Ubc1 and HIP2, nor attempt to show the exact interaction surfaces
used in dimerization.

55
function through dimerization (10, 11). If these E2 enzymes do indeed dimerize, they
may do so directly (Fig 2.1B) or dimerize through the creation of the E2~Ub thiolester by
providing the additional interaction surface of Ub to the E2 enzyme (Fig 2.1C).
Determination of the strength of these possible dimeric interactions will aid in
determining the mechanism by which Ubc1 and HIP2 function. One possible mechanism
for the creation of a poly-Ub chain through an E2 dimer involves the placing of the K48
side chain of one Ub in close proximity to the reactive thiolester of a second Ub to allow
a Ub-Ub connection. In this process the chain extends via multiple charging of the E2
enzymes with the building chain transferring onto newly charged E2 enzymes (Fig 2.1D).
The determination of Kd1 and Kd2 in Figure 2.1B and C will indicate the plausibility of
these models for Ubc1 and Hip2 function.

2.2 Materials and Methods
2.2.1 Cloning
Wild-type HIP2 cDNA in a pET28a vector was a generous gift from the
Structural Genomics Consortium (Toronto).

A C170S substitution in HIP2 was

introduced using the Quikchange Site-Directed Mutagenesis (Stratagene, La Jolla, CA)
protocol. The design of forward and reverse complement primers also included base
changes for L169 to convert it from a rare to common E. coli. codon.
Ubiquitin (Ub) and Ubc1 from S. cerevisiae were expressed from a pET3a vector
as described previously (11). Incorporation of substitutions into Ub and Ubc1 were
accomplished by traditional PCR methods or the Quikchange protocol.

Kathryn R.
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Barber incorporated all substitutions in Ub and Ubc1. These substitutions include a
G76C substitution (UbG76C) and/or a K48R substitution (UbK48R) in yeast Ub, and a K93R
substitution in Ubc1 (Ubc1K93R) to inhibit auto-ubiquitination. Human Ub with an Nterminal cysteine tag (GPCLGS) in the pGEX-6P1 GST fusion vector was a kind gift
from Dr. Leo Spyrocopoulos (University of Alberta) and was modified to generate a
K48R version by the Quikchange protocol. All substitutions were confirmed to be
correct by DNA sequencing performed at the London Regional Genomics Centre.

2.2.2 Protein expression and purification of HIP2, Ubc1 and substituted ubiquitins
Various substituted ubiquitins and Ubc1K93R (hence forward just Ubc1) from S.
cerevisiae were over expressed in BL21(DE3)pLysS E. coli strain and purified using a Q
anion exchange column, followed by a Sephadex G75 (GE Healthcare) size exclusion
column as previously described (11).

Electrospray ionization mass spectrometry

confirmed the integrity of Ubc1 (MWobs 24162.4 ± 0.8Da, MWcalc 24162.2). Kathryn R.
Barber purified Ubc1. Protein concentrations of Ubc1 were determined through Bradford
(BioRad) reactions performed in triplicate.

Protein concentrations of Ub were

determined by weight of lyophilized proteins.
Hexahistidine (His6) tagged HIP2C170S (hence forward just HIP2) was
overexpressed in the BL21(DE3)star E. coli strain. The bacteria were grown at 37 °C
overnight in LB media (10 mL) containing the antibiotic kanamycin (30 µg / mL). The
culture was then diluted 1:100 into 1 L of LB containing the same antibiotics and grown
at 37 °C to an A600 between 0.60-0.75. Protein expression was induced for 16-20 hours
with 0.7 mM IPTG at 15 °C. Harvested cells were re-suspended in 20 mM Tris-HCl, 200
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mM NaCl, 1 mM TCEP, 5 mM imidazole at pH 8.0 with the addition of a COMPLETE
mini EDTA-free protease inhibitor cocktail tablet (Roche Diagnostics). Cells were lysed
with a French pressure cell and cellular debris was removed by centrifugation at 95500
xg. All following purification procedures were performed at 4 °C to minimize protein
degradation. The clarified extract containing His6-HIP2 was applied to Ni-NTA Agarose
(Qiagen) and washed with 20 mM Tris-HCl, 200 mM NaCl, 1 mM TCEP, 10 mM
imidazole at pH 8.0 to elute non specifically bound material. His6-HIP2 was eluted with
20 mM Tris-HCl, 200 mM NaCl, 1mM TCEP, 200 mM imidazole pH 8.0. The protein
was concentrated and loaded on to a Superdex 75 10/300 GL column (GE Healthcare) in
20 mM Tris-HCl, 200 mM NaCl, 1mM TCEP, 10 mM imidazole pH 8.0. Thrombin (2
µg / mL) was utilized to cleave the His6 tag at room temperature for two hours and a
subsequent Ni-NTA Agarose column was utilized to remove the tag and any uncut
protein from HIP2. A final Superdex 75 10/300 GL column run in 20 mM Tris-HCl, 200
mM NaCl, 1 mM TCEP pH 8.0 was used to remove residual thrombin from the purified
HIP2 protein. Purification steps were monitored using SDS-PAGE. SDS-PAGE was
performed using 16.5% tris-tricine gels in a mini-gel system (BioRad) and was stained
with Coomassie dye. HIP2 concentrations were determined through Bradford (BioRad)
reactions performed in triplicate.

Purified HIP2 was confirmed using electrospray

ionization mass spectrometry (MWobs 22534.8 ± 0.3Da, MWcalc 22534.7).

2.2.3 Protein expression and purification of NCys-Ub and NCys-UbK48R
Human Ub proteins were modified to contain a cysteine residue in a peptide
extension (GPCLGS) at the N-terminus of both wild type Ub (NCys-Ub) and UbK48R
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(NCys-UbK48R). GST fusion proteins of NCys-Ub and NCys-UbK48R were over expressed in
the BL21(DE3)pLysS E. coli strain. Cell cultures were grown overnight in LB media (10
mL) containing the antibiotic carbenicillin (50 µg / mL). The culture was then diluted
1:100 in LB media containing the same antibiotic and grown at 37 °C to an A600 of 0.60.
Protein expression was induced with 0.5 mM IPTG for 4 hours at 37 °C. Harvested cells
were re-suspended in binding buffer consisting of 25 mM Tris-HCl, 100 mM NaCl, 3
mM DTT at pH 7.5 with the addition of a COMPLETE mini EDTA-free protease
inhibitor cocktail tablet (Roche Diagnostics). Cells were lysed with a French pressure
cell and cellular debris was removed by centrifugation at 95500 xg. The lysate was
purified using a GST affinity column (GE Biosciences), washed with the same binding
buffer and eluted with 25 mM Tris-HCl, 100 mM NaCl, 3 mM DTT, and 20 mM
glutathione. The GST affinity tag was cut using TEV (Shaw lab; 50 µg / mL) and
removal of the GST tag, any uncut protein and the TEV protease was achieved by size
exclusion chromatography on a Sephadex G-75 column (GE Healthcare) with 25 mM
Tris-HCl, 100 mM NaCl, 0.5 mM EDTA pH 7.4. Purification steps were monitored
using SDS-PAGE. SDS-PAGE was performed using 16.5% tris-tricine gels in a mini-gel
system (BioRad) and was stained with Coomassie dye.

NCys-Ub and NCys-UbK48R

concentrations were determined through SDS-PAGE comparison to Ub substitutions.
Purified NCys-Ub and NCys-UbK48R were confirmed using electrospray ionization mass
spectrometry (NCys-UbK48R: MWobs 9107.61 ± 0.42 MWcalc 9107.4; NCys-Ub: MWobs
9079.08 ± 0.94 MWcalc 9079.44).
NCys-Ub and NCys-UbK48R were then reacted with Alexa-Fluor 680 C2-Maleimide
(Invitrogen) to fluorescently label the Ub and UbK48R. The cysteine in NCys-Ub and NCys-
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UbK48R reacts with the C2-maleimide to yield Alexa-Ub and Alexa-UbK48R.

These

reactions were performed by a 10:1 (v/v) mixing of 100 µM NCys-Ub in 100 mM NaCl,
0.5 mM EDTA, 25 mM Tris-HCl pH 7.4 and 5 mM Alexa-Flour in 100% isopropanol
respectively. This reaction was stopped with the addition of 5 mM DTT, and then
purified using a PD-10 desalting column (GE Healthcare) and extensive dialysis with 25
mM Tris-HCl, 100 mM NaCl pH 7.3 was used to remove unreacted Alexa dye. Ub
molecules were confirmed to be labelled with Alexa via electrospray ionization mass
spectrometry (Alexa-UbK48R MWobs 10089.21 ± 0.31 agrees with expected values for
NCys-UbK48R (9107.46 Da) and Alexa dye (~982 Da)); Alexa-Ub MWobs 10061.89 ± 0.40
agrees with expected values for NCys-Ub (9079.44 Da) and Alexa dye (~982 Da)).

2.2.4 E2-Ub disulphide complex formation
Two different versions of disulphide complexes were created for both HIP2 and
Ubc1. UbK48R-G76C (shortened to UbCys) was used for all protein interaction studies while
UbG76C (UbK48Cys) was used for activity assays on disulphide chain extension. Since the
choice of UbCys or UbK48Cys is immaterial to purification, only UbCys shall be described for
simplicity. Solutions of UbCys, Ubc1 or HIP2 (0.1 mM) were fully reduced with 2 mM
TCEP. Ubc1 or HIP2 was combined with an excess of UbCys and dialyzed at 4 °C against
several changes of 100 mM Na2HPO4/NaH2PO4, 100 mM NaCl, 10 µM CuCl2 at pH 7.5.
The progress of the disulphide complex formation was monitored by non-reducing SDSPAGE and was considered complete when Ubc1 or HIP2 was exhausted, usually
requiring 72-96 hours. The completed E2-UbCys reaction also contains the disulphide byproducts UbCys-UbCys and E2-E2 dimers. The protein solution was concentrated and the
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by-products removed by size exclusion chromatography on a Sephadex G-75 column
with 25 mM Tris-HCl, 1 mM EDTA, and 150 mM NaCl (Ubc1-UbCys) or 400 mM NaCl
(HIP2-UbCys), at pH 7.5. Purification steps were monitored using SDS-PAGE. SDSPAGE was performed using 16.5% tris-tricine gels in a mini-gel system (BioRad) and
was stained with Coomassie dye. Ubc1-UbCys and HIP2-UbCys concentrations were
determined through Bradford (BioRad) reactions performed in triplicate. HIP2-UbCys
concentrations for SAXS studies were determined with amino acid analysis (Advanced
Protein Technology Center). Fractions containing pure Ubc1-UbCys or HIP2-UbCys were
pooled and their purity and identity confirmed by mass spectrometry (Ubc1-UbCys MWcalc
32791.1, MWobs 32,794.59 ± 4.0Da; HIP2-UbCys MWobs 31163.2 ± 1.0Da, MWcalc
31163.5).

2.2.5 Analytical ultracentrifugation
Sedimentation equilibrium experiments were performed on a Beckman Optima
XL-A analytical ultracentrifuge capable of UV/VIS wavelength scanning. An An-60 Ti
analytical rotor was used with six-channel equilibrium double sector Epon-charcoal
center pieces, which contain three protein/buffer pairs. Quartz windows were used on the
ends of the 12 mm thick center pieces to allow absorbance values to be collected at either
250 or 280 nm in 0.002 cm radial steps and averaged over 10 readings. Experiments
were performed at 5 °C and at rotor speeds of 15000, 18000, 22000 and 26000 rpm. A
delay of 20 hours (Ubc1, HIP2) or 16 hours (Ubc1-UbCys, HIP2-UbCys) was used to reach
the initial state of equilibrium, and further increases in speed were allowed 8 hours to
reach equilibrium before readings were measured.

At each speed two scans were
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performed two hours apart. These scans were superimposed to confirm that a state of
equilibrium had been properly achieved. Protein sample cells were loaded with 100 µL
protein and reference sample cells were loaded with 110 µL buffer. All protein samples
were dialyzed into their respective buffers (Ubc1 and Ubc1-UbCys: 25 mM Tris-HCl, 1
mM EDTA, 150 mM NaCl at pH 7.5 (plus 2 mM TCEP for Ubc1); and HIP2: 20 mM
Tris-HCl, 200 mM NaCl, 1 mM TCEP at pH 8.0; and HIP2-UbCys: 25 mM Tris-HCl, 400
mM NaCl, 1 mM EDTA at pH 7.5) and diluted with this dialysis buffer to the desired
concentrations. The experiments were performed on Ubc1 and HIP2 with concentrations
of 14.7 µM and 9.6 µM respectively. Three different concentrations were analyzed for
both HIP2-UbCys (7.2, 14.4 and 24 µM) and Ubc1-UbCys (10.8, 21.5 and 43 µM). The
solvent densities were calculated from published tables of buffer components (12) (13).
Partial specific volumes of all proteins were calculated using their amino acid
compositions (14). Data was analyzed using Prism 4 (Graphpad) with two different
models using a global analysis for multiple data sets on an Apple iMac G4 computer.
One analysis involved the single ideal species model defined by equation 1,
Cr = Co exp[(ω2/2RT)Mobs(1-υρ)(r2-ro2)]+Io

(1)

where Cr is the protein concentration at radius r, Co is the concentration at the reference
radius ro, ω is the angular velocity of the rotor, R is the ideal gas constant, T is the
temperature in Kelvin, Mobs is the protein molecular weight, υ is the partial specific
volume of the protein, ρ is the density of the solvent, and Io is the baseline offset. A selfassociating model defined by equation 2 was also used to fit data for a monomer-dimer
equilibrium,
Cr={Coexp[(ω2/2RT)Mp(1-υρ)(r2-ro2)]}+{Co2Kaexp[(ω2/2RT)2Mp(1-υρ)(r2-ro2)]}+Io (2)
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Kd = 1/Ka = [monomer]2 / [dimer]

(3)

where Mp is the mass of the monomer, Ka and Kd are the equilibrium association and
dissociation constants (in absorbance units, AU) defined by equation 3, and all other
terms are identical to equation 1. Kd values were converted from absorbance units to
molarity using the extinction coefficients calculated for each protein from low speed
scans.

2.2.6 Small angle X-ray scattering
Small angle X-ray scattering (SAXS) data was collected on three separate
occasions at BioCAT Beamline ID-18 of the Advanced Photon Source (Argonne, Illinois)
using X-rays with a wavelength of 1.03 Å. The beam centre was determined from silver
behenate powder diffraction, and the sample to detector distance varied from 1892 mm to
2810 mm. Data were recorded on a Brandeis II or Mar165 CCD detector.
The sample chamber consisted of a 1.5 mm diameter quartz capillary mounted in
a brass holder maintained at 10 °C and connected to a syringe pump. Three to ten
exposures (approximately 2 s each) were recorded for each sample and its matched
buffer. During the recording the sample (80 µL volume) was kept moving through the
capillary to limit radiation-induced aggregation. The two dimensional images were
radially integrated using either Fit2D (15) or Igor Pro (Wavemetrics, Lake Oswego,
Oregon), and the individual frames were averaged after removal of outliers. Scattering
from buffer alone was subtracted from the protein-containing samples to yield scattering
from the hydrated protein. Additional data processing was carried out in Microsoft Excel
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and/or the Igor Pro macros developed at BioCAT. The momentum transfer (Q) is defined
as 4πsinθ/λ, where 2θ is the scattering angle.
The buffer conditions used for SAXS data collection are identical to
sedimentation equilibrium studies, except HIP2-UbCys that had a pH change to 8.0. A
second data set for HIP2-UbCys SAXS data was collected in 100 mM phosphate, 400 mM
NaCl, 3 mM EDTA at pH 7.4. The change in buffer conditions had little affect on HIP2UbCys protein scattering.
CRYSOL (16) was used to calculate theoretical scattering from atomic
coordinates and adjust hydration parameters to compare to experimental data.

The

quality of the match of theoretical scattering to experimental scattering is measured with
a goodness of fit value (χ2) that is defined as:
χ2 = 1/N (NΣi=1) [ (Ie(si) – cIc(si))/σ(si) ]2

(4)

where N is the number of data points, s is the magnitude of the scattering vector, c is a
scale factor, Ie is the experimental intensity, Ic is the calculated intensity, and σ is the
experimental error (16).
All figures for SAXS CRYSOL curves were produced using the default input
parameters for CRYSOL curve fitting (16). The PDB files used in CRYSOL analysis
figures were 1TTE (for Ubc1), 1UBQ (for ubiquitin), 1YLA (for HIP2), 1FXT (for the
Ub position in the ‘compact’ thiolester), and 2GMI (for the Ub position in the ‘elongated’
thiolester).
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2.2.7 E2 poly-ubiquitination activity assays
Ubiquitination reactions were performed with purified E2 enzymes, disulphide
complexes and unlabelled Ub proteins.

Several reactions were performed which

contained different combinations of E2 enzymes and Ub proteins. All reactions contain a
subset of the following final protein concentrations: 150 nM E1 enzyme, 4.1 µM HIP2
conjugating enzyme, 2.0 µM HIP2-UbK48Cys thiolester mimic, 4.1 µM Ubc1 conjugating
enzyme, 2.0 µM Ubc1-UbK48Cys thiolester mimic, 11.0 µM Ub, and 10.8 µM UbK48R. All
reactions also had final concentrations of 10 mM Mg-ATP and 50 mM Hepes pH 8.0.
Reaction protein species were visualized using 16.5% tris-tricine gels in a mini-gel
system (BioRad) stained with Coomassie dye. Reactions were carried out for 5 min, 30
min and 1 hour with the HIP2 conjugating enzyme, and 5 min, 2 hours, and 5 hours with
the Ubc1 conjugating enzyme since Ubc1 seems to have a lower poly-ubiquitination
activity. Each reaction was stopped with excess EDTA buffer and then combined with
non-reducing SDS running buffer and heated for 5 min at 95 °C.

2.2.8 HIP2 and Ubc1 activity assays with Alexa labeled Ub
Alexa dye labelled ubiquitination reactions were performed with purified E2
enzymes, disulphide complexes and Alexa fluorescent dye labelled NCys-Ub or NCysUbK48R. Several reactions were performed with different combinations of E2 enzymes
and Ub proteins. All HIP2 enzyme reactions had a subset of the following final protein
concentrations: 225 nM E1 enzyme, 12 µM HIP2 conjugating enzyme, 15.2 µM HIP2UbK48Cys thiolester mimic, 3.9 µM Alexa-UbK48R, and 3.9 µM Alexa-Ub. All Ubc1
reactions had a subset of the following final protein concentrations: 214 nM E1 enzyme,
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12.3 µM Ubc1 conjugating enzyme, 10.5 µM Ubc1-UbK48Cys thiolester mimic, 5.5 µM
Alexa-UbK48R, and 5.5 µM Alexa-Ub.

Both of the above reactions use final

concentrations of 10 mM Mg-ATP and 50 mM Hepes pH 8.0. Reactions were carried out
in a manner similar to previous activity assays except the Ubc1 reaction was performed
for 4 hours, and the HIP2 reaction was performed for 1 hour. Reactions were visualized
using 16.5% tris-tricine gels in a mini-gel system (BioRad) stained with Coomassie dye
or visualized by fluorescence using an Odyssey imaging system (LI-COR).
Additional activity assays were performed utilizing purified E2 thiolesters to
remove E1 from poly-ubiquitination reactions. The Alexa-UbK48R thiolester was formed
with either Ubc1 or HIP2 in a 30 min reaction with final concentrations of 18.3 µM
Alexa-UbK48R, 12.3 µM Ubc1, 214 nM E1 for the Ubc1 thiolester and 16.4 µM AlexaUbK48R, 32.8 µM HIP2, 214 nM E1 for the HIP2 thiolester. This thiolester reaction
mixture was then immediately loaded onto a Sephadex G75 10/300 size exclusion
column to purify the thiolester from unconjugated Alexa-UbK48R and E1 enzyme.
Thiolesters were then concentrated with a 3K Nanosep concentrator (Pall). Purified
thiolesters were then reacted with different mixtures of purified proteins. All Ubc1
thiolester reactions contained a subset of the following final protein concentrations: 500
nM reactive Alexa dye, 90 µM Ub, 90 µM UbK48R, 9.2 µM Ubc1-UbK48Cys. All HIP2
thiolester reactions contained a subset of the following final protein concentrations: 500
nM reactive Alexa dye, 54 µM Ub, 54 µM UbK48R, 6 µM HIP2-UbK48Cys. HIP2 thiolester
reactions proceed for 1 hour at 37 °C, while Ubc1 thiolester reactions proceeded for 5
hours at 37 °C. All of the above reactions used final concentrations of 10 mM Mg-ATP
solution, and 50 mM Hepes at pH 8.0.
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2.3 Results
2.3.1 Expression and purification of HIP2
A C170S substitution was introduced into the E2 enzyme HIP2 to ensure that the active
site C92 was the only cysteine residue available for the future creation of a disulphide
thiolester mimic. Previous studies have shown this C170S substitution does not affect
enzyme activity (17). HIP2C170S (hence forward just HIP2) was overexpressed with an Nterminal hexahistidine (His6) tag and was soluble in BL21(DE3)star E. coli cells when
induced with IPTG (Fig 2.2A).

Purification of His6-HIP2 from E. coli cells was

performed by cell lysis with a French Press, followed by centrifugation to remove cellular
debris. The remaining lysate was then subjected to Ni2+-affinity chromatography that
selectively binds to the N-terminal His6 fusion tag (Fig 2.2B – lane 5). The fusion tag
was removed by the cleavage enzyme thrombin leaving an N-terminal GS extension on
the normally 200 amino acid long HIP2 protein. A second Ni2+-affinity chromatography
purification step was performed on thrombin treated protein leaving only the purified
HIP2 in the flow through fraction (Fig 2.2B - lane 7). Size exclusion purification was
then performed on the pure protein to remove any minor trace proteases and residual
thrombin. Using electrospray ionization mass spectrometry, a single major peak was
observed (MWobs 22534.8 ± 0.3Da) at the expected molecular weight (MWcalc 22534.7)
confirming that the purified HIP2 protein was intact (Fig 2.2C).
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Figure 2.2 Expression and purification of the E2 conjugating enzyme HIP2. The E2 conjugating
enzyme HIP2 was first expressed with a His6 tag. (A) Protein expression testing of His6-HIP2
was performed using 2 mL LB cultures, and analyzed using SDS-PAGE samples on cell cultures.
The Coomassie stained gel shows first uninduced sample (lane 1) followed by IPTG induced cells
showing the expression of His6-HIP2 (lane 2), and finally the soluble fraction of protein was
isolated by lysozyme cell lysis and centrifugation to remove insoluble protein (lane 3). (B)
Purification of His6-HIP2 depicted by Coomassie stained SDS-PAGE gels following procedures
listed in Section 2.2.2. The HIP2 purification gel is loaded from left to right with induced cells
(lane 1), lysate following centrifugation (lane 2), Ni 2+-affinity column flow through (lane 3),
wash (lane 4) and elution (lane 5), HIP2 following thrombin cleavage (lane 6) and flow through
from the second Ni2+ affinity column (lane 7). Molecular weight standards are listed in kDa to
the left of each gel. (C) Electrospray ionization mass spectrometry analysis of purified HIP2
indicates the correct mass.
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2.3.2 Expression and purification of substituted ubiquitins
Specific Ub substitutions are essential for the creation of E2-Ub thiolester mimics
and for use in wild type and blocked poly-Ub chain activity assays with HIP2 and Ubc1.
The Ub molecule carrying a G76C substitution was required for C-terminal disulphide
formation used to make E2 enzyme thiolester mimics while a K48R substitution on Ub
was utilized to block K48-linked poly-Ub chain extension. Wild type Ub and UbK48R
(UbK48R) were purified for use in poly-Ub chain activity assays as functional and blocked
Ub species respectively. UbK48R-G76C (shortened to UbCys) and UbG76C (UbK48Cys) were
used to create blocked and extendable thiolester mimics respectively. All of these Ub
substitutions were purified as previously described (11, 18).

2.3.3 Formation and purification of HIP2-Ub disulphide thiolester mimics
Ubc1 and HIP2 conjugating enzymes function by allowing a highly reactive
thiolester to be formed between their active site cysteine side chain and the C-terminal
carboxylic acid of G76 in ubiquitin.

This thiolester intermediate is susceptible to

hydrolysis at basic pH and thus only lasts a few hours in solution (19). The instability of
the thiolester limits in depth structural studies on these species. Through the use of a Ub
G76C substitution a much more stable thiolester mimic can be created by the formation
of a disulphide bond between the newly added C-terminal cysteine side chain on Ub and
the active site cysteine on the E2 enzyme. This disulphide bond will persist for months
allowing direct study of the E2 intermediate. Previous NMR studies on this disulphide
show that the E2-Ub interactions are nearly identical compared to the activated thiolester,
and thus the E2-Ub disulphide model accurately mimics the E2~Ub thiolester
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intermediate (18). NMR chemical shift index analysis of this disulphide bond has also
shown that the secondary structures of the E2 enzyme and Ub undergo no major changes
upon bond formation (18, 20).
HIP2 disulphide complexes were created for both UbCys that is blocked from K48
poly-Ub chain formation and UbK48Cys that has an available K48 residue for poly-Ub
chain formation. UbCys was used for all protein interaction studies while UbK48Cys was
used for activity assays on disulphide chain extension. UbCys and UbK48Cys are purified
identically so only purification of UbCys shall be described for simplicity. In order to
create the disulphide intermediate, both HIP2 and UbCys are chemically reduced and then
dialyzed into an oxidization buffer over the course of 72-96 hrs promoting the formation
of disulphide bonds (Fig 2.3A). The resulting HIP2-UbCys disulphide was contaminated
with the disulphide by-products of HIP2-HIP2 and UbCys-UbCys dimers as well as
unreacted HIP2.

These unwanted by-products were removed by size exclusion

chromatography yielding pure HIP2-UbCys disulphide (Fig 2.3B). Using electrospray
ionization mass spectrometry, a single major peak was observed (MWobs 31163.2 ±
1.0Da) at the expected molecular weight (MWcalc 31163.5) confirming that the purified
HIP2-UbCys thiolester mimic was the correct mass (Fig 2.3C).

2.3.4 Expression and Purification of Ubc1 and the Ubc1-Ub disulphide
The E2 enzyme Ubc1 is the yeast homolog of HIP2 and was purified as previously
described (11, 18). The Ubc1-UbCys and Ubc1-UbK48Cys disulphides were created and
purified in an identical manner to the HIP2-UbCys and HIP2-UbK48Cys disulphides. An
example SDS-PAGE gel shows a single band demonstrating the extent of purification
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Figure 2.3 Creation and purification of the HIP2-UbCys disulphide. (A) Purified and TCEP
reduced Ub Cys (lane 1) is mixed with purified and TCEP reduced HIP2 (lane 2) and dialyzed into
an oxidation buffer containing 10 µM CuCl2 driving disulphide bond creation to produce HIP2HIP2, HIP2-Ub Cys and Ub Cys-UbCys (lane 3). (B) Protein purification of HIP2-UbCys from other
disulphide byproducts using size exclusion chromatography (Sephadex G-75) depicted by
Coomassie stained SDS-PAGE. A sample set of size exclusion elution fractions are shown
whereby the larger HIP2-HIP2 byproduct elutes first (lane 1-5), followed by overlap of the HIP2UbCys disulphide (lane 1-13), and finally unreacted HIP2 elutes last (lane 10-13). Pure HIP2UbCys fractions (lane 7-8) are combined with other runs to give the final purified HIP2-Ub Cys
disulphide preparation (lane 14). Molecular weight standards are listed in kDa to the left of each
gel. (C) Electrospray ionization mass spectrometry analysis of purified HIP2-Ub Cys indicating the
protein is the correct mass.
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of Ubc1 and Ubc1-UbCys (Fig 2.4A). Using electrospray ionization mass spectrometry, a
single major peak was observed for both Ubc1 and Ubc1-UbCys confirming the correct
mass of the proteins (Ubc1: MWobs 24162.4 ± 0.8Da, MWcalc 24162.2; Ubc1-UbCys
MWcalc 32791.1, MWobs 32794.59 ± 4.0Da).

2.3.5 Expression and purification of N-terminal cysteine tagged ubiquitin
The sensitivity of activity assays was improved through the use of Alexa-Fluor 680 C2maleimide fluorescent dye to label Ub proteins.

The fluorescent Alexa dye was

covalently bound to Ub molecules containing a cysteine residue in an N-terminal peptide
extension (GPCLGS) on Ub (NCys-Ub) and UbK48R (NCys-UbK48R). The GST fusion
proteins GST-NCys-Ub and GST-NCys-UbK48R were overexpressed and soluble in E. coli
BL21(DE3)pLysS cells when induced with IPTG. Purification of these GST fusion
proteins from E. coli cells was performed by cell lysis with a French Press, followed by
centrifugation to remove cellular debris. The remaining lysate was subjected to GSTaffinity chromatography that selectively binds to the N-terminal GST-fusion tag leaving
mostly purified protein (Fig 2.4B - lane 4). The GST fusion tag was cut off by the
cleavage enzyme TEV (50 µg / mL) and removal of the GST-fusion tag, any uncut
protein, and the TEV enzyme was accomplished with size exclusion chromatography
leaving purified NCys-Ub or NCys-UbK48R (Fig 2.4B - lane 6).

Using electrospray

ionization mass spectrometry, a single major peak was observed at the expected
molecular weights confirming that the purified NCys-Ub and NCys-UbK48R proteins were
the correct mass (NCys-UbK48R: MWobs 9107.61 ± 0.42, MWcalc 9107.4; NCys-Ub: MWobs
9079.08 ± 0.94, MWcalc 9079.44). These N-terminally cysteine tagged ubiquitins are then
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Figure 2.4 Purity check of Ubc1 and Ubc1-UbCys, and purification of NCys-Ub. (A) SDS-PAGE
gels run on purified samples of Ubc1 (lane 1 and with DTT lane 2) and Ubc1-UbCys (lane 3) show
proteins to be relatively pure for further studies. (B) Protein purification GST-NCys-Ub depicted
by Coomassie stained SDS-PAGE shows centrifuged cell lysate of overexpressed GST-NCys-Ub
(lane 1) followed by GST affinity chromatography flow through (lane 2), wash (lane 3), and
elution with 20mM Glutathione (lane 4). The GST is then removed by addition of the cleavage
enzyme TEV (lane 5) and finally a size exclusion column (Sephadex G-75) is used to purify NCysUb (lane 6) from uncut protein and freed GST fusion tag. Molecular weight standards are listed
in kDa to the left of each gel, and protein species are listed to the right of each gel.
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reacted with Alexa-Fluor 680 C2-maleimide to yield Alexa-NCys-Ub (Alexa-Ub) and
Alexa-NCys-UbK48R (Alexa-UbK48R). Purification of Alexa-Ub and Alexa-UbK48R was
performed using desalting columns and extensive dialysis to remove unreacted Alexa
dye.

The identity of Alexa-Ub and Alexa-UbK48R were confirmed by electrospray

ionization mass spectrometry (Alexa-UbK48R MWobs 10089.21 ± 0.31 agrees with
expected values for NCys-UbK48R (9107.46 Da) and Alexa dye (~982 Da)); Alexa-Ub
MWobs 10061.89 ± 0.40 agrees with expected values for NCys-Ub (9079.44 Da) and Alexa
dye (~982 Da)).

2.3.6 HIP2 and Ubc1 can build poly-Ub chains on their E2-UbK48Cys disulphides
The best example of an E2~Ub thiolester interacting with another E2~Ub
thiolester involves the Ube2g2 (Ubc7) E2 enzyme. In this example, poly-Ub chains form
on the E2 active site presumably assisted by dimerization (2, 3). A similar approach was
used to test the dimerization capacity of Ubc1 and HIP2 by testing the possible reaction
of an E2~Ub thiolester with an E2-Ub disulphide. This reaction was accomplished using
two specific Ub substitutions, UbK48Cys and UbK48R (Fig 2.5A/2.6A). UbK48Cys containing
a reactive K48 residue was used as the ubiquitin acceptor, while UbK48R, which is blocked
from K48 chain extension, was used as the ubiquitin donor. A reaction containing ATP,
UbK48R, E1, and either E2 enzyme was used to create the E2~UbK48R thiolester that is
unable to build poly-Ub chains on its own. The E2~UbK48R thiolester can however, act as
a ubiquitin donor. The E2-UbK48Cys disulphide was formed to incorporate an available
K48 residue on the attached Ub, and therefore act as the acceptor in poly-Ub chain

Figure 2.5 HIP2 activity gels showing Ub transfer from the HIP2~UbK48R thiolester onto the HIP2-UbK48Cys disulphide. (A) Reaction of the
HIP2-UbK48Cys disulphide and the HIP2~UbK48R thiolester to produce HIP2-UbK48Cys-UbK48R (HIP2-Ub2). The use of UbK48R or Alexa-UbK48R
result in similar products. (B) HIP2 enzyme reactions contain a subset of the following: 150 nM E1, 4.1 µM HIP2, 2.0 µM HIP2-UbK48Cys
disulphide, 11.0 µM Ub (wild type), 10.8 µM UbK48R, 10 mM Mg-ATP solution, in 50 mM Hepes pH 8.0. (C) Reactions from (B) repeated with
Alexa-Ub and Alexa-UbK48R and visualized with Coomassie (top gel) or 700 nm fluorescence (bottom gel). Each reaction contains a subset of
the following: 225 nM E1, 12 µM HIP2, 15.2 µM HIP2-UbK48Cys disulphide, 3.85 µM Alexa-Ub, 3.85 µM Alexa-UbK48R, 10 mM Mg-ATP
solution, in 50 mM Hepes pH 8.0. Reaction components are listed above each gel with a (+) or (-). Reactions were performed for 1 hr at 37 °C,
and reducing agent is only added to lane 9 (10 mM DTT and 10 mM TCEP) to break the disulphide. Ub-Ub attachments are indicated by the
filled black/yellow circles. Molecular weight standards and protein species are listed to the left and right of each gel respectively.
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Figure 2.6 Ubc1 activity gels showing Ub transfer from the Ubc1~UbK48R thiolester onto the Ubc1-UbK48Cys disulphide. (A) Reaction of Ubc1UbK48Cys disulphide and the Ubc1~UbK48R thiolester to produce Ubc1-UbK48Cys-UbK48R (Ubc1-Ub2). The use of UbK48R or Alexa-UbK48R result in
similar products. (B) Ubc1 enzyme reactions containing a subset of the following purified proteins: 150 nM E1, 4.1 µM Ubc1, 2.0 µM Ubc1UbK48Cys disulphide, 11.0 µM Ub (wild type), 10.8 µM UbK48R, 10 mM Mg-ATP, in 50 mM Hepes pH 8.0. (C) Reactions from (B) repeated with
Alexa-Ub and Alexa-UbK48R and visualized with Coomassie (top gel) or 700 nm fluorescence (bottom gel). Reactions contain a subset of: 214
nM E1, 12.3 µM Ubc1, 10.5 µM Ubc1-UbK48Cys disulphide, 5.5 µM Alexa-Ub, 5.5 µM Alexa-UbK48R, 10 mM Mg-ATP, in 50 mM Hepes pH
8.0. Reaction components are listed above each gel with a (+) or (-). Reactions were performed for (B) 5 hrs and (C) 4 hrs at 37 °C, and
reducing agent is only added to lane 9 (10 mM DTT and 10 mM TCEP) to break the disulphide. Ub-Ub attachments are indicated by the filled
black/yellow circles. Molecular weight standards and protein species are listed to the left and right of each gel respectively.
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extension. Therefore, a mixture of E2~UbK48R and E2-UbK48Cys will only be able to form
one possible poly-Ub chain resulting from the transfer of UbK48R to E2-UbK48Cys to form
E2-UbK48Cys-UbK48R. This reaction is predicated on the proposal that the E2~UbK48R
thiolester and E2-UbK48Cys thiolester mimic can indeed interact to allow a Ub-Ub
connection to occur representing the basis for poly-Ub chain formation (Fig 2.5A/2.6A).
Several reactions were carried out with identical controls using purified HIP2 and
HIP2-UbK48Cys (Fig 2.5B) as well as Ubc1 and Ubc1-UbK48Cys (Fig 2.6B). HIP2 and
Ubc1 contain minute traces of the oxidized disulphide E2-E2 dimer, but these trace high
MW bands will have no bearing on any observed products as their active sites are joined
together and are therefore unreactive (Fig 2.5B/2.6B – lane 1). A standard ubiquitination
reaction with the presence of E1, ATP, Ub, and either E2 yields a clearly visible
HIP2~Ub or Ubc1~Ub thiolester as well as formation of free Ub2 species thus showing
the enzymes Ubc1 and HIP2 are active (Fig 2.5B/2.6B – lane 5). In the case of HIP2,
higher molecular weight poly-Ub unanchored chains are visible since HIP2 has a high
activity for unanchored chain formation (10). UbK48R was used with E1, E2 and ATP to
form the E2~UbK48R thiolester, and the lack of Ub2 formation proves HIP2 and Ubc1
poly-Ub activity is K48 specific (Fig 2.5B/2.6B – lane 6). When either E2-UbK48Cys
disulphide was mixed with E1, Ub and ATP, no reaction was seen to occur for both HIP2
and Ubc1 (Fig 2.5B/2.6B – lane 7). This indicates that a reactive active site on these E2
enzymes is essential for their poly-Ub activity, and that the E1~Ub thiolester cannot
directly react with either the HIP2-UbK48Cys or Ubc1-UbK48Cys disulphide. In the next
reaction the E2-UbK48Cys disulphide is combined with all of the components used to form
the E2~UbK48R thiolester, and a larger molecular weight band forms that corresponds to a
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E2-Ub2 for both HIP2 and Ubc1 (Fig 2.5B/2.6B – lane 8). The apparent E2-Ub2 was
produced only with addition of the E2-UbK48Cys disulphide as the same components used
previously did not produce this species with either HIP2 or Ubc1 (Fig 2.5B/2.6B – lane 6
vs lane 8). This reaction therefore represents the nucleophilic attack of the K48 residue
in the E2-UbK48Cys disulphide to the E2~UbK48R thiolester to allow formation of E2UbK48Cys-UbK48R (E2-Ub2). This reaction product accumulates for both HIP2 and Ubc1 as
the distal Ub is now blocked from further reactions by the K48R substitution (solid black
dot on Fig 2.5B/2.6B – lane 8). Addition of reducing agent leads to reduction of the
disulphide separating the HIP2 or Ubc1 E2 enzyme and Ub2 proving the product is E2Ub2 (solid black dot in Fig 2.5B/2.6B – lane 9).
These activity assays were repeated using Alexa fluorophore (680 nm) tagged
forms of Ub (Alexa-Ub) and UbK48R (Alexa-UbK48R) and the use of the untagged E2UbK48Cys complex for both HIP2 and Ubc1. In this way, the donor Ub protein is provided
by E2~Alexa-Ub and E2~Alexa-UbK48R thiolesters that can be independently tracked by
fluorescence imaging. Reactions using Alexa labelled proteins can be visualized through
standard Coomassie dye staining (Fig 2.5C/2.6C – top gel) or the Alexa label can be
directly observed through fluorescence (Fig 2.5C/2.6C – bottom gel). These reactions
distinctly show the formation of E2-UbK48Cys-Alexa-UbK48R (E2-Ub2-Alexa) and
reduction of this disulphide separates E2 and UbK48Cys-Alexa-UbK48R (Ub2-Alexa). The
reaction of the E2~Alexa-UbK48R thiolester with the E2-UbK48Cys disulphide shows that
these two molecules can indeed interact to place the K48 sidechain of the disulphide in
reactive distance to the thiolester bond to create a Ub-Ub connection (Fig 2.5C/2.6C –
lane 8, 9).
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These activity assays show that the thiolester mimic and active thiolester can
associate and react to form an E2 attached Ub2 molecule. These results may be consistent
with a dimerization mechanism for the observed poly-Ub chain formation activity of
HIP2 and Ubc1. Further studies to investigate direct dimerization of the Ubc1 and HIP2
enzymes and their HIP2-Ub and Ubc1-Ub thiolester mimics were performed.

2.3.7 HIP2, Ubc1, HIP2-UbCys and Ubc1-UbCys show minimal tendency to dimerize
at low concentrations
Sedimentation equilibrium was utilized to assess the propensity of the E2
enzymes Ubc1 and HIP2 to dimerize. This technique is ideal for acquiring accurate
molecular weights in solution since it is not dependant on protein standards. Molecular
weights determined by sedimentation equilibrium are also not affected by protein shape,
which is important as Ubc1 and HIP2 are expected to be elongated proteins (21).
Sedimentation equilibrium experiments were performed at four different rotor speeds on
14.7 µM Ubc1 and 9.6 µM HIP2. Global fits using all rotor speeds were first performed
for an ideal monomeric species model. The global fit for the HIP2 enzyme to an ideal
monomeric species yielded a mass of 23441 ± 136 Da that was within 4% of the expected
monomeric mass of 22534.7 Da (Table 2.1). A representative solution curve of the
global fit to an ideal monomeric species is shown for HIP2 at 22000 rpm (Fig 2.7A).
Similar results were acquired upon analysis of the Ubc1 enzyme whereby the
experimental weight yielded a mass of 24464 ± 107 Da that agrees within 1.3% of the
expected monomeric mass of 24162.2 Da (Table 2.1). A representative solution curve of
the global fit to an ideal monomeric species is shown for Ubc1 at 26000 rpm (Fig 2.7C).
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Table 2.1 Observed molecular weight of E2 enzymes and their thiolester mimics by
sedimentation equilibrium
Proteina

Concentration (µM)

MWCalc (Da)

MWObsb (Da)

Kdc (µM)

Ubc1

14.7

24162.2

24464 ± 107

1920 ± 658

Ubc1-UbCys

43.0

32791.1

31347 ± 222

N/A

Ubc1-UbCys

21.5

32791.1

32536 ± 212

N/A

Ubc1-UbCys

14.3

32791.1

35238 ± 265

376 ± 55

HIP2

9.6

22534.7

23441 ± 136

455 ± 74

HIP2-UbCys

24.0

31163.5

34619 ± 175

266 ± 16

HIP2-UbCys

14.4

31163.5

34220 ± 169

214 ± 14

HIP2-UbCys

7.2

31163.5

34461 ± 219

105 ± 9

a

Hip2 and Ubc1 were analyzed at 280 nm, while Ubc1-Ub Cys and HIP2-UbCys were
analyzed at 250nm to allow for higher protein concentrations.
b
Molecular weight determined using global fits of 15k, 18k, 22k and 26k rpm to a
single species model
c
Kd values for self-association determined using global fits of 15k, 18k, 22k and
26k rpm to a self association model with molecular weights fixed to the expected
monomeric weight

Figure 2.5 HIP2 activity gels showing Ub transfer from the HIP2~UbK48R thiolester onto the HIP2-UbK48Cys disulphide.
Figure 2.6 Ubc1 activity gels showing Ub transfer from the Ubc1~UbK48R thiolester onto the Ubc1-UbK 48Cys disulphide.
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Figure 2.7 Sedimentation equilibrium analysis indicates both HIP2 and Ubc1, and their HIP2UbCys and Ubc1-UbCys disulphides do not significantly dimerize. Sedimentation equilibrium was
performed on each sample at four different rotor speeds (15k, 18k, 22k, and 26k rpm) at 5 °C to
determine their solution based molecular weight. Experimental data was globally fit from
triplicate measurements at each rotor speed to a single species model. A representative data set
(open circles) is graphed with the globally fit line (solid line) for (A) 9.6 µM Hip2 at 22k rpm,
(B) 24 µM HIP2-Ub Cys at 22k rpm, (C) 14.7 µM Ubc1 at 26k rpm, and (D) 21.5 µM Ubc1-Ub Cys
at 26k rpm. Residuals of the data points to the fit line (filled diamonds) are shown above each
curve fit. The expected curve for the monomer (dotted line) and dimer (dashed line) species for
HIP2-UbCys and Ubc1-UbCys are also plotted using fixed molecular weights and the same baseline
offset as was used in that window for the global fits.
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Experimental data points compared to the globally fit curves for both proteins showed a
random spread of the residual errors, indicating that the single species model was
appropriate (Fig 2.7A,C). The observed molecular weights for Ubc1 and HIP2 are within
the accuracy of this technique, which is around 5% (Biomolecular Interactions and
Conformations Facility – UWO – personal communication).
Assuming that the 1.3% and 4% increase in molecular weights observed for Ubc1
and HIP2 respectively, were the result of dimerization, this data was fit to a selfassociation model.

The global fit for HIP2 to a self-associating model yielded a

dimerization Kd of 455 ± 74 µM (Table 2.1). The global fit for Ubc1 to a self-associating
model yielded a dimerization Kd of 1920 ± 658 µM (Table 2.1). The quality of the fits
and spread of residuals in the self-associating model fits are of equal quality to those
observed with a single species model, and therefore the simplified equation for the single
species solution is preferred to the self-associating solution. Since the experimental
protein concentrations of Ubc1 and HIP2 are significantly lower than the determined Kd
values, and since calculated molecular weights are within the accuracy range for a
monomeric species, these Kd values are for illustrative purposes and any minute selfassociation cannot be accurately determined without the use of higher protein
concentrations. Overall these Kd values are extremely weak and molecular weights are
very close to the expected monomeric species showing these enzymes have minimal
tendency to dimerize at low concentrations.
Sedimentation equilibrium experiments on HIP2-UbCys and Ubc1-UbCys
disulphides were performed in a similar manner to the isolated E2 enzymes. Three
different concentrations of the protein complexes were used to determine any possible
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concentration dependence that might arise due to oligomerization. Global fits were
performed for an ideal monomeric species model using all rotor speeds for each protein
concentration. Experiments on HIP2-UbCys at concentrations of 7.2, 14.4 and 24 µM
yielded masses of 34461 ± 219, 34220 ± 169 and 34619 ± 175 Da respectively (Table
2.1). These masses are 10.6% (7.2 µM), 9.8% (14.4 µM) and 11.1% (24 µM) larger than
the expected monomeric mass of 31163.5 Da. These results are beyond the expected
error rate of 5%. This overestimation of molecular weight could be consistent with weak
dimerization of HIP2-UbCys, however, molecular weight would then be expected to
increase as concentration was elevated from 7.2 µM to 24 µM, and no such increase was
observed (Table 2.1).

A representative solution curve of the global fit to an ideal

monomeric species is shown for 24µM HIP2-UbCys at 22000 rpm (Fig 2.7B). A random
spread of residual errors from the data showed that the single species equation used to
analyze the data was acceptable even though molecular weight was larger than expected
(Fig 2.7B).
By fitting the data to a self-association model, the dimerization capacity of HIP2UbCys can be measured, although use of this model did not improve the quality of fits or
residuals. The global fit for all speeds of HIP2-UbCys to a self-associating model yielded
Kd values of 105 ± 9, 214 ± 14, and 266 ± 16 µM for concentrations of 7.2, 14.4, and
24.0 µM HIP2-UbCys respectively (Table 2.1). These dimerization Kd values for HIP2UbCys vary widely from 7.2 to 24.0 µM and since the concentrations are much less than
the observed dissociation constants, these Kd values are not reliable.

These results

illustrate that the dimerization Kd of HIP2 is at best in the order of 100’s of µM.
Although the observed molecular weights for HIP2-UbCys are slightly higher than
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expected, they are relatively consistent while protein concentration is increased indicating
it is highly likely that the true Kd for HIP2-UbCys dimerization is significantly higher than
the range of 105-266 µM.
Similar experiments were performed on the Ubc1-UbCys disulphide with four rotor
speeds and three different concentrations of 14.3, 21.5 and 43 µM. Global fits were
performed for all speeds at each protein concentration and the data was fit to a single
species model. Experiments on Ubc1-UbCys at concentrations of 14.3, 21.5 and 43.0 µM
yielded masses of 35238 ± 265, 32536 ± 212 and 31347 ± 222 Da respectively (Table
2.1). These masses are 4.4% (43.0 µM), and 1.8% (21.5 µM) lower than the expected
monomeric mass, and 7.5% (14.3 µM) larger than the expected monomeric mass of
31163.5 Da respectively. Only one of these measurements is beyond the expected error
rate of 5%. If molecular weights were affected by dimerization of Ubc1-UbCys, then
these values would be expected to increase as concentration was elevated from 14.3 µM
to 43.0 µM, but the opposite was observed (Table 2.1). A representative solution curve
of the global fit to an ideal monomeric species is shown for 21.5 µM Ubc1-UbCys at
26000 rpm (Fig 2.7D). A random spread of residual errors from the data showed that the
single species equation used to analyze the data was appropriate (Fig 2.7D).
By fitting the data to a self-association model, the dimerization capacity of Ubc1UbCys was measured, although use of this model did not improve the quality of fits or
residuals. The global fit for all speeds of Ubc1-UbCys to a self associating model yielded
Kd values that are negative (non-existent) for 21.5 and 43.0 µM experiments, and 376 ±
55 µM for 14.3 µM Ubc1-UbCys (Table 2.1). Since the molecular weights apparently
reduced upon concentration increase, the Kd value for Ubc1-UbCys is not accurate. These
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results indicate Ubc1-UbCys does not appear to dimerize to any degree at the
concentrations tested, and thus higher concentrations need to be analyzed to determine if
there is any significant dimerization of this protein.
The sedimentation equilibrium results provide strong evidence that the propensity
for HIP2, Ubc1, and their disulphide thiolester mimics to dimerize at the concentrations
tested is extremely low, as this technique has shown the observed molecular weights
closely agree with the expected molecular weights.

2.3.8 HIP2, Ubc1, HIP2-UbCys and Ubc1-UbCys show minimal tendency to dimerize
at high concentrations
In order to provide greater detail about the degree of association, size, and shape
of the E2 enzymes and their disulphide complexes, small angle X-ray scattering (SAXS)
experiments were performed.

SAXS is a method that is used to investigate low-

resolution structural details of proteins at high concentrations in solution. The increased
concentration range for the study of HIP2 and Ubc1 should be complementary to the
sedimentation equilibrium analysis. SAXS experiments can be used to determine the
radius of gyration (Rg) for a protein, which is the root mean square of the distances of all
electrons from their common center of mass, and the forward scattering (Io), which is
proportional to the molecular weight (MW) of the protein. The Rg and MW values are
acquired using the low angle region of the scattering curves that when plotted using
Guinier plots are linear near the axis. Guinier plots were produced for HIP2, HIP2-UbCys,
Ubc1 and Ubc1-UbCys for five protein concentrations ranging from 36-284 µM, 44-218
µM, 29-235 µM, and 24-197 µM respectively. These Guinier plots display excellent

85
linear relationships indicating these proteins behave in a monodisperse fashion in solution
(Fig 2.8). Large protein aggregates would cause a significant upwards inflection in the
Guinier plots near the y-axis and since these effects are not observed, the proteins tested
were considered well behaved.
The Rg and apparent MW values were calculated for each protein in a dilution
series to determine the variation of these values in regards to protein concentration. If
self-association of any of these proteins occurs as protein concentration increases, than
significant increases in Rg and apparent MW values will also be observed. The Rg for
HIP2 increases from 20.9 to 22.4 Å as protein concentration is increased from 36 to 284
µM (Fig 2.9A – open triangles). The Rg for Ubc1 was found to be slowly increasing
from 23.1 to 24.3 Å over a protein concentration range of 29-235 µM (Fig 2.9B – open
circles). The increase in Rg values for HIP2 and Ubc1 are very small, indicating a
relatively stable protein shape in solution for both HIP2 and Ubc1 over a relatively large
increase in protein concentrations.

These results provide minimal support for a

significant self-association of HIP2 and Ubc1.

Comparison of Rg values to high-

resolution structures will be reported later in this chapter (Section 2.3.9 and 2.3.10).
SAXS data was also used to calculate the apparent MW of HIP2 and Ubc1 using a known
concentration of a cytochrome C standard. The apparent MW of HIP2 was observed to
increase from 24.3 to 27.8 kDa (Fig 2.9C – open triangles), which was 8% to 23.5%
higher than the expected MW of 22.5 kDa. The apparent MW of Ubc1 ranges from 27.8
to 30.5 kDa over the concentration range of 29-235 µM (Fig 2.9D – open circles). These
MW values are 14.9% to 26% higher than the expected monomeric weight of 24.2 kDa
for Ubc1. SAXS can determine MWs within an accuracy of 10% (22), but small errors in
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Figure 2.8 SAXS data displayed using Guinier plots for HIP2, HIP2-Ub Cys, Ubc1 and Ubc1UbCys at various concentrations. Data is presented for five concentrations of each protein
whereby the top curve (solid line) is the most concentrated sample followed by successive
dilutions for lower curves (solid lines) whereby all data is normalized to the top concentration.
Data was collected for (A) HIP2 at 284, 213, 142, 71.0 and 35.5 µM (B) HIP2-UbCys at 218, 175,
131, 87.3 and 43.6 µM (C) Ubc1 at 235, 176, 118, 58.8, and 29.4 µM (D) Ubc1-Ub Cys at 197,
148, 98.7, 49.3 and 24.6 µM. Similar angular ranges are used to calculate the linear region (open
circles) for each data set allowing for a good comparison between experiments. Each data set
was fit over the linear region (thick straight line) to determine the forward scattering (Io) and
radius of gyration (Rg) at each concentration.
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Figure 2.9 Radius of gyration and apparent MW data displayed for HIP2, HIP2-Ub Cys, Ubc1 and
Ubc1-UbCys at various concentrations. (A) and (C) show data points for the proteins HIP2 (open
triangles) and HIP2-UbCys (filled triangles) at five different concentrations of 284, 213, 142, 71.0
and 35.5 µM HIP2 and 218, 175, 131, 87.3 and 43.6 µM HIP2-UbCys. (B) and (D) show data
points for the proteins Ubc1 (open circles) and Ubc1-UbCys (filled circles) at five different
concentrations of 235, 176, 118, 58.8, and 29.4 µM Ubc1 and 197, 148, 98.7, 49.3 and 24.6 µM
Ubc1-UbCys. The expected molecular weight for HIP2 and Ubc1 (dashed line) as well as HIP2UbCys and Ubc1-Ub Cys (dotted line) are displayed on the apparent MW graphs. There are various
expected radius of gyration values depending on positioning of the UBA tail domain and the
position of attached Ub in relation to the catalytic core for these E2 enzymes and thus no one
value is displayed for an expected radius of gyration for each protein. (E) and (F) show the
theoretical binding curves for dimerization of HIP2-UbCys and Ubc1-UbCys respectively whereby
the Kd is listed to the right of the line in µM.
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protein concentrations of either sample or standards will affect the accuracy of the
apparent MWs reported. Since this experiment was performed with a series of dilutions,
the trend of MW change over the change in protein concentration is more accurate than
the absolute value of any single MW measurement. The apparent MWs undergo minimal
change (11.1% for Ubc1 and 15.5% for HIP2) as concentration is increased significantly,
thus indicating HIP2 and Ubc1 are undergoing minimal dimerization as detailed by this
technique up to concentrations of 284 and 235 µM respectively. If these apparent MW
trends are plotted against a series of theoretical curves defined by a Kd of 10, 100, 1000
and 10000 µM, the trend in MW change is consistent with a Kd of at least 1000 µM. The
trends in apparent molecular weight and Rg appear relatively stable across the large
concentration range tested, it is therefore very likely that these E2 enzymes do not
dimerize in solution with a Kd lower than 1000 µM (1 mM).
The Rg and apparent MW values were also calculated for HIP2-UbCys and Ubc1UbCys to determine if these proteins had an increased capacity for dimerization. The Rg
for HIP2-UbCys increases from 24.7 to 26.3 Å as protein concentration is increased from
44 to 218 µM (Fig 2.9A – filled triangles). The Rg for Ubc1-UbCys slowly increases from
26.5 to 29.5 Å over a protein concentration range of 25-197 µM (Fig 2.9B – filled
circles). The change in Rg values for HIP2-UbCys (1.6 Å) and Ubc1-UbCys (3 Å) is larger
than was observed for HIP2 (1.5 Å) and Ubc1 (1.2 Å) alone over similar concentration
increases. Although the increase in Rg values is more prominent for the disulphide
complexes, the increase is still small thus providing only weak support for increased selfassociation of these proteins. SAXS data was also used to calculate the apparent MW of
HIP2-UbCys and Ubc1-UbCys. The apparent MW of HIP2-UbCys was observed to vary

89
between 29.1 to 35.8 kDa as concentration was varied between 44 and 218 µM (Fig 2.9C
– filled triangles). These MWs ranged from 6.6% smaller to 14.9% larger than the
expected MW of 31.2 kDa, but there was no overall trend in the MW changes as
concentration was increased. The apparent MW of Ubc1-UbCys increased from 31.8 to
40.4 kDa over the concentration range of 25-197 µM (Fig 2.9D – filled circles). The
highest MW value for Ubc1-UbCys was 23% higher than the expected monomeric weight
of 32.8 kDa. The apparent MW of Ubc1-UbCys also increased as protein concentrations
were increased, which could indicate minimal dimerization. There are not enough data
points from these results to accurately produce a curve to determine the Kd of
dimerization for either HIP2-UbCys or Ubc1-UbCys. A series of theoretical curves defined
by a Kd of 10, 100, 1000 and 10000 µM, however, can be used on a comparative basis to
find an appropriate range for Kd values that are consistent with the experimental data
points for HIP2-UbCys and Ubc1-UbCys (Fig 2.9E, F). The trend in MW change for both
HIP2-UbCys and Ubc1-UbCys is consistent with a Kd of dimerization of at least 1000 µM.
The overall trends of increasing values for Rg and apparent MW for both HIP2
and Ubc1 is consistent with an extremely weak dimerization of these enzymes. The
addition of Ub in HIP2-UbCys and Ubc1-UbCys appears to increase the dimerization
capacity of these enzymes. The dimerization capacity of HIP2, HIP2-UbCys, Ubc1, and
Ubc1-UbCys however, is on the whole very weak, as the dimerization Kd values were
found to be >1000 µM. Since the concentrations tested in SAXS are far below 1000 µM,
the reported Kd values are not accurate, but still indicate that HIP2, Ubc1, HIP2-UbCys,
and Ubc1-UbCys proteins are predominantly monomeric in solution during these
experiments.
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2.3.9 HIP2 and Ubc1 SAXS data comparison to high-resolution structures
SAXS is a method that is used to investigate low-resolution structural details of
proteins at high concentrations in solution.

The overall shape of proteins can be

determined through analysis of the radius of gyration (Rg) for a protein acquired from the
low angle regions of SAXS.

Analysis of the full scattering curves in SAXS were

performed using the program CRYSOL (16) that allows experimental scattering curves to
be compared to the theoretical scattering curves calculated from high-resolution structural
PDB coordinates. In this way NMR and X-ray crystallographic structures of HIP2,
HIP2-UbCys, Ubc1, and Ubc1-UbCys can be directly tested against the experimental data.
If the proteins are predominantly monomeric, the experimental data should allow a
quality fit to the experimental data.
Ubc1 is an elongated, two-domain protein possessing a 15-residue flexible linker that
separates the catalytic core and UBA domains, thus allowing a variety of spatial
arrangements between the UBA and the catalytic core (21). In order to sample unique
UBA domain positions with respect to the core domain, 13 of the 21 lowest energy Ubc1
NMR structures (PDB: 1TTE) (21) that vary the UBA domain position were analyzed.
These Ubc1 structures were analyzed by CRYSOL (16) to give theoretical scattering
curves that could be fit to the experimental data. The most important region in these
scattering curve fits are at low scattering angles (low q values), which are most closely
related to the overall averaged shape of the molecule. The quality of the fits of these
various Ubc1 structures to the experimental data was assessed by the goodness of fit
value (χ2) defined by Equation 4 (Section 2.2.6). The representative data set (118 µM
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Ubc1) was best fit to a Ubc1 structure that oriented the UBA domain directly opposite the
N-terminus and close to helix 4 of the catalytic core (Fig 2.10A). Structures where the
UBA domain was moved away from this position yet retained a similar Rg (Fig 2.10B) or
the UBA domain was extended further away from the catalytic core (Fig 2.10C) result in
poorer fits. Similar results were obtained on all other concentrations of Ubc1 fit to these
various structures. For all Ubc1 structures analyzed, the best fits were consistently
acquired from models where the UBA domain is not fully extended away from, nor
tightly associated with the catalytic core. This general UBA domain positioning is best
fit by Figure 2.10A, and thus this structure likely represents the average UBA position for
Ubc1 in solution. The CRYSOL calculated Rg for the best fit Ubc1 structure is 24.95 Å.
SAXS Guinier plot analysis of Ubc1 reveals the experimental Rg to be 23.1 Å to 24.3 Å
over a protein concentration range of 29-235 µM (Table 2.2). These experimental Rg
values are at most 7.4% lower than the expected value of 24.95 Å showing good
agreement to the best fit Ubc1 structure (Fig 2.10A). The best fit structure of Ubc1 is
therefore supported by both high quality fits to the full scattering curves and close
agreement to experimental Rg values. The fact that this monomeric model can be well fit
to the data also supports the notion that Ubc1 is predominantly monomeric at the
concentrations examined, providing further support for very weak (>1000 µM) Kd values.
Unlike Ubc1, wild type HIP2 was initially solved as a dimer (PDB: 1YLA) by Xray crystallography. Recently, two more X-ray crystallography structures of wild type
HIP2 were solved as monomers (PDB: 2BEP, 3K9P) (23, 24). These structures were
backbone residue aligned to the catalytic core (1-155) of 1YLA giving RMSD
measurements of 0.53 Å and 1.09 Å respectively. These results indicate these structures

Figure 2.10 CRYSOL analysis allows SAXS data to be compared to high-resolution structures of Ubc1. SAXS data is presented for Ubc1 (118
µM), where the momentum transfer (q) is plotted versus the normalized log of scattering intensity (measured in arbitrary units). Experimental
data points are shown in black (filled triangles) and the theoretical scattering of the PDB structure is shown in red (solid line). The structure
used for theoretical scattering is located directly above the scattering curve. Three representative structures were selected, (A) Ubc1 NMR
structure 18 (cyan) (χ2 of 2.20, Rg of 24.95 Å), (B) Ubc1 NMR structure 17 (purple) (χ2 of 8.10, Rg of 24.59 Å), (C) Ubc1 NMR structure 4
(pink) (χ2 of 16.86, Rg of 27.60 Å), whereby the major variation is the location of the UBA domain (coloured) in comparison to the core
domain (grey). Panel (A) represents the best fit of all structures tested, with all other quality fits similar to this UBA orientation. χ2 defines the
quality of the fits whereby a lower score indicates a better fit.
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Table 2.2 Radius of gyration and molecular weight for E2 enzymes and their
thiolester mimics derived from Small Angle X-ray Scattering Guinier Plots
Protein
Ubc1

Ubc1-UbCys

HIP2

HIP2-UbCys

Conc. (µM)

Rg (Å)

MWObsa (kDa)

MWExp (kDa)

29.4

23.1

28.3

24.2

58.8

23.4

27.8

24.2

118

23.8

30.5

24.2

176

24.3

30.5

24.2

235

24.3

30.0

24.2

24.6

26.5

31.8

32.8

49.3

27.0

36.9

32.8

98.7

28.1

38.0

32.8

148

28.8

39.3

32.8

197

29.5

40.4

32.8

35.5

20.8 ± 0.8

24.3 ± 0.4

22.5

71.0

21.2 ± 0.4

25.5 ± 0.2

22.5

142

21.4 ± 0.2

26.4 ± 0.1

22.5

213

22.2 ± 0.1

27.8 ± 0.1

22.5

284

22.4 ± 0.1

27.8 ± 0.1

22.5

43.6

24.7 ± 0.2

35.8 ± 0.2

31.2

87.3

24.5 ± 0.1

29.1 ± 0.1

31.2

131

24.9 ± 0.1

29.5 ± 0.1

31.2

175

26.0 ± 0.1

34.1 ± 0.1

31.2

218

26.3 ± 0.1

31.8 ± 0.1

31.2

a

Molecular Weight determined by comparison to cytochrome c samples of similar
concentration
b
Error analysis only available for data analyzed by Igor Pro (HIP2 and HIP2-UbCys).
Error analysis based on I0 errors.
Figure 2.10 Crysol analysis allows SAXS data to be compared to high resolution structures of Ubc1.

Figure 2.11 Crysol analysis allows SAXS data to be compared to high resolution structures of HIP2.
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are redundant and therefore only the 1YLA was utilized as the high-resolution HIP2
structure to fit to experimental data. A representative SAXS data set (142 µM HIP2) was
found to poorly fit the dimeric model (Fig 2.11A), while a much better fit was acquired
for the monomeric model (Fig 2.11B, half of the dimer coordinates). Similar results were
obtained on all other concentrations of HIP2 consistently showing much better fits to the
monomeric model. Guinier plot analysis of HIP2 SAXS data reveals the experimental Rg
to be 20.8 Å to 22.4 Å over a protein concentration range of 29-235 µM (Table 2.2).
These experimental values are 6.1% to 14.3% larger than the expected Rg of 19.6 Å
calculated from the monomer crystal structure of HIP2 (Fig 2.11B). On the assumption
the UBA domain of HIP2 is connected by a flexible linker, the position of the UBA
domain was moved to a similar location seen in the well fit Ubc1 structure. The resulting
‘relaxed’ UBA position for HIP2, which places the UBA domain further away from the
catalytic core, had an Rg of 21.8 Å that agreed more closely with the Guinier determined
Rg values of 20.8-22.4 Å. This ‘relaxed’ HIP2 structure provided a better fit than the
crystal monomer at all concentrations, and is illustrated by the representative data set in
Figure 2.11C. These results support the idea that the HIP2 crystal structure may have the
UBA domain positioned too closely to the catalytic core and may be a crystal artifact. It
is therefore likely that HIP2, like Ubc1, contains a flexible linker region allowing the
UBA domain to act as a tethered yet independent element in relation to the catalytic core
domain, thus explaining a more extended structure in solution than was observed in
crystal structures. This ‘relaxed’ HIP2 structure therefore likely represents the average
position of the UBA domain in solution during SAXS experiments. The fact

Figure 2.11 CRYSOL analysis allows SAXS data to be compared to high-resolution structures of HIP2. SAXS data is presented for HIP2 (142
µM), where the momentum transfer (q) is plotted versus the normalized log of scattering intensity (measured in arbitrary units). Experimental
data points are shown in black (filled triangles) and the theoretical scattering of the PDB structure is shown in red (solid line). The structure
used for theoretical scattering is located directly above the scattering curve. (A) shows data fit to the dimeric crystal structure of HIP2 for
1YLA (χ2 of 11.10, Rg of 23.48 Å) and (B) shows data fit to the resulting monomeric structure of HIP2 (χ2 of 2.18, Rg of 19.55 Å). The core
domain is coloured grey, and the UBA domain is coloured magenta. (C) shows data fit to the same monomeric HIP2 with the UBA domain
(cyan) slightly moved in the direction similar to the Ubc1 monomer UBA orientation (χ2 of 0.62, Rg of 21.79 Å). χ2 defines the quality of the
fits whereby a lower score indicates a better fit.
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that a monomeric model of HIP2 can be well fit to the data supports the notion that these
proteins are predominantly monomeric at the concentrations examined, providing further
support for very weak (>1000 µM) Kd values.

2.3.10 HIP2-UbCys and Ubc1-UbCys SAXS data comparison to high-resolution
structures
SAXS analysis performed on Ubc1-UbCys and HIP2-UbCys can be used to
determine the general position of Ub within the thiolester mimic.

To perform this

analysis high-resolution structures of Ubc1-UbCys and HIP2-UbCys need to be created to
compose theoretical scattering curves to compare to experimental data. Previous NMR
studies show that the UBA domain in Ubc1 does not interact with the thiolester bound Ub
(18). As a result the average UBA position found to match SAXS data from Ubc1 alone
(Fig 2.10A) should be unperturbed and thus was used as a starting point to position the
Ub molecule onto Ubc1 in Ubc1-UbCys. An NMR based model for the short lived
Ubc1~Ub thiolester has been previously determined with a Ubc1 truncation (Ubc1∆) and
Ub (PDB: 1FXT) (19). This Ubc1∆~Ub model was aligned with the full length Ubc1
protein structure modelled from SAXS data (Fig 2.10A) to generate a model for Ubc1UbCys. The theoretical scattering curves for this model fit the experimental scattering
curves poorly at all concentrations, and is illustrated by the representative data set (99
µM) in Figure 2.12A. These results indicate that this model does not accurately depict
the average shape of the Ubc1-UbCys complex in solution (Fig 2.12A). To determine if
poor fits to this model were due to the presence of dimeric Ubc1-UbCys, several
theoretical models were produced to sample possible dimeric structures. No quality fits
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Figure 2.12 CRYSOL analysis allows SAXS data to be compared to high-resolution structures of
Ubc1-UbCys. SAXS data is presented for Ubc1-Ub Cys (99 µM), where the momentum transfer (q)
is plotted versus the normalized log of scattering intensity (measured in arbitrary units).
Experimental data points are shown in black (filled triangles) and the theoretical scattering of the
PDB structure is shown in red (solid line). The structure used for theoretical scattering is located
directly above the scattering curve. (A) SAXS data fit to the ‘compact model’ for Ubc1-UbCys (χ2
of 13.39, Rg of 25.18 Å). The ‘compact model’ was produced with the full length Ubc1 structure
(Fig 2.10A) with the covalently attached Ub modelled by alignment to the truncated Ubc1~Ub
(1FXT) structure. (B) SAXS data fit to the ‘elongated model’ for Ubc1-Ub Cys (χ2 of 3.41, Rg of
29.78 Å). The ‘elongated model’ was produced with the full length Ubc1 structure (Fig 2.10A)
and the covalently attached Ub modelled by alignment to the Ubc13 portion of the
hMms2/Ubc13~Ub (2GMI) structure. χ2 defines the quality of the fits whereby a lower score
indicates a better fit.
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could be produced for Ubc1-UbCys from any dimeric structure or mixture of the
monomeric and dimeric species.
The expected structure of Ubc1-UbCys does not represent the average position of
the disulphide bound Ub, and thus alternative models were investigated. There are
presently four other E2~Ub conjugate structures that place the Ub in various positions:
Ubc13-Ub (PDB: 2GMI (7)), UbcH8-Ub (PDB: 2KJH (20)), and two structures for
UbcH5b-Ub (PDB: 3A33 (25), and PDB: 3JW0 (26)). Alternative models for Ubc1UbCys were created from these four structures. All of these new models position the Ub
molecule in varying positions further from the catalytic core. These structures are more
elongated and thus the model built in Figure 2.12A (PDB: 1FXT/1TTE) is termed the
‘compact’ model. The theoretical scattering curves for these new ‘elongated’ models
were compared to a representative data set (99 µM) with the best fit belonging to the
most extended Ubc1-UbCys structure based on the Ubc13-Ub complex (PDB: 2GMI) (Fig
2.12B). The other new models fit more poorly than the ‘elongated’ model (Fig 2.12B),
but better than the ‘compact’ model (Fig 2.12A) and these fits are consistent across all
concentrations examined.

Guinier plot analysis of the Ubc1-UbCys reveals the

experimental Rg to be 26.5 Å to 29.5 Å over a protein concentration range of 25-197 µM
(Table 2.2). The Rg value of the poorly fit ‘compact’ model for Ubc1-UbCys is 25.18 Å
and the Rg value of the well fit ‘elongated’ model for Ubc1-UbCys is 29.78 Å. The
increasing experimental Rg values vary between the expected Rg values for both the
‘elongated’ and ‘compact’ models of Ubc1-UbCys structure indicating that some
dimerization or aggregation may be occurring. In either case, the experimental Rg values
are closer to the expected Rg for the ‘elongated’ Ubc1-UbCys structure indicating Guinier
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plots also support this model. These results indicate that the ‘elongated’ model best
represents the average shape of Ubc1-UbCys in solution (Fig 2.12B). Since the Ubc1UbCys SAXS data can be fit to a monomeric structure, this further supports a very weak
(>1000 µM) Kd value describing dimerization of this protein complex.
In a similar analysis to Ubc1-UbCys, two models of HIP2-UbCys were constructed
to analyze SAXS data.

These HIP2-UbCys models were built by alignment to the

‘compact’ and ‘elongated’ models created for Ubc1-UbCys whereby the Ubc1 is replaced
with the HIP2 ‘relaxed’ UBA structure from Figure 2.11C. As was seen for the Ubc1UbCys, the theoretical scattering curves for the ‘elongated’ model of HIP2-UbCys fit the
experimental scattering curves very well at all concentrations, and is illustrated by the
representative data set (96 µM) in Figure 2.13A. The theoretical scattering curves for the
‘compact’ model of HIP2-UbCys fit the experimental scattering curves poorly at all
concentrations tested, and is illustrated by the representative data set (96 µM) in Figure
2.13B. Alternative models built from the other E2~Ub structures provided fitting score
values in between the ‘compact’ and ‘elongated’ models. Again, no reasonable fits could
be produced for HIP2-UbCys SAXS data with any dimeric structure or mixture of
monomeric and dimeric species. Guinier plot analysis of HIP2-UbCys SAXS data reveals
the Rg to vary between 24.7 Å to 26.3 Å over a protein concentration range of 44-218 µM
(Table 2.2). The expected Rg for the ‘elongated’ model is 26.85 Å, while the ‘compact’
model has an Rg of 22.33 Å. The experimental Rg values are closer to the expected Rg for
the ‘elongated’ HIP2-UbCys structure indicating Guinier plots also support this model.
Based on these results, it can be concluded that the ‘elongated’ model (Fig 2.13A) for
HIP2-UbCys best represents the average shape of HIP2-UbCys in solution. The fact that
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Figure 2.13 CRYSOL analysis allows SAXS data to be compared to high-resolution structures of
HIP2-UbCys. SAXS data is presented for HIP2-UbCys (96 µM), where the momentum transfer (q)
is plotted versus the normalized log of scattering intensity (measured in arbitrary units).
Experimental data points are shown in black (filled triangles) and the theoretical scattering of the
PDB structure is shown in red (solid line). The structure used for theoretical scattering is located
directly above the scattering curve. (A) SAXS data fit to the ‘elongated model’ for HIP2-Ub Cys
(χ2 of 0.97, Rg of 26.85 Å). The ‘elongated model’ was produced with the ‘relaxed’ HIP2
structure (Fig 2.11C) with the covalently attached Ub modelled by alignment to the truncated
Ubc1~Ub (1FXT) structure. (B) SAXS data fit to the ‘compact model’ for HIP2-UbCys (χ2 of
6.44, Rg of 22.33 Å). The ‘compact model’ was produced with the ‘relaxed’ HIP2 structure (Fig
2.11C) and the covalently attached Ub modelled by alignment to the Ubc13 portion of the
hMms2/Ubc13~Ub (2GMI) structure. χ2 defines the quality of the fits whereby a lower score
indicates a better fit.

Figure 2.14 Purified HIP2~Alexa-UbK48R thiolester reacts with both HIP2-UbK 48Cys disulphide and free Ub.
K48R

Figure 2.15 Purified Ubc1~Alexa-Ub

thiolester reacts with both Ubc1-UbK48

Cys

disulphide and free Ub.
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HIP2-UbCys SAXS data can provide a good fit to a monomeric structure further supports
very weak (>1000 µM) Kd values describing dimerization of this protein.

2.3.11 Activity assays on HIP2 and Ubc1 show that E2~UbK48R is the primary
reactive molecule and directly interacts with E2-UbK48Cys or free Ub
Initial activity reactions (Section 2.3.6) provided evidence that the E2-Ub
disulphide and the E2~Ub active thiolester for both HIP2 and Ubc1 might associate to
form an E2-Ub2 molecule. These results implied a possible E2 dimerization mechanism
driving poly-Ub chain formation.

Analytical ultracentrifugation and SAXS results,

however, indicate Ubc1 and HIP2 alone as well as Ubc1-UbCys and HIP2-UbCys have very
little tendency (Kd >1000 µM) to self-associate. In order to clarify the mechanism for
formation of the E2-Ub2 product, experiments were expanded to include the purification
of the E2~Ub thiolester to determine the direct contribution of the E2 enzyme to
reactivity.
Activity assays were performed with the use of Alexa fluorophore (680 nm)
tagged Ub such that the reactivity of the E2~Alexa-Ub thiolester can be tracked directly
through fluorescence imaging. The use of UbK48R ensures that the E2~UbK48R thiolester
can only act as a Ub donor in future reactions, as K48 poly-Ub chain elongation is
blocked. This blocked thiolester was made by mixing E1, E2, ATP and Alexa tagged
UbK48R (Alexa-UbK48R) that react to give the E2~Alexa-UbK48R thiolester. This reaction
was then subjected to size exclusion chromatography to remove the E1 enzyme, the
MgATP solution, and the unreacted Alexa-UbK48R. These purified E2~Alexa-UbK48R
thiolesters were produced for HIP2 (Fig 2.14) and Ubc1 (Fig 2.15). Reactions were then
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performed by mixing these E2~Alexa-UbK48R thiolester Ub donors with varying purified
proteins that may contain Ub acceptors. HIP2 and Ubc1 reactions were performed nearly
identically and for simplicity only the HIP2 experiments will be explained in detail.
Reactive free Alexa dye was utilized to visualize any unconjugated E1 or E2
enzymes, and the lack of a fluorescent band confirmed the removal of E1 enzyme from
the HIP2~Alexa-UbK48R thiolester (Fig 2.14B – lane 1,2). The purified thiolester was
shown to be intact (Fig 2.14B – lane 3) and its reactivity is confirmed through reduction
by DTT that can break the thiolester (Fig 2.14B – lane 4). The HIP2~Alexa-UbK48R
thiolester was then tested for reactivity with three different possible Ub acceptors:
unlabelled UbK48R (Fig 2.14B – lane 5), unlabelled wild type Ub (Fig 2.14B – lane 6 and
7), and the HIP2-UbK48Cys disulphide complex (Fig 2.14B – lane 8, 9).
The HIP2~Alexa-UbK48R thiolester reacted with the HIP2-UbK48Cys disulphide as
was seen in previous assays (Section 2.3.6) only in this instance E1 is absent. The
presence of E1 is therefore not required for this reaction to proceed showing that the
HIP2~Alexa-UbK48R thiolester is directly interacting with HIP2-UbK48Cys to yield HIP2UbK48Cys-Alexa-UbK48R (marked with (1) and a solid dot, Fig 2.14B – lane 8). Addition
of reducing agent shows the appearance of the Ub2 (UbK48Cys-Alexa-UbK48R) band (Fig
2.14B – lane 9). This proves that reaction scheme (1) shown in Figure 2.14A is in fact
occurring and that E1 was not causing the reaction or indirectly assisting the reaction.
The purified HIP2~Alexa-UbK48R thiolester was also reacted with two forms of free Ub,
the substituted UbK48R, and wild type Ub. The HIP2~Alexa-UbK48R thiolester reacted
with wild type Ub to yield free Ub2, while the UbK48R mutant does not react to

Figure 2.14 Purified HIP2~Alexa-UbK48R thiolester reacts with both HIP2-UbK48Cys disulphide and free Ub. (A) Mechanisms detailing
HIP2~Alexa-UbK48R thiolester reaction with (1) HIP2-UbK48Cys disulphide, (2) wild type Ub, and (3) UbK48R. (B) Coomassie stained image
(top gel) and fluorescent image at 700 nm (bottom gel) of HIP2~Alexa-Ub K48R thiolester reactions. Thiolester formation was performed for
30 min at 37 °C with 214 nM E1, 32.8 µM HIP2, 16.4 µM Alexa-UbK48R, 10mM Mg-ATP solution, in 50mM Hepes pH 8.0. Purified
thiolester was reacted with either 6 µM HIP2-UbK48Cys, 54 µM wild type Ub, or 54 µM UbK48R for 1 hr at 37 °C. Reaction components are
listed above each gel with a (+) or (-). All components for thiolester formation are signified in lane 1 with (*) while ‘purified’ HIP2~AlexaUbK48R thiolester for all other lanes contains no E1 or ATP. Unconjugated E1 and E2 are visualized with 500 nM reactive Alexa dye, and
10mM DTT is used for reducing disulphides. Reaction products for scheme (1) (HIP2-UbK48Cys-Alexa-UbK48R) and (2) (Ub-Alexa-UbK48R) are
labeled with filled black/yellow circles. Molecular weight standards are listed to the left and protein species to the right of each gel.
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Figure 2.15 Purified Ubc1~Alexa-UbK48R thiolester reacts with both Ubc1-UbK48Cys disulphide and free Ub. (A) Mechanisms detailing
Ubc1~Alexa-UbK48R thiolester reaction with (1) Ubc1-UbK48Cys disulphide, (2) wild type Ub, and (3) UbK48R. (B) Coomassie stained image
(top gel) and fluorescent image at 700 nm (bottom gel) of Ubc1~Alexa-UbK48R thiolester reactions. Thiolester formation was performed for
30 min at 37 °C with 214 nM E1, 12.3 µM Ubc1, 18.3 µM Alexa-UbK48R, 10mM Mg-ATP solution, in 50mM Hepes pH 8.0. Purified
thiolester was reacted with either 9.2 µM Ubc1-UbK48Cys, 90 µM wild type Ub, or 90 µM UbK48R for 5 hrs at 37 °C. Reaction components are
listed above each gel with a (+) or (-). All components for thiolester formation are signified in lane 1 with (*) while ‘purified’ Ubc1~AlexaUbK48R thiolester for all other lanes contains no E1 or ATP. Unconjugated E1 and E2 are visualized with 500 nM reactive Alexa dye, and
10mM DTT is used for reducing disulphides. Reaction products for scheme (1) (Ubc1-UbK48Cys-Alexa-UbK48R) and (2) (Ub-Alexa-UbK48R)
are labeled with filled black/yellow circles. Molecular weight standards are listed to the left and protein species to the right of each gel.
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any significant extent (Fig 2.14B – lane 5, 6). This Ub2 was also stable to reducing agent
(Fig 2.14B – lane 7). Due to the absence of ATP and E1, the reactive Ub molecules must
remain free and cannot form a thiolester with the E2 enzyme. This indicates that the free
forms of Ub are conclusively the reactive Ub acceptors for the HIP2 thiolester bound
Alexa-UbK48R donors. These results illustrate that the HIP2~Alexa-UbK48R thiolester can
directly react with any free Ub with an available K48 residue to cause chain extension
(Fig 2.14A, reaction scheme (2) and (3)). This assay also shows that reaction scheme (1)
and reaction scheme (2) can both occur, and therefore both free Ub and HIP2-UbK48Cys
can act as ubiquitin acceptors when reacted with the HIP2~Alexa-UbK48R thiolester
ubiquitin donor. Since the HIP2~Alexa-UbK48R thiolester can interact with either free
wild type Ub or the HIP2-UbK48Cys disulphide, it is possible that the HIP2-UbK48Cys
disulphide is simply acting as a reactant because it is being treated as a free Ub molecule
albeit attached to another protein. This reaction would then not be driven by dimerization
of E2 enzymes but simply by HIP2 and Ubc1’s affinity and reactivity towards any Ub
molecule, either free or attached to another protein. This would make reaction scheme
(1) mechanistically the same as reaction scheme (2), whereby both simply rely on an
available and at least temporarily exposed K48 residue in Ub (Fig 2.14A). The nearly
identical reaction procedure produces very similar results for the reaction of the
Ubc1~Alexa-UbK48R thiolester with both free Ub and Ubc1-UbK48Cys indicating these
enzymes are functionally very similar (Fig 2.15).
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2.4 Discussion
2.4.1 Previous evidence for E2 dimerization
Recently there have been numerous experiments performed to shed light on the
mechanism of poly-Ub chain formation and transfer in regards to the E1, E2, and E3
enzymes in various ubiquitination pathways. The observation that Ub-Ub linkages can
be formed in many of these systems prior to interaction with substrates provides evidence
that poly-Ub chains may be assembled prior to attachment to substrates. One hypothesis
for how these Ub-Ub linkages are created involves E2 dimerization. Solid structural
evidence for E2 dimerization has been found for Ubc13/Mms2, while reactive
experimental evidence for E2 dimerization has been found for Ube2g2, Cdc34, and Ubc1
(2-9, 27). In this chapter, HIP2 and Ubc1 enzymes were investigated for dimerization.
These enzymes are highly active in poly-Ub chain formation in the absence of E3
enzymes and substrates, indicating a simple E2-E2 mechanism could exist for these
enzymes (10, 11). Previous studies on Cdc34 also indicated that the presence of the
Cdc34~Ub thiolester may be required for dimerization. Therefore, thiolester mimics
(disulphide complexes) of Ubc1 and HIP2 were also created and studied. In addition to
understanding HIP2 and Ubc1 function, insights into the mechanisms utilized by these
enzymes may shed light on more complicated ubiquitination systems involving E3
enzymes and substrates.
Many early experiments on E2 enzymes including Ubc1 and HIP2 used size
exclusion elution profiles and chemical crosslinking to test for possible dimerization.
Both Ubc1 and HIP2 had early size exclusion elution profiles that implied significant
dimerization (17, 27). The high-resolution structures of these proteins have since been
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solved, and their elongated shapes were likely the cause for early elution profiles.
Crosslinking experiments were also performed on both of these proteins where Ubc1 was
observed to chemically crosslink (27), and HIP2 did not (17). These results likely do not
properly predict dimerization since the Ubc1 and HIP2 structures illustrate the presence
of unstructured flexible linkers that can explain their reactivity to lysine reactive crosslinking agents. Ubc1 contains a rather long unstructured tether between its two domains
(21) with an exposed and highly mobile K157 residue that may be responsible for the
observed crosslinking activity. This is supported by another study where the removal of
this flexible tether, including the UBA domain, greatly reduced crosslinking (27). HIP2
contains a shorter tether that lacks an exposed lysine residue, which may explain why this
protein does not crosslink. These observations support that these crosslinking studies
measure specific lysine reactivity as opposed to actual E2 dimerization. The previous
studies on the dimerization of HIP2 and Ubc1 are clearly debatable and therefore more
specific experimentation is required.

2.4.2 In depth studies into dimerization of HIP2 and Ubc1
The possible dimerization of HIP2 and Ubc1 as well as HIP2-UbCys and Ubc1UbCys was thoroughly investigated. Sedimentation equilibrium was used as a technique
to investigate dimerization since it reports molecular weights to high accuracy, it is not
sensitive to protein shape, and it offers the ability to quantify any type of oligomerization.
The molecular weights (MW) for HIP2 and Ubc1 were found to be within 4% of the
expected value. These results are in good agreement with an expected error rate of 5%.
HIP2-UbCys and Ubc1-UbCys were within 11.1% of the expected values. These MW
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measurements were larger than expected and if these small increases are interpreted as
self-association, we can calculate Kd values around 500 and 2000 of µM for HIP2 and
Ubc1 respectively, and Kd values around 200-300 of µM for HIP2-UbCys and Ubc1UbCys. These reported Kd values for self-association are much too high to be considered
reliable since the concentrations used in sedimentation equilibrium are in the range of 1020 µM.

To further characterize any possible self-association of these enzymes, SAXS

was performed at higher protein concentrations in the range of around 25-250 µM. The
MW measurements from SAXS were acquired with a dilution series, so any change in
MW as concentrations are increased are more reliable. It is important to note the exact
MW values determined by SAXS can be distorted by inaccurate concentrations of
proteins or standards in addition to the 10% accuracy of MWs reported by this technique
(22). There are not enough data points to accurately fit an entire Kd curve, however,
approximate Kd limitations can be determined by comparing the experimental data to
theoretical Kd curves. The Kd for dimerization of HIP2 and Ubc1 as well as HIP2-UbCys
and Ubc1-UbCys were determined to be >1000 µM, and these Kd’s may in fact be much
weaker. Since HIP2-UbCys and Ubc1-UbCys appear to increase in MW and Rg more so
than HIP2 or Ubc1 alone, it is likely that these disulphide species increase the very weak
dimerization capacity of these enzymes. Although the Kd for dimerization is affected by
disulphide formation with Ub, these proteins are still predominantly monomeric in
solution even at concentrations up to ~200 µM. The cellular concentration of Ub is
roughly 10 µM (28, 29) and the cellular concentrations of E2 enzymes are likely in the
low µM (<10 µM) to nM range. Comparison of these cellular concentrations to the E2
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and E2-Ub Kd for dimerization of >1000 µM (1 mM) indicates these proteins are almost
exclusively monomeric at cellular concentrations.

2.4.3 Dimerization scaffold proteins are not used for Ubc1 or HIP2
Previous experiments on the E2 enzyme Ube2g2 have indicated poly-Ub chain
formation occurs between two different Ube2g2 enzymes and this activity required the
E3 enzyme gp78 (2).

Subsequent studies on this enzyme deduced that these E2

interactions were aided by the dimerization of the E3 enzyme, indicating the E3 enzyme
may be a scaffold for E2 dimerization in the Ube2g2 pathway (3). The Ubc1 and HIP2
enzymes have poly-Ub chain activity without an E3 enzyme indicating that they do not
require an E3 scaffold like Ube2g2. The only protein left in our reactions that could act
as a dimerization scaffold is the E1 enzyme. There is currently no evidence that an E1
enzyme can bind two E2 enzymes, however, HIP2 and Ubc1 retain the ability to form
Ub-Ub linkages upon removal of the E1 enzyme, which suggests that the E1 enzyme
does not act as a scaffold for E2 dimerization. These results indicate that there are no
additional proteins present in the activity assays performed in this work that increase the
Kd of dimerization of Ubc1 or HIP2.

2.4.4 The E1 enzyme is not directly used to create Ub-Ub linkages
It has been previously reported that the E1 enzyme may be directly responsible
for the formation of a poly-Ub chain on the E2 enzyme Ubc1 (30). This proposed
function of E1 is novel and was performed with K93 auto-ubiquitination on a truncated
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version of Ubc1, which lacks the UBA domain (30). The Ubc1 enzyme utilized in this
chapter has a K93R substitution to avoid auto-ubiquitination, and retains the UBA
domain to ensure proper enzymatic function. Activity assays on the full length HIP2 and
Ubc1 do not support an E1 catalyzed poly-Ub chain formation mechanism since the
addition of E1 enzyme, ATP, and wild type Ub could not react with the HIP2-UbK48Cys or
Ubc1-UbK48Cys disulphides. These results demonstrate that the K48 residue on disulphide
bound Ub does not act as a Ub acceptor with the E1~Ub thiolester.
The requirement for the E1 enzyme was further investigated by forming E2~Ub
thiolesters followed by a purification procedure to remove the E1 enzyme. This process
created ‘purified’ E2~Ub thiolesters to determine if they can react alone with Ub
acceptors. The ‘purified’ E2~Ub thiolesters reacted with both E2-UbK48Cys disulphides
and free wild type Ub to create Ub2 in the absence of the E1 enzyme. Therefore, the E1
is only required for E2 thiolester charging, and not required for the extension of poly-Ub
chains.

2.4.5 A proposed monomeric mechanism for Ubc1 and HIP2 activity
Poly-ubiquitination activity assays with HIP2 and Ubc1 were performed without
E3 enzymes or substrates, indicating only E1 and E2 enzymes are involved in poly-Ub
chain formation. Activity assays demonstrated that the E1 was only required for E2
charging, proving that poly-Ub activity is driven solely by HIP2 and Ubc1. Initial work
on E2 enzymes in several pathways suggested that these enzymes function using a
dimeric mechanism. The HIP2 and Ubc1 enzymes were determined to have a weak Kd of
dimerization of >1000 µM (Fig 2.16A). Weak dimerization could occur through
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Figure 2.16 A schematic representation of the strength of protein interactions and possible
mechanisms involved in poly-Ub chain formation activity observed for the E2 enzymes Ubc1 and
HIP2. The strength of protein interactions are reported as dissociation constants (Kd values). (A)
The self-association of E2 enzymes presumably through core-core interactions. (B) The selfassociation of E2~Ub enzymes presumably driven by UBA domain interactions with attached
ubiquitin. (C) The association of Ub with the UBA domain resulting in reaction with the E2~Ub
thiolester causing the formation of Ub2. (D) The association of Ub2 with the E2 UBA domain.
(E) The association of the disulphide attached Ub with the UBA domain of another E2~Ub
thiolester reacting to yield E2-Ub2. All reactions shown with arrows account for the nucleophilic
attack of a K48 side chain to a thiolester attached Ub, resulting in a Ub-Ub K48-linked poly-Ub.
Each arrow between Ub molecules represents the K48 side chain nucleophilic attack to the
reactive thiolester of a second Ub.
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catalytic core interactions between E2 enzymes (7) or through UBA-UBA domain
interactions (31). Another method for E2 dimerization would be through the formation of
an E2~Ub thiolester. The HIP2 and Ubc1 C-terminal UBA domains have been observed
to bind Ub non-covalently (21, 23, 32, 33). These UBA/Ub binding interactions could
drive dimerization whereby the UBA domain of each E2 could interact with the Ub
attached to the neighbouring E2 enzyme (Fig 2.16B). By examining HIP2-UbCys and
Ubc1-UbCys disulphides designed to mimic the active thiolester the dimerization capacity
was determined to also have a weak Kd of >1000 µM. The models depicted in Figure
2.16A and 2.16B have weak Kd values indicating that these E2 enzymes alone and in
their thiolester mimic form are predominantly monomeric at typical cellular protein
concentrations in the range of low µM to nM. Although the Kd of >1000 µM indicates
<1% of these enzymes are dimeric during the activity assays performed, this weak
dimeric mechanism may still explain the reaction of purified E2~UbK48R thiolester with
the E2-UbK48Cys disulphide for both HIP2 and Ubc1. The low amount of dimerization
may be the reason these reactions occur slowly, on the order of hours.
Both purified HIP2~UbK48R and Ubc1~UbK48R thiolesters can react with
unconjugated wild type Ub. Previous studies have also implied the use of free Ub in
HIP2 unanchored poly-Ub chain formation through the use of C-terminal Ub truncations
that could not form thiolesters (10, 17). The use of free Ub as an acceptor indicates that
the activity of the HIP2 and Ubc1 enzymes may be driven by UBA affinity towards free
Ub. This activity can be rationalized with a monomeric mechanism. HIP2 and Ubc1
have the ability to interact with at least two Ub molecules at once, one through a
thiolester linkage and a second Ub non-covalently through the UBA domain (21, 33).
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The UBA/Ub binding may simply increase the local concentration of Ub or the UBA
could provide the E2 enzyme with an ability to place 2 Ub molecules in close proximity
to assist in the formation of a Ub-Ub linkage (Fig 2.16C). The monomeric mechanism
depicted in Figure 2.16C would be driven by UBA affinity for an acceptor Ub that would
be positioned so its K48 residue can perform a nucleophilic attack on the thiolester bound
donor Ub. The Kd3 value in Figure 2.16C represents the UBA domain’s affinity for Ub
and has been previously measured to be 400 µM for HIP2 (33) and 228 ± 69 µM for
Ubc1 (21). Upon comparison to the dissociation constants for dimerization (Kd1 and Kd2
>1000 µM), the affinity of E2 to Ub is stronger than the monomer-dimer equilibrium for
both these enzymes (Fig 2.16A, B, C). This Kd comparison means the E2 enzymes have
higher affinity for free Ub than another E2 enzyme.

Therefore, if the monomeric

mechanism can occur, it would be more probable than the dimeric mechanism.
A previous study on several isolated UBA domains has shown a higher affinity
for poly-Ub chains than single Ub molecules (33). In this study, the HIP2 UBA domain’s
affinity for Ub4 was measured to have a Kd of 155 µM showing that the UBA domain
binds poly-Ub chains more strongly than a single Ub with a Kd of 400 µM (33). It is
likely the UBA domain in Ubc1 behaves in a similar manner. Figure 2.16D depicts the
affinity of E2 for Ub2 that likely has a Kd4 that lies somewhere between the 155 and 400
µM for HIP2 and less than 228 ± 69 µM for Ubc1 (21, 33). The fact that the value for
Kd4 is less than that for Kd3 indicates that the association seen in Figure 2.16D is stronger
than that for Figure 2.16C. This affinity difference may explain why HIP2 has previously
been shown to kinetically favor Ub2 as a Ub acceptor over a single Ub (10). These
results indicate that poly-Ub chains should be extended faster than a single Ub.
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A monomeric mechanism for HIP2 and Ubc1 function does not initially seem to
explain the reaction of E2~UbK48R thiolesters with E2-UbK48Cys disulphides. However, if
the mechanism depicted in Figure 2.16C is redrawn with a disulphide in place of Ub (Fig
2.16E) the reaction that proceeds would be very similar. The common feature of both
reactants is simply a reactive K48 residue available in the Ub acceptor. In this manner,
both the E2-UbK48Cys disulphide and free wild type Ub may react with E2~UbK48R by the
same mechanism. The Kd5 is likely >1000 µM as the affinity for E2~UbK48R thiolester
and E2-UbK48Cys disulphide should be identical to the Kd measured for the selfassociation of E2-UbCys disulphide. The Kd5 comparison to Kd3 indicates that the E2UbK48Cys disulphide is a less efficient Ub acceptor than free wild type Ub, presumably due
to a partially or transiently blocked Ub surface. SAXS results show the E2-UbK48Cys
disulphides have an exposed disulphide bound Ub that could be recognized by the UBA
domain.

The idea of a partially exposed thiolester bound Ub is also supported by

previous experimentation on E2~Ub conjugates suggesting that the Ub is highly mobile
on the surface of the E2 (34). Therefore, the reaction of E2~UbK48R thiolesters and E2UbK48Cys disulphides may occur only due to lack of a preferred free Ub acceptor in these
reactions. Comparison of the Kd’s in the mechanisms in Figure 2.16 indicates free Ub
and poly-Ub chains are the preferred acceptors for the E2~UbK48R thiolesters.

2.4.6 UBA domain and Ub positioning in HIP2 and Ubc1 structures
SAXS experiments yield low-resolution structural data for HIP2 and Ubc1 and
their disulphide complexes that can be used to determine the average shape of these
proteins in solution. These low-resolution shapes are sufficient to distinguish between
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greatly varying positions for the UBA domain and disulphide bound Ub, however the fine
details describing the exact orientation of the UBA domain or Ub in relation to the
catalytic core domain cannot be determined. SAXS analysis in comparison to highresolution structures allowed for the determination of the average position of the UBA
domain in relation to the catalytic core for both HIP2 and Ubc1. These results indicated
that both HIP2 and Ubc1 contain few interactions between their catalytic core and UBA
domains. This result indicates that the UBA domain is likely mobile in relation to the
core domain.
The position of Ub in HIP-UbCys and Ubc1-UbCys adheres more closely to the
‘elongated’ models (Fig 2.12B, 2.13A) than the ‘compact’ models (Fig 2.12A, 2.13B).
Although the ‘elongated’ models are based on a rigid high-resolution structure, the high
quality fits to SAXS data indicates that these structures accurately represent the average
position of both the mobile UBA domain, and bound Ub in the E2-UbCys disulphides.
Alternative structures with varied positions for the UBA domain and Ub as well as
dimeric structures yielded poor fits to the SAXS data.
SAXS data for both HIP2-UbCys and Ubc1-UbCys disulphides can be fit to models
where the hydrophobic surface of Ub is highly exposed to solution. However, previous
NMR experiments on the Ubc1Δ~Ub thiolester (no UBA) show that there are significant
contacts between the hydrophobic face of Ub and the Ubc1 enzyme (19).

Similar

contacts were also observed in NMR studies with HIP2-UbCys (Chapter 4). These results
indicate that the hydrophobic face of Ub is at least partially blocked from solution in
Ubc1-UbCys and HIP2-UbCys. These results are consistent with previous experiments on
E2~Ub structures that indicated the thiolester attached Ub on E2 enzymes may be highly
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mobile (34). SAXS experiments provide the general position of Ub in the E2-UbCys
‘elongated’ models, but the orientation of the hydrophobic face of Ub may in fact point
towards the core domain accounting for the partially blocked Ub surface in this extended
structure. Since E2-UbK48Cys disulphides can be reacted with the E2~UbK48R thiolesters,
the K48 residue of Ub must be occasionally exposed to allow a reaction. This means that
regardless of the exact position of the disulphide bound Ub, there is likely a dynamic
equilibrium between a partially blocked and a more fully exposed disulphide bound Ub.

2.4.7 Purpose of the UBA domain
The poly-Ub chain formation activity of Ubc1 and HIP2 seems to be driven by
reactivity towards attached or free Ub (Fig 2.16C, D, E). This reactivity towards Ub is
likely due to the UBA domains of Ubc1 and HIP2 that have been shown to bind Ub
through NMR titration experiments (21, 23, 32). Complicating the theory that UBA/Ub
binding drives Ubc1 and HIP2 activity, is the fact that both HIP2 (32, 35) and Ubc1 (11,
30, 36) retain some poly-Ub chain activity upon UBA domain removal. The removal of
the UBA domains from both HIP2 and Ubc1 reduced the full processivity of these
enzymes causing shorter poly-Ub chains to form (32, 36). These results indicate that the
UBA domain aids in reaction efficiency, but is not essential for poly-Ub chain formation.
In previous studies a chimeric protein created with the catalytic core of the E2 enzyme
Ubc4 with addition of the HIP2 UBA domain, was not active in poly-Ub chain formation
(17). This result suggests the addition of HIP2’s UBA domain on any E2 enzyme is not
solely responsible for poly-Ub chain formation and that the HIP2 catalytic core domains
contain unique residues directly responsible for proper Ub placement to allow formation
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of poly-Ub chains. This may imply that their catalytic cores have some affinity for Ub
themselves. However, Ub has not been observed to bind at the catalytic core of either
Ubc1 or HIP2 in previous NMR titration experiments (21, 23). The crystal structure of
HIP2 with non-covalently bound Ub also did not show any contacts between the catalytic
core and Ub (23). The fact that these enzymes still retain some activity upon UBA
domain removal is perplexing, although it is possible that the UBA domain aids in
reaction efficiency by increasing the local concentration of reactant (Ub or Ub chains),
but is not completely required for specific orientation of an acceptor Ub for reaction with
the reactive thiolester. The UBA domain may also increase the rate of reaction through
efficient physical placement of two Ub molecules in close proximity. There is currently
no clear mechanism defining how HIP2 and Ubc1 accomplish K48-linkage specificity in
these poly-Ub chain formation reactions.

2.4.8 Purpose of chain building by Ubc1 and HIP2
HIP2 and Ubc1 are homologs from human and yeast respectively, and appear to
function in a similar manner as both have been shown to build K48-linked poly-Ub
chains. Activity assays have demonstrated that E2-UbK48R thiolesters can react with
either E2-UbK48Cys disulphides to form E2-Ub2 or free Ub to form unanchored Ub2.
Comparison of Kd values favours free poly-Ub chains and free Ub as the acceptor for
HIP2~Ub and Ubc1~Ub thiolesters.

Removal of the E1 enzyme in activity assays

indicates that the E2~UbK48R thiolester is the sole reactive enzyme in poly-Ub chain
extension and is directly responsible for reaction with free Ub. These free Ub acceptors
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must then be non-covalently interacting with the E2 enzyme presumably through the
UBA domain and possibly additional contacts on the E2 catalytic core.
The resulting reaction from these E2 enzymes is the formation of unanchored
poly-Ub chains, with HIP2 producing much longer chains (10, 11). The purpose of
unanchored poly-Ub chains remains unknown, but free unconjugated poly-Ub chains are
found in vivo (38). Previous experimentation has found that Ub2 and Ub4 chains can be
just as easily activated on E1 and transferred to E2 as mono Ub (10, 38). Therefore, free
Ub chains can be utilized to form thiolester intermediates and then act as Ub donors. The
creation of these poly-Ub chains without substrate, and the fact that these chains can be
loaded onto E2 enzymes to act as poly-Ub chain donors, supports the mechanism of
preassembling chains prior to attachment to substrate.
It is also possible that HIP2 and Ubc1 are involved in a sequential addition model
by extending chains on ubiquitinated substrates by a method similar to that seen in
unanchored chain assembly. This mechanism is supported by recent work on Ubc4 and
Ubc1 that found both enzymes can ubiquitinate APC (large RING E3 complex)
substrates. These enzymes appear to have different functions as Ubc4 is more active in
initial Ub attachment to substrates and Ubc1 is more active at extending chains on
substrates that already have a single attached Ub (36). The in vitro poly-Ub chain
activity in the absence of E3 enzymes and substrates may then be a non-physiological byproduct reaction due to lack of a preferred mono or poly ubiquitinated substrate.
Therefore, the poly-Ub chain activity of these enzymes in vivo may prefer ubiquitinated
substrate, but in the absence of this substrate, free Ub or auto-ubiquitinated proteins may
act as substitute reactants.
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The activity assays performed show direct interaction of E2 thiolesters with both
free Ub and E2-Ub thiolester mimics. E2 dimerization is likely not a driving factor for
these reactions. These results point towards Ubc1 and HIP2 functioning primarily in a
monomeric manner in solution with the components tested. The creation of poly-Ub
chains may be an artifactual activity due to limited reactants in the sequential addition
model, or could be the first steps of poly-Ub chain formation in a preassembly model.
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Chapter 3
1

H, 15N, and 13C Backbone Resonance Assignments of the E2
Conjugating Enzyme HIP2

3.1 Introduction
HIP2 is a Class II E2 conjugating enzyme containing the conserved catalytic core
and a C-terminal UBA domain. Importantly, it is the only human E2 enzyme known to
possess this domain. HIP2 also appears to be one of the most active E2 enzymes in polyUb chain assembly (1), and yet very few E3 enzymes have been documented to function
with HIP2.

These results may indicate that HIP2 has a rather novel function in

comparison to other E2 enzymes. Most importantly HIP2 has been shown to interact
with several disease related substrates including the huntingtin protein found to be polyubiquitinated in Huntington’s disease and UBB+1, a frame shift mutant of Ub that HIP2
can effectively incorporate into poly-Ub chains known to be a factor in Alzheimer’s
disease.
The structure of HIP2 has been determined through X-ray crystallography (PDB:
1YLA and 3E46) (unpublished) (2). A limited number of physical studies on the HIP2
enzyme prompted the need for NMR experimentation that can be utilized to determine
protein interactions with residue specific information. In order to perform mechanistic
and structural studies of HIP2, the assignment of 1H,

15

N and

13

C backbone resonances

are required. These to be determined resonance assignments will be used in future
experiments (Chapter 4) to determine interaction surfaces between HIP2 and attached Ub
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or Ub2 to develop a more thorough understanding of the purpose and function of the
HIP2 conjugating enzyme.

3.2 Materials and Methods
3.2.1 Cloning
The hexahistidine (His6)-tagged HIP2C170S (HIP2) cDNA was inserted in the
pET28a vector (Chapter 2). This vector was then mutated to swap the thrombin cleavage
site for a TEV (tobacco etch virus) cleavage site. The 18 DNA bases encoding the TEV
cleavage sequence was substituted for 12 DNA bases encoding the thrombin cleavage
sequence in the pET28a vector using the Quikchange Site-Directed Mutagenesis protocol
(Stratagene, La Jolla, CA). Forward and reverse complement primers were subjected to
polymerase chain reaction (PCR) against the pET28a template, followed by digestion of
the methylated template by DpnI for 1 hour at 37 °C. The PCR product was then
transformed into the JM-109 E. coli strain and the correct substitutions were confirmed
by DNA sequencing.

This plasmid was also transformed into the BL21

CodonPlus(DE3)RIL E. coli cell line for protein expression.

3.2.2 Protein expression and purification
For

the production

of

uniformly

15

N,

13

C-labelled

His6-HIP2,

BL21

CodonPlus(DE3)RIL cells were grown at 37 °C in M9 minimal media (10 mL) with
unlabelled ingredients to ensure growth, then diluted 1:100 into 1L of M9 minimal media
containing 1.0 g / L 15NH4Cl and 2 g / L 13C-glucose as well as kanamycin (30 µg / mL)

126
and chloramphenicol (34 µg / mL). The culture was grown to an A600 between 0.60-0.75
and protein expression was induced with 0.7 mM IPTG. The temperature was reduced to
15 °C and cells were allowed to grow for 16-20 hrs. Harvested cells were re-suspended
in 25 mM Tris-HCl, 200 mM NaCl, 1 mM TCEP, 5 mM imidazole at pH 7.5 with the
addition of a COMPLETE mini EDTA-free protease inhibitor cocktail tablet (Roche
Diagnostics).

All the following purification procedures were performed at 4 °C to

minimize protein degradation. Cells were lysed with a French Press and cellular debris
was removed via centrifugation at 95500 xg. The clarified extract containing His6-HIP2
was applied to Ni-NTA Agarose (Qiagen) and washed with 25 mM Tris-HCl, 200 mM
NaCl, 1mM TCEP, 10 mM imidazole at pH 7.5 to elute non specifically bound material.
His6-HIP2 was eluted with 25 mM Tris-HCl, 200 mM NaCl, 1mM TCEP, 200 mM
imidazole pH 7.5. TEV (Shaw lab) (50 µg / mL) was added to cleave the His6-tag at
room temperature for 1.5 hours and then overnight at 4 °C while dialyzing into the same
buffer containing 10 mM imidazole. A subsequent Ni-NTA Agarose column was utilized
with the same buffer to remove the His6 fusion tag, any uncut protein and hexahistidine
tagged TEV. Immediately following the final Ni-NTA Agarose column, 1 mM EDTA is
added to the buffer. EDTA was essential for avoiding subsequent protein degradation by
trace proteases. Another tablet of COMPLETE mini EDTA-free protease inhibitor tablet
(Roche) was also added to avoid protein degradation. A final Superdex 75 10/300 GL
column (GE Biosciences) was used to remove trace impurities and perform buffer
exchange into 25 mM Tris-HCl, 200 mM NaCl, 5 mM DTT, 1 mM EDTA pH 7.5.
Earlier purifications of HIP2 used for optimization of NMR samples to avoid degradation
and oxidization, used final buffers with 1 mM TCEP, and no EDTA. Purification of 15N,
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13

C-labelled HIP2 was monitored using SDS-PAGE using 16.5% tris-tricine gels in a

mini-gel system (BioRad) and was stained with Coomassie dye. HIP2 concentrations
were determined through Bradford (BioRad) reactions performed in triplicate. HIP2
molecular weight was confirmed using electrospray ionization mass spectrometry (MWobs
23779.0 ± 1.4Da, MWcalc 23812.8).

3.2.3 NMR sample preparation
Purified

15

N,

13

C-labelled HIP2 used for initial NMR optimization experiments

was dialyzed into 25 mM Tris-HCl, 200 mM NaCl, 1 mM TCEP pH 7.5. HIP2 buffer
conditions were optimized to be 25 mM Tris-HCl, 200 mM NaCl, 5 mM DTT, 1 mM
EDTA pH 7.5 was used for NMR backbone assignments. The relatively high DTT
component was substituted for TCEP used during purification as DTT was found to be a
more stable reducing agent over the long experimental times required for NMR
experiments.

15

N,

13

C-labelled HIP2 was concentrated using a 10000 MWCO Amicon

spin concentrator (Millipore).

NMR samples (575 µM) were prepared from this

concentrated HIP2 solution by adding 10% D2O (v/v), 1% 10 mM DSS (v/v), 0.05%
NaN3 (v/v), and 0.8% Complete MINI EDTA-free protease inhibitor tablet (Roche)
solubilized with 1 mL H2O (v/v). The final HIP2 concentration in NMR samples was
320 µM for degradation observations, 750 µM for initial optimization tests, and 575 µM
for samples used in triple resonance experiments for backbone assignments.
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3.2.4 NMR spectroscopy
All NMR spectra were acquired using a Varian INOVA 600 MHz spectrometer
(University of Western Ontario) equipped with a pulse field gradient triple resonance
cold probe. It was determined that triple resonance experiments were of much higher
quality at 30 °C then at 25 °C, and thus NMR resonance assignments of 15N, 13C-labelled
HIP2 were performed at 30 °C.
For all NMR experiments, the carrier frequencies for 1H, 15N, 13Cα, 13Cβ and 13C’
were set to 4.73, 117.01, 57.39, 45.91 and 173.90 ppm respectively.

1

H-15N HSQC (3)

spectra were collected with 1024 complex data points and a spectral width of 8000 Hz in
the 1H (F2) dimension and 128 increments with a spectral width of 1900 Hz in the 15N
(F1) dimension. Sequential assignment of the polypeptide backbone resonances of HIP2
were completed utilizing the following triple resonance experiments: HNCA (4),
HN(CO)CA (5), HNCACB (6), HBCBCA(CO)NH (7), HC(CO)NH (8), HNCO (9). For
all these experiments, the 1H (F3) dimension was collected with 1024 complex data
points with a spectral width of 8000 Hz, and the 15N (F2) dimension was collect with 32
increments and a spectral width of 1900 Hz. The 13C (F1) dimension for the HNCA and
HN(CO)CA experiments used 32 increments and a spectral width of 4524 Hz. The 13C
(F1) dimension for the HNCACB and HBCBCA(CO)NH experiments used 56 and 52
increments respectively with spectral widths of 9000 Hz. The 13C (F1) dimension for the
HNCO experiment used 24 increments with a spectral width of 3300 Hz, and the 13C (F1)
dimension for the HC(CO)NH experiment used 40 increments with a spectral width of
10000 Hz.
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All data was processed using NMRPipe and NMRDraw (10). Linear prediction
was used in the F2 dimension to double the number of points, and zero-filling was
performed in the F1 and F3 dimensions to 512 and 1024 points respectively. A π/3 phase
shifted sine2 bell was applied to the F2 and F3 dimensions, and a π/2 phase shifted sine2
bell was applied to the F1 dimension prior to Fourier transformation of data. All spectra
were analyzed with NMRView (11).

3.2.5 Determination of HIP2 secondary structure
The secondary structure of HIP2 was predicted using Chemical Shift Indexing
(CSI) (12, 13) by comparing the assigned

13

Cα,

13

Cβ and

13

C’ chemical shift values of

HIP2 to chemical shift values expected for these atoms if they adopt a random coil. The
CSI program assigns an index value of -1, +1 or 0 indicating that a particular atom has a
chemical shift similar to an α-helical, β-strand or random coil region respectively. Three
or more consecutive residues possessing a value of +1 will result in assignment of a βstrand secondary structure, while four or more densely packed -1 values will result in
assignment of an α-helical secondary structure. A consensus secondary structure is
produced from the analysis of all analyzed atoms. The secondary structure from the CSI
calculation was compared to the previously solved X-ray crystal structure of HIP2 (PDB:
1YLA) (unpublished).
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3.3 Results
3.3.1 Mutagenesis
The pET28a vector contained the His6-HIP2 fusion protein with a thrombin
cleavage site for fusion tag removal (Chapter 2). The TEV (tobacco etch virus) cleavage
sequence was substituted for the thrombin cleavage sequence in the pET28a-LIC vector
using the Quikchange Site-Directed Mutagenesis protocol (Stratagene, La Jolla, CA).
Insertion of the new cleavage site was confirmed by DNA sequencing (London Regional
Genomics Centre - UWO).

3.3.2 Expression and purification of 15N, 13C-labelled HIP2 for NMR studies
The production of uniformly 15N, 13C-labelled HIP2 was performed by growth in
M9 minimal media containing

15

NH4Cl and

13

C-glucose with IPTG used for protein

induction. The key changes to the previously described purification protocol (Chapter 2)
include the buffer pH being lowered from 8.0 to 7.5, and the use of TEV enzyme to
remove the His6 tag from HIP2 after the first Ni2+-affinity purification step. Since the
TEV enzyme was also a hexahistidine tagged fusion protein (His6-TEV), a second Ni2+affinity column was used to remove the cleaved His6 tag, any remaining uncut His6-HIP2
protein and all the His6-TEV enzyme leaving only purified HIP2 in the flow through (Fig
3.1 B – lane 6). Once the final Ni2+-affinity column was performed, it was essential to
add EDTA to the protein solution as well as another Roche tablet of protease inhibitors to
prevent protein degradation by trace proteases (details in Section 3.3.3). The 15N,

13

labelled HIP2 was then subjected to an additional size exclusion column to remove any

C-

Figure 3.1 Expression and purification of 15N, 13C-labelled HIP2. (B) The E2 conjugating enzyme HIP2 was isotopically labelled with
15
N and 13C by protein expression in M9 media containing 15NH4Cl and 13C-glucose. The purification of HIP2 was monitored by
Coomassie stained SDS-PAGE gels following procedures listed in Section 3.2.2. The protein purification gel is loaded from left to
right containing initial expression of His6-HIP2 centrifuged lysate (lane 1), Ni2+ affinity column flow through (lane 2), wash (lane 3)
and elution (lane 4), TEV-cleaved protein (lane 5) and second Ni2+ affinity column flow (lane 6), and a size exclusion purification is
performed representing purified HIP2 (lane 7). (A) Electrospray ionization mass spectrometry analysis of purified 15N, 13C-labelled
HIP2 indicates the protein is the correct mass.
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trace proteases (Fig 3.1B – lane 7). Using electrospray ionization mass spectrometry, a
single major peak was observed at a molecular weight of 23779.0 ± 1.4 Da which
accounts for 97.3% of the expected molecular weight of full isotopic incorporation of
23812.8 Da (Fig 3.1 A).

3.3.3 NMR sample preparation and optimization
In order to obtain high quality NMR spectra, HIP2 must be exposed to high
temperatures (>25 °C). Initial NMR experiments on purified

15

N,

13

C-labelled HIP2

resulted in severe protein degradation within days due to prolonged exposure to these
high temperatures. The original purpose of TEV substitution of the thrombin cleavage
site was to minimize HIP2 degradation by using a highly pure and removable cleavage
enzyme. Even though TEV enzyme was used, NMR samples would degrade in roughly
72 hours causing obvious changes in the NMR spectra (Fig 3.2). This degradation was
confirmed with SDS-PAGE analysis (Fig 3.2 – insets). The NMR spectral changes are
caused by a drastic decrease in signal from intact HIP2 as the protein degrades (Fig 3.2 –
upper boxed region), as well as the appearance of many new signals in the spectrum (Fig
3.2 – lower boxed region) from the creation of small polypeptides. Protease inhibitor
tablets (Roche) and NaN3 were added to all future NMR samples to reduce degradation
and inhibit possible contaminant growth, respectively. These measures alone resulted in
minimal increases in HIP2 sample stability.

The addition of EDTA immediately

following Ni2+-affinity chromatography was essential to increase protein stability of HIP2
NMR samples from days to weeks. This indicates that trace amounts of metalloproteases

Figure 3.2 Illustration of degradation effects on the 1H-15 N HSQC spectrum of HIP2. Backbone amide signals are shown for 1 H-15N HSQC
spectra of (A) HIP2 and (B) HIP2 after 72 hour exposure at 25 °C. The inset gel shows a protein sample from each HSQC spectrum identified
with an arrow. Boxed signals are to aid in visual comparison of spectral regions. These spectra were collected using an 15N, 13C-labelled HIP2
sample (320 µM) in 10% D2 O, 200 mM NaCl, 1 mM TCEP, 25 mM Tris-HCl pH 7.5 at 25 °C (No EDTA).
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were the likely cause of HIP2 degradation. Therefore, the addition of EDTA to all NMR
buffers was required to obtain high quality NMR spectra.
NMR samples of the 15N, 13C-labelled HIP2 were then optimized for experimental
temperatures. NMR experiments were performed at 25 °C and 30 °C. Analysis of the
resulting 1H-15N HSQC spectra showed that data collected at 30 °C showed higher signal
intensity due to narrower linewidths (Fig 3.3 – boxed signals) and improved signal
resolution was obtained (Fig 3.3 – circled signals). At this experimental temperature,
there was sufficient signal intensity for unambiguous resonance assignments of the triple
resonance experiments.
In addition to stability problems, depletion of reducing agent affected spectral
appearance of certain signals over time, presumably through oxidation. To alleviate this
problem, TCEP was replaced with the longer-lived reducing agent DTT to keep the
sample sufficiently reduced for several weeks. The final NMR samples used for 1H-15N
HSQC and triple resonance experiments were prepared with all the optimized conditions
described.

3.3.4 Sequential backbone assignments of HIP2
A series of standard multidimensional NMR experiments were used to determine
the sequential backbone resonance assignment of HIP2.

Sequential assignment of

residues in any protein is made possible through a series of paired experiments that
compare the current residue (i) and the previous residue (i-1). The first pair of NMR
experiments used for backbone assignments were the HNCA and HN(CO)CA (4, 5).

Figure 3.3 1H-15N HSQC spectrum of HIP2 at varying temperatures. Backbone amide signals are shown for 1H-15N HSQC spectra of HIP2 at
(A) 25 °C and (B) 30 °C. Boxed and circled signals are added to aid in visual comparison of spectral regions, showing increased signal intensity
and resolution respectively at 30 °C. The spectra were collected on a 15N, 13C-labelled HIP2 sample (750 µM), in 10% D2O, 200 mM NaCl, 1
mM TCEP, 1 mM EDTA, 25 mM Tris-HCl pH 7.5.

135

136
These two experiments correlate the backbone amide proton and nitrogen chemical shifts
to the Cα resonances, with HNCA showing the current (i) residue and the preceding (i-1)
residue, whereas the HN(CO)CA shows only the preceding (i-1) residue.

These

experiments alone can provide backbone residue linkage, but a moderately high level of
Cα resonance overlap necessitates the use of a second set of paired experiments, the
HNCACB and HBCBCA(CO)NH (6, 7).

The HNCACB and HBCBCA(CO)NH

experiments allow for the determination of both Cα and Cβ resonances. The HNCACB
experiment correlates the backbone amide proton and nitrogen chemical shifts to the Cα
and Cβ resonances, while the Cα(i-1), Cβ(i-1) correlations can often be observed at a
lower intensity. The HBCBCA(CO)NH experiment correlates the amide and nitrogen
chemical shifts to the Cα(i-1), Cβ(i-1) resonances.

When analyzed together, these

experiments can be used to connect the Cα and Cβ resonances for the i and i-1 residues.
These results when combined with the HNCA and HN(CO)CA experiments usually leads
to unambiguous strings of connected backbone residues. By comparing the chemical
shifts of these atoms to the BMRB (Biological Magnetic Resonance Data Bank) standard
chemical shift tables, the amino acid identity can be determined to complete the
assignment of the HIP2 protein sequence. Figure 3.4 shows the sequential assignment of
HIP2 residues A115, L116, L117, A118, and A119 depicted in a strip plot of the
HNCACB and HBCBCA(CO)NH experiments. When Cα and Cβ resonances do not
provide enough variance to unambiguously assign a residue, the HC(CO)NH (8)
experiment provides resonances for any Cγ, Cδ, and Cε atoms present in the i-1 residue.
By combining information from all of these triple resonance experiments, and through
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Figure 3.1 Expression and purification of 15 N, 13 C-labelled HIP2.
Figure 3.2 Illustration of degradation effects on the 1 H-15 N HSQC spectrum of HIP2.
Figure 3.3 Temperature optimization of the 1 H- 15 N HSQC spectrum of HIP2.

Figure 3.4 Sequential backbone assignment of HIP2. The strip plot shows alternating panels of
the HBCBCA(CO)NH spectrum (left) and HNCACB spectrum (right) for each residue of A115
through A119. Each strip depicts a 15N plane of the triple resonance experiment, leaving a 2D
representation of the remaining 1H and 13C correlations. For each residue the Cα (black) and Cβ
(red) are shown in the HNCACB spectrum and the corresponding Cα and Cβ for the previous
residue (i-1) are shown in the HBCBCA(CO)NH (both black). Connections between i and i-1
residues are indicated with a dashed line. The spectra were collected using a 15N, 13C-labelled
HIP2 sample (575 µM) in 10% D2 O, 200 mM NaCl, 5 mM DTT, 1 mM EDTA, 25 mM Tris-HCl
pH 7.5 at 30 °C.

138
the use of distinct chemical shifts for glycine, serine, threonine, and alanine residues,
almost every residue in HIP2 can be sequentially assigned in an unambiguous manner.
Finally an HNCO (9) experiment is performed to assign the backbone carbonyl carbons
for each residue.

3.3.5 Assignment of the 1H-15N HSQC spectrum of HIP2
In a 1H-15N HSQC spectrum of HIP2, each amino acid residue is depicted by a single
signal based on the amide correlation of the 1H and 15N atoms, and is the primary type of
spectra used to illustrate NMR resonance assignments. The 1H-15N HSQC spectrum for
HIP2 was assigned by comparison to the assigned triple resonance values for 1H and 15N
on Cα and Cβ signals. The 1H-15N HSQC spectra for HIP2 assignment of 175 out of 187
(94%) non-proline 1H and

15

N amide resonances (Fig 3.5). Many of the remaining

unassigned 12 residues are located in the N-terminus (M1, N3), the loop between α1 and
β1 (E20, T22), the loop between β1 and β2 (D33, E34, F36), and within the proposed
flexible linker between the catalytic core and UBA domain (V157, S159, E161). These
residues are likely in highly flexible and solvent exposed regions, resulting in their 1H
and

15

N amide resonances to be unobservable due to fast amide exchange with water.

Table 3.1 shows all the chemical shift assignments acquired from a combination of the
HSQC experiment and all triple resonance experiments. These assignments include the
amide H and N, Cα and C’ protein backbone atoms, as well as many Cβ, Cγ, Cδ, and Cε
atoms in each amino acid residue.
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Figure 3.5 Assigned 1 H-15N HSQC spectrum of HIP2. Backbone amide signals are labelled by
amino acid single letter code and sequence number. Signals connected by lines indicate side
chain amide resonances from Asn and Gln residues. The signals marked with (*) represent side
chain amides from Trp residues, while arrows indicate signals that are shifted further downfield
in 1H than 10ppm. The spectra was collected using a 15N, 13C-labelled HIP2 sample (575 µM) in
10% D2 O, 200 mM NaCl, 5 mM DTT, 1 mM EDTA, 25 mM Tris-HCl pH 7.5 at 30 °C.
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Table 3.1 1 H, 15N and 13C backbone resonance assignments for HIP2a
Residue
M1
A2
N3
I4
A5
V6
Q7
R8
I9
K10
R11
E12
F13
K14
E15
V16
L17
K18
S19
E20
E21
T22
S23
K24
N25
Q26
I27
K28
V29
D30
L31
V32
E34
N35
F36
T37
E38
L39
R40
G41
E42
I43
A44
G45
P47
D48
T49
P50
Y51
E52
G53
G54
R55
Y56
Q57
L58
E59
I60
K61
I62
P63
E64
T65
Y66
P67
F68
N69

HN

N

8.344

124.8

8.288
7.887
7.798
8.055
8.181
8.441
8.361
7.488
8.874
9.393
7.606
8.139
8.007
7.974
7.587
7.857

120.2
124.8
117.0
117.6
119.4
119.6
120.4
119.0
121.8
122.7
118.5
118.0
118.5
121.5
115.9
117.0

8.992

118.0

7.944
7.812
8.281
8.486
7.009
8.478
8.024
8.854
8.695
8.236

120.5
119.0
116.5
116.0
110.2
121.8
118.2
122.4
121.9
121.8

7.903

116.6

8.320
7.868
9.254
8.982
9.062
8.828
8.650
8.320
8.780

104.8
123.4
123.4
122.8
111.7
120.9
116.3
125.8
107.7

9.025
7.391

115.5
105.8

6.922
7.513
9.364
8.335
8.486
8.736
9.547
9.143
9.091
8.084
9.272
8.647

113.1
123.3
115.1
106.2
121.8
121.4
121.4
121.9
124.6
126.2
127.1
125.8

9.053
7.034
7.670

119.6
102.4
126.8

8.799
7.128

125.3
115.9

C’
176.08
176.57
177.08
179.37
177.46
179.50
178.07
177.77
179.54
179.40
180.11
176.79
178.45
179.69
178.95
178.48
176.76
178.65
175.26
175.82
176.13
175.02
175.49
174.47
174.29
172.30
175.04
177.15
175.64
173.38
174.85
173.39
175.72
176.15
171.76
174.83
174.91
178.99
176.18
175.07
173.98
176.85
175.75
174.25
173.34
174.25
174.48
176.14
175.03
174.63
173.85
175.35
176.60
174.93
174.72
175.38

Cα
55.83
52.86
54.60
63.47
55.88
66.28
58.98
58.48
62.29
61.07
59.49
59.97
61.57
59.56
59.11
67.01
58.02
55.90
59.64
58.68
61.05
65.17
61.23
56.55
54.34
57.45
58.99
55.90
60.48
53.07
55.23
63.67
57.30
52.97
60.30
62.45
55.55
53.54
53.77
43.79
55.65
58.78
51.14
44.35
62.67
55.83
59.66
63.68
56.40
58.27
45.19
43.50
55.40
57.79
55.16
53.64
55.36
60.30
54.61
55.07
59.02
60.54
58.22
63.35
60.48
50.34

Cβ
33.22
19.28
38.57
38.09
19.33
31.87
28.58
28.80
36.19
32.42
30.15
30.72
39.68
32.29
29.80
31.29
41.95
32.50
64.86
29.80
28.69
71.24
62.92
32.53
37.81
29.94
42.19
36.54
35.78
45.61
42.64
32.73
29.31
39.59
69.93
32.05
46.08
32.26

Others

Cγ1 28.32, Cγ2 17.33, Cδ1 13.72
Cγ1 20.94
Cγ 33.95
Cγ1 28.03, Cγ2 18.77
Cδ 29.87
Cγ 27.26, Cδ 40.40
Cγ 33.85
Cγ 25.41, Cδ 29.57, Cε 41.58
Cγ 36.43
Cγ1 22.05
Cγ 24.64, Cδ 28.95, Cε 42.16
Cγ 36.41

Cγ 25.64, Cδ 29.32
Cγ1 26.77, Cγ2 17.91
Cγ 24.98, Cδ 29.44
Cγ1 22.01
Cδ1 24.72
Cγ 36.23

Cγ 36.35
Cγ 26.81
Cγ 27.43, Cδ 42.58

34.25
42.31
20.16

Cγ 37.71
Cγ2 17.83

32.27
39.26
71.28
32.67
38.54
30.06

Cγ 27.59

32.69
40.41
30.82
45.79
33.10
40.09
34.59
36.94
32.55
29.61
68.74
40.61
33.11
37.93
41.00

Cγ 27.48, Cδ 42.63

Cγ 27.28
Cγ 35.51

Cγ 34.33
Cγ 27.17
Cγ 37.10
Cγ1 27.50, Cγ2 21.42, Cδ1 17.15
Cγ 26.08, Cδ 29.42
Cγ 36.16
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Table 3.1 continued 1 H, 15N and 13C backbone resonance assignments for HIP2a
Residue
P71
K72
V73
R74
F75
I76
T77
K78
I79
W80
H81
P82
N83
I84
S85
S86
V87
T88
G89
A90
I91
C92
L93
D94
I95
L96
K97
D98
Q99
W100
A101
A102
A103
M104
T105
L106
R107
T108
V109
L110
L111
S112
L113
Q114
A115
L116
L117
A118
A119
A120
E121
P122
D123
D124
P125
Q126
D127
A128
V129
V130
A131
N132
Q133
Y134
K135
Q136
N137

HN

N

8.621
8.847
8.360
9.472
8.917
7.306
8.193
8.524
8.040
10.570

120.5
126.2
123.4
124.8
124.4
119.0
126.3
120.4
129.9
131.1

11.296
7.756
9.086
9.955
8.020
8.189
7.881
7.747
8.708
8.864
7.460
9.292
8.530
7.331
7.939
8.621
7.759
7.241
6.706
8.044
7.049
7.597
7.405
9.134
8.476
7.862
8.480
8.286
8.479
8.409
8.154
7.884
7.995
7.786
7.459
7.286
7.935
8.184
9.005

117.4
121.4
118.5
129.7
121.4
106.2
109.7
121.8
119.3
127.8
125.9
130.6
117.2
113.6
122.9
119.5
115.4
121.4
129.7
120.4
116.0
120.0
103.8
120.0
117.2
114.1
123.9
119.4
117.5
118.1
123.9
118.6
120.0
120.9
118.0
117.5
125.8
122.9
118.9

8.475
7.202

117.9
119.4

8.678
7.124
8.937
7.920
7.162
8.293
8.212
7.641
8.572
7.705
8.488
8.793

117.6
118.0
128.7
118.4
121.2
120.3
115.1
121.5
117.5
113.6
115.6
116.1

C’
179.71
176.05
173.26
175.75
175.97
177.47
173.46
176.17
170.26
174.11
176.70
171.32
174.65
177.59
174.09
178.05
176.46
173.94
176.48
175.81
172.11
176.35
180.28
173.36
176.76
175.92
176.86
174.66
175.30
175.33
176.72
178.53
172.70
176.54
178.35
177.06
178.43
177.30
178.73
181.18
176.94
177.84
177.72
180.28
179.48
177.03
176.79
174.00
176.46
175.02
175.36
177.09
174.59
179.78
178.96
178.29
178.54
176.89
176.97
176.62
178.42
177.24

Cα
61.72
55.09
60.19
54.69
60.18
62.51
63.44
56.92
60.95
54.52
56.01
65.44
55.66
59.04
58.89
61.72
64.76
61.67
46.55
52.95
60.67
57.75
54.42
58.52
64.51
53.64
56.41
55.80
54.59
58.90
50.10
53.91
52.39
57.21
58.94
58.23
60.76
66.78
67.39
58.87
58.06
62.73
57.51
60.76
54.87
56.64
58.26
52.56
51.54
52.11
52.30
64.32
55.07
51.75
62.96
55.10
52.80
55.38
66.01
65.61
55.62
56.43
59.94
61.55
59.00
57.62
50.93

Cβ
31.80
32.46
34.47
34.84
38.80
39.01
70.89
32.84
41.84
29.12

Others
Cγ 26.25
Cγ 24.28, Cδ 28.96, Cε 41.81
Cγ1 22.14
Cγ 27.54

32.51
41.05
42.93
63.14
63.52
34.18
71.74

Cγ 27.57

19.39
42.72
26.42
45.60
38.99
38.30
41.38
32.84
40.90
28.14
30.33
22.24
18.50
19.05
32.26

Cγ1 28.22, Cγ2 16.92
Cγ 24.78, Cδ 28.54

Cγ1 21.20

Cγ1 28.54, Cγ2 18.58
Cγ 26.70
Cγ2 18.73, Cδ1 14.41
Cγ 26.30, Cδ1 21.60
Cγ 24.59, Cδ 29.51, Cε 41.64
Cγ 33.53

43.00
30.03
68.57
31.55
41.35
41.14

Cδ1 25.18
Cγ 27.69

41.90
29.75
17.85
42.29
40.58
19.61
18.95
19.45
30.02
31.94
40.24
40.93
33.54
30.25
43.82
18.75
31.62
32.03
18.80
38.34
31.64
39.15
33.76
29.62
39.35

Cδ1 27.03
Cγ 35.29

Cγ1 20.68
Cγ 27.10, Cδ1 23.65
Cγ 25.92

Cγ 28.30, Cδ1 23.86
Cδ1 21.96

Cγ 27.35
Cγ 30.22
Cγ 33.39

Cγ 36.34
Cγ 25.78, Cδ 29.56
Cγ 34.06
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Table 3.1 continued 1 H, 15N and 13C backbone resonance assignments for HIP2a
Residue
P138
E139
M140
F141
K142
Q143
T144
A145
R146
L147
W148
A149
H150
V151
Y152
A153
G154
A155
V157
S158
E161
Y162
T163
K164
K165
I166
E167
N168
L169
S170
A171
M172
G173
F174
D175
R176
N177
A178
V179
I180
V181
A182
L183
S184
S185
K186
S187
W188
D189
V190
E191
T192
A193
T194
E195
L196
L197
L198
S199
N200
a

HN

N

8.543
7.568
9.070
8.439
7.921
8.646
9.037
8.193
7.894
9.253
9.035
8.626
8.737
8.183
7.328
7.555
8.067

117.6
120.9
123.7
120.6
115.6
120.4
124.8
119.2
122.9
120.9
128.3
120.5
116.8
113.6
120.8
106.8
124.1

C’
179.19
178.70
180.29
176.58
178.68
179.46
175.14
180.62
178.27
180.13
181.17
174.70
176.74
178.29
176.33
177.85
174.61
174.15

7.450

117.5

7.461
7.931
7.893
7.315
7.884
8.539
8.394
7.685
8.766
7.959
7.385
7.837
6.681
8.800
8.711
8.183
8.000
8.509
8.160
8.191
8.440
8.310
7.435
7.789
7.217
7.927
8.714
7.288
8.736
8.760
8.135
8.495
8.104
7.344
7.372
7.847
7.796
7.635
7.736

119.1
114.6
121.4
118.0
118.0
121.4
118.0
119.0
116.6
123.4
115.4
105.3
118.0
122.4
126.4
115.1
124.0
119.9
120.4
122.9
124.8
115.5
113.1
112.5
120.4
112.1
110.2
119.5
127.1
122.9
114.1
124.8
114.1
119.5
119.9
121.0
117.6
115.0
125.8

179.01
178.27
176.57
178.62
178.70
179.32
179.38
177.65
180.05
177.89
178.68
175.91
173.78
174.64
176.59
177.91
177.10
180.96
176.99
179.69
178.20
178.71
178.50
174.88
174.95
176.20
172.89
172.90
175.45
178.69
179.44
178.27
178.55
175.06
179.08
179.76
178.77
177.75
173.50

Cα
65.53
59.62
58.30
62.01
60.84
58.46
68.27
55.92
58.92
57.86
62.78
55.70
58.23
65.86
59.07
51.16
46.22
51.25
62.07
56.65
59.23
58.13
67.05
59.52
60.47
64.34
59.32
56.09
57.83
62.21
54.19
56.39
44.80
56.60
54.68
60.53
56.86
55.12
66.90
67.10
68.01
55.72
57.84
62.31
60.79
52.85
60.10
59.47
53.39
66.92
60.65
65.55
55.58
68.01
59.57
57.90
57.35
55.84
59.18
55.09

Cβ
31.83
28.96
33.82
38.60
32.62
28.11
69.24
17.85
30.77
40.46
28.23
18.66

Others
Cγ 27.59, Cδ 50.29
Cγ 35.83
Cγ 31.22

32.78
39.65
22.46

Cγ1 19.74

18.15
33.61
64.70
29.00
35.80
68.10
32.05
33.81
38.80
29.36
38.30
42.76
62.99
18.11
32.79
41.81
43.28
30.81
37.84
17.88
31.48
38.01
32.03
18.82
40.86
63.60
29.69
61.14
24.53
42.53
31.98
29.37
68.44
18.35
29.54
42.17
40.83
42.82
64.10
40.85

Cδ 26.65, Cε 38.71
Cγ 33.03
Cγ 27.59, Cδ 43.42
Cγ 25.51, Cδ1 21.45

Cγ1 20.51
Cγ 36.09
Cγ2 22.08
Cγ 24.73, Cδ 29.04
Cγ1 29.54, Cδ1 16.82
Cγ 35.97
Cγ 28.86, Cδ1 24.95

Cγ 27.81, Cδ 43.33
Cγ1 25.02
Cγ2 16.07, Cδ1 13.94
Cγ1 20.84
Cγ 27.34, Cδ1 23.13

Cγ1 22.08
Cγ 36.57
Cγ2 22.78
Cγ 36.03
Cγ 25.51
Cγ 26.85, Cδ1 22.75
Cγ 26.30, Cδ1 22.61

Referenced to DSS at 0 ppm in 1H. HIP2 NMR data was obtained at 30 °C in 200 mM NaCl, 5
mM DTT, 1 mM EDTA, and 25 mM Tris-HCl pH 7.5. Residues D33, P46, P70, P156, S159 and
P160 were not assigned
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3.3.6 Determination of HIP2 secondary structure
The backbone chemical shift values of HIP2 (Table 3.1) were used to calculate the
secondary structure to ensure that the C170S substitution caused no major structural
changes. The assigned chemical shift values for

13

Cα,

13

Cβ and

13

C’ from HIP2 were

utilized to predict the secondary structure using the Chemical Shift Index (CSI) protocol
(12, 13). The CSI compares chemical shift assignments to their deviation from random
coil chemical shift values to determine if those particular atoms have a propensity to be
α-helical or β-strand in structure. Specifically, 13Cα and 13C’ chemical shifts are located
more upfield if they are in a β-strand conformation and shifted more downfield in an αhelical conformation, while 13Cβ atoms experience opposite field shifts when located in
these secondary structures (12, 13). The secondary structure calculated for each atom
was combined by CSI to give a consensus for each residue. The calculated secondary
structure for HIP2 showed residues A5-S19, E20-K24, T105-A120, A128-Y152, P160M172, R176-W188, and V190-L198 were in an α-helical conformation and residues I27D30, E38-A44, and R55-K61 were in the β-strand conformation (Fig 3.6). The positions
of the CSI calculated α-helices and β-strands are in excellent agreement with secondary
structural elements observed in the X-ray crystal structure of HIP2 (PDB: 1YLA)
(unpublished).

This result indicates that there are no major secondary structural

differences of HIP2 in solution compared to that observed in the X-ray crystal, and that
the C170S substitution is non-perturbing.
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Figure 3.6 Secondary structure calculation of HIP2 by the chemical shift index. Chemical shift
values for 13Cα, 13Cβ and 13C’ for each residue are compared to the chemical shift index to
determine propensity for α-helical and β-strand secondary structure. The calculated structure is
labelled as NMR and is compared to the X-ray crystal structure for HIP2 (PDB: 1YLA) labelled
as X-ray. Secondary structural elements are shown pictorially as cylinders for α-helices and
arrows for β-strands with the protein sequence listed above. Secondary structure elements are
numbered above the protein sequences according to the X-ray structure labelling.
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3.4 Discussion
3.4.1 Mutagenesis
The purified His6-HIP2 fusion protein after thrombin cleavage undergoes
degradation at high temperatures (>25 °C). Commercially available thrombin is purified
from blood and its purity is measured through specific activity as opposed to finding a
single band in SDS-PAGE. Therefore, the thrombin enzyme may contain trace amounts
of other proteases.

To avoid possible HIP2 degradation from trace proteases, the

thrombin cleavage site was replaced with TEV. The use of a His6-tagged form of the
TEV enzyme allows for higher quality purification. The His6-tag on TEV also allows for
efficient

removal

after

His6-HIP2

cleavage

by

Ni2+-affinity

chromatography.

Unfortunately, degradation of HIP2 was still noticed after TEV use and removal, likely
due to trace proteases from the E. coli.

3.4.2 Optimization of purification protocols and NMR conditions
There were specific changes to the HIP2 purification protocol (outlined in Section
3.2.2) that were required to ensure protein stability for NMR data collection. The first
change involved lowering the pH of the buffer from 8.0 to 7.5 to slow the rate of amide
exchange. Amide exchange can be acid or base catalyzed and previous studies have
shown that amide exchange of an exposed HN in a peptide backbone is minimized at
roughly pH 4 depending on surrounding side chain groups (14). The pH was reduced
from 8.0 to 7.5 to minimize amide exchange and to increase NMR signal intensity.
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Importantly, this lower pH was still several pH units away from HIP2’s isoelectric point
at pH 5.33.
During the purification of HIP2, TCEP was used instead of DTT and EDTA was
omitted to ensure the proper functioning of the Ni2+-affinity column. Once Ni2+-affinity
chromatography was completed, it was important to substitute DTT for TCEP and to add
EDTA to the buffer. EDTA was essential for increased stability of HIP2 at the higher
temperatures required to collect quality HSQC data.

This indicated that HIP2

degradation was likely due to trace amounts of a metalloprotease from E. coli. The
addition of various serine and cysteine protease inhibitors (Roche tablets) had little effect
on HIP2 stability. The use of DTT in lieu of TCEP was required due to its more stable
reducing activity, which was needed to maintain protein stability during NMR data
collection. Lastly, NMR data collection was significantly improved upon increasing the
temperature to 30 °C. The increase in temperature allows for an increased rate of protein
tumbling. Increased protein tumbling leads to increased signal intensity by decreasing
the spin-spin (1/T2) relaxation rate. The triple resonance experiments for HIP2 at 25 °C
were too low in signal-to-noise to perform backbone assignments. In contrast, the signalto-noise of triple resonance experiments at 30 °C was significantly increased.

The

combination of lowering the pH, adding EDTA, using DTT and increasing experimental
temperature to 30 °C allowed for the complete unambiguous assignment of HIP2
backbone residues.
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3.4.3 Resonance assignments for HIP2
The triple resonance experiments allowed for assignment of the amide H and N,
Cα and C’ protein backbone atoms, as well as many Cβ, Cγ, Cδ, and Cε atoms in each
amino acid residue. The 1H-15N HSQC spectra for HIP2 has every visible signal assigned
to yield a 94% assignment (175 / 187) of non-proline residues.

NMR protein

assignments can be used to study protein-protein interactions in solution.

Residue

specific protein interaction surfaces can be detected using an assigned 1H-15N HSQC
spectrum as specific residues will undergo chemical shift changes upon binding to
another protein. The 1H-15N HSQC spectrum of HIP2 will be utilized in this manner to
characterize protein interactions in Chapter 4.

3.4.4 Asparagine 83 in HIP2 displays a distinctly deshielded amide proton
An interesting feature of the 1H-15N HSQC spectrum of HIP2 is the distinct
downfield amide 1H chemical shift of N83 (1H: 11.296 ppm, 15N: 117.43 ppm). The N83
residue is structurally near the active site cysteine residue (C92) and is part of a highly
conserved HPN motif found in many other E2 enzymes (15, 16). To perform an in depth
structural analysis to explain this unique chemical shift, a comparison of the active sites
of other E2 enzymes containing the HPN motif was conducted. Every E2 enzyme that
has a high-resolution structure and NMR chemical shift assignment was investigated.
Nine human E2 enzymes and the yeast HIP2 homolog Ubc1 have 1H-15N HSQC spectral
assignments (Biological Magnetic Resonance Data Bank – BMRB) as well as a highresolution structures: HIP2 (PDB: 1YLA, 2BEP, 3E46) (unpublished) (2, 17), Ubc1
(PDB: 1TTE, BMRB: 6202) (18), UbcH5A (PDB: 2C4P, BMRB: 6584) (unpublished),
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UbcH5B (PDB: 2ESK, BMRB: 6277) (19), Ubc2b (PDB: 1JAS, BMRB: 5038) (20),
Ubc9 (PDB: 1A3S, BMRB: 4132) (21), UbE2G2 (PDB: 2CYX, BMRB: 16404) (22),
Ubc13 (PDB: 1J7D, BMRB: 15092) (23), UbcH7 (PDB: 1FBV, BMRB: 15498) (24),
and UbcH8 (PDB: 1WZV and 2KJH, BMRB: 16321) (unpublished) (25). A segment of
the sequence alignment of these 10 proteins is shown in Figure 3.7A. The HPN motif of
these proteins can also be structurally aligned showing that the HPN motif adopts a tight
turn adjacent to the active site cysteine in all of these proteins. The important catalytic
residues include the active site C92, which forms the thiolester linkage with the Ub Cterminus, and the Asn residue in the HPN motif, which has been suggested to stabilize an
oxyanion intermediate formed during nucleophilic attack by a substrate lysine (16, 26,
27).
Closer inspection of the structure of the HIP2 active site (PDB: 2BEP) (17) shows
that the amide proton of N83 is involved in a hydrogen bond to the side chain δ nitrogen
atom of H81 (Fig 3.7B). Comparison to other HIP2 structures (PDB: 3E46, 1YLA) (2)
(unpublished) shows that the H81 ring is flipped and a hydrogen bond can form between
the H81 protonated ε nitrogen atom and the N83 side chain δ oxygen atom (Fig 3.7C).
Although both of these orientations are possible, the purpose of side chain interactions of
His and Asn residues in the HPN motif could possibly regulate the oxyanion hole by
assuming acidic and basic states (15). However, the fact that His is not solvent exposed
argues against this acid/base catalysis function, and indicates that the N83 residue alone
likely regulates the oxyanion hole (16).

Hydrogen bonds are known to have a

deshielding effect on amide protons (28), indicating the highly deshielded N83 amide
proton is consistent with the hydrogen bond depicted in Figure 3.7B and cannot
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Figure 3.7 Structural analysis of the HPN motif in HIP2. (A) Segment of a sequence alignment
of 9 human E2 enzymes and Ubc1 (yeast HIP2 homolog) for which NMR chemical shift data and
PDB structures exist. Conserved residues are pink, and unique HIP2 residues are blue. (B) HIP2
(2BEP) structure and (C) HIP2 (3E46) structure showing variations in H81 ring orientation and
hydrogen bonding in the HPN motif adjacent to the C92 active site. (D) HIP2 (2BEP) structure
showing hydrogen bonded water to the H81 amide and surrounding chemical groups (some
sidechains hidden for clarity). (E) Overlay of HIP2 (2BEP – orange) from (D) showing side
chains from UbcH5A (2C4P - purple), Ubc13 (1J7D - magenta), and UbcH8 (1WZV - green)
with backbone residues in grey. Hydrogen bonds are shown as thick dashed green/grey lines, and
distance measurements are shown in thin dashed red lines. Colour scheme for atoms are nitrogen
(blue), oxygen (red), carbon (grey) and protons are not shown.
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be explained by the absence of the hydrogen bond depicted in Figure 3.7C. In addition to
the hydrogen bond, the deshielding of this amide proton is also affected by orientation of
the H81 ring such that the deshielding effects of the ring current face the amide bond.
This evidence suggests that the HIP2 structure depicted in Figure 3.7B contains the
correct H81 orientation and protonation state, while the HIP2 structure depicted in Figure
3.7C incorporates an incorrect orientation for H81 in the HPN motif.
The structures of the other nine E2 enzymes analyzed also display little consensus
on the HPN histidine ring orientation. All of these nine proteins however, contain a
significantly downfield shifted Asn amide proton in the HPN motif as in HIP2.
Therefore, it is likely the His orientation and hydrogen bond depicted in Figure 3.7B is
similar for all other E2 enzymes with the HPN motif. Substitutions in the His or Pro
residues in the HPN motif for Ubc13 resulted in the production of mostly insoluble
protein (16). These results indicate that the His side chain is not involved in stabilizing
the oxyanion hole in any E2 enzyme’s HPN motif. The purpose of the His hydrogen
bond to the Asn amide is therefore very important in strengthening the HPN tight turn
(Pro trans configuration) to stabilize the catalytic core domain fold. This means the His
in the HPN motif structurally stabilizes the active site. The purpose of this important
HPN motif structure near catalytic site is likely to properly position the Asn sidechain to
stabilize the oxyanion hole. Since all reported E2 enzymes contain this significantly
downfield shifted Asn amide proton, the HPN tight turn motif must aid in proper Asn
positioning to aid in the function of all E2 enzymes.
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3.4.5 Histidine 81 in HIP2 displays a distinctly deshielded amide proton
Another feature of the 1H-15N HSQC spectrum of HIP2 is the distinct downfield
amide 1H chemical shift of H81 (1H: 10.570 ppm,

15

N: 131.11 ppm) in the HPN motif.

Unlike the highly downfield shifted amide proton of N83 that is common in all 10 E2s
analyzed, the downfield shift of the H81 amide proton is unique to HIP2 and its yeast
homolog Ubc1. There was no observed hydrogen bonding of the H81 amide proton to
any other amino acid backbone or side chain atoms. However, the observation of a
hydrogen bonded water molecule could account for the deshielded environment
experienced by the H81 amide proton (Fig 3.7D). The electronegative atoms from S86
and D127 side chains are outside of hydrogen bonding distance but possibly affect the
polar orientation of the water molecule, which would strengthen the hydrogen bond with
the H81 amide proton. This is supported by the fact that the D127 residue is unique to
HIP2 and the S86 residue, although not unique, is very close to the unique T88 residue
insertion in HIP2 that affects the positioning of S86 (Fig 3.7A, D). Comparison to
several other E2 enzymes (UbcH5A, Ubc13 and UbcH8) indicated that a hydrogen
bonded water molecule was also present in these structures. However, downfield shifted
His amide protons were not observed in these other E2 enzymes. To explain the lack of a
similar His amide chemical shift, these E2 structures were aligned by the HPN motif and
overlayed to display structural differences (Fig 3.7E). There are no additional hydrogen
bonds that explain why the HIP2 H81 amide is uniquely downfield shifted. The most
obvious difference between HIP2 and UbcH5A, Ubc13 and UbcH8, are the residue
identities and geometry equivalent to S86 and D127 in HIP2. In HIP2 S86 and D127
provide electronegative groups that may aid in orientation of the hydrogen bonded water
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molecule. This may strengthen the hydrogen bond to H81. The other three E2 enzymes
do not retain these proximal electronegative groups. The negative charge on D127 in
HIP2 is replaced by positive R121, polar N123 and a hydrophobic V120 in UbcH8,
Ubc13 and UbcH5A respectively, which accounts for an obvious change in environment
that would not favorably interact with the positive side of a polar water molecule. The
insertion of T88 in HIP2 is unique and may cause the S86 sidechain to be moved into
closer proximity of this water molecule than S80, K82 or E80 in UbcH5A, Ubc13, and
UbcH8 respectively.

The proximity and location of electronegative atoms located

opposite the hydrogen bonded water appears unique to HIP2 (and Ubc1) and thus
hydrogen bond stabilization by these groups is the most reasonable explanation for the
H81’s unique downfield shifted amide proton. Although the H81 amide unique chemical
shift does not seem to adversely affect the active site, these residues may be necessary for
the structural stabilization of the active site of the HIP2 enzyme.
Previous experimentation shows that a HIP2 S86Y substitution loses the ability to
make poly-Ub chains (29). The S86 residue is not adjacent to the active site cysteine or
HPN asparagine side chain, but it is close to the HPN histidine backbone amide (Fig
3.7D, E).

The S86Y substitution would likely disrupt the hydrogen bonded water

depicted in Figure 3.7D, but this substitution will also affect the structure of the HPN
motif through steric hindrance by the large hydrophobic Y86 residue with the H81
backbone.

Therefore, the S86Y substitution may alter the HPN tight turn structure

resulting in a changed orientation of N83 near the active site.

This may cause a

destabilized oxyanion hole resulting in the loss of poly-Ub chain function.
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3.4.6 The predicted secondary structure of HIP2 agrees with the crystal state
Using the NMR chemical shift assignments, the secondary structure of HIP2 was
determined and when compared to the secondary structure observed in the crystal state,
all of the major α-helices and β-strands are retained in solution. This is an important
result supporting the validity of using the crystal structure as an accurate representation
of HIP2 in solution. The matching secondary structure also provides evidence that the
C170S substitution is non-perturbing, supporting previous enzymatic evidence that this
substitution remains fully functional (30). The resonance assignments of HIP2 can now
be used to perform studies where interacting residues can be identified.

3.4.7 General conclusions
The E2 conjugating enzymes are crucial components involved in both Ub transfer
and poly-Ub chain formation in the ubiquitin proteosome pathway. Although all of the
enzymes involved in these processes have been identified, the understanding of the
structural mechanisms detailing how Ub is built into chains is still poorly explained. The
structure of the HIP2 enzyme was solved through X-ray crystallography (unpublished)
(2), but there were no NMR experiments or data for HIP2 available in the literature. To
expand the structural knowledge of HIP2 and its function, the backbone resonances were
assigned for the purpose of interaction studies between attached Ub and Ub2 (Chapter 4).
Since NMR provides residue specific details, these interactions can be mapped onto the
high-resolution structure of HIP2 that will provide important information on the
mechanisms of HIP2 function in Ub transfer and poly-Ub chain formation.
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Chapter 4
Novel Intramolecular Contacts Observed Between the HIP2
UBA Domain and Ubiquitin within a HIP2-Ub2 Thiolester
Mimic

4.1 Introduction
The enzyme HIP2 (E2-25K) is known to produce unanchored K48-linked polyUb chains in solution using only the E1 activating enzyme and ubiquitin (Ub) molecules
as substrates (1). The biological significance of unanchored chain building by HIP2
remains debatable, but a better understanding of how HIP2 accomplishes this activity
should shed light on how K48-linked poly-Ub chains are constructed. Experiments in
Chapter 2 demonstrate that HIP2 and its thiolester mimic do not significantly dimerize. It
was also demonstrated that the HIP2~Ub thiolester is the sole reactive species needed to
form poly-Ub chains. Therefore, further studies with HIP2 thiolesters should help clarify
the mechanisms for HIP2 function. Multiple mechanisms have been proposed for the
assembly of poly-Ub chains in various ubiquitination pathways. These mechanisms
include the formation of poly-Ub chains on the E2 enzyme, formation of free poly-Ub
chains in solution that could then be loaded onto E2 enzymes for transfer to the substrate
in a single transfer reaction, and a sequential addition mechanism where a poly-Ub chain
bound to a substrate is sequentially extended through a series of transfer reactions. HIP2
may function biologically by any of these mechanisms.

Results from Chapter 2

demonstrated that free Ub and HIP2-Ub disulphide could act as Ub acceptors in poly-Ub
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chain formation. This indicates that mechanisms of preassembly of poly-Ub chains built
on HIP2 or freely in solution and followed by loading these chains onto HIP2 could result
in the creation of HIP2~Ubn thiolester intermediates.
In order to study these possible intermediates, HIP2~Ub and HIP2~Ub2 thiolester
mimics were produced for structural investigation. The backbone assignment of HIP2
from Chapter 3 was essential to determine residue specific chemical shift values for the
HIP2 enzyme.

NMR studies can provide residue specific information that allows

determination of interaction surfaces within HIP2-Ub and HIP2-Ub2. These studies will
help clarify possible mechanisms of HIP2 function.

4.2 Materials and Methods
4.2.1 Protein expression and purification
Ubiquitin variants UbK48R and UbG76C were overexpressed as either unlabelled or
15

N,

13

C-labelled proteins and purified as described previously (2). HIP2C170S (simply

referred to as HIP2) was overexpressed as either unlabelled, uniform

15

N, or

15

N, 13C-

labelled and purified as described previously (Section 3.2.2). The identity of purified
HIP2 was confirmed by mass spectrometry (HIP2 – MWobs 22534.8 ± 0.3 Da, MWcalc
22534.7;
Da).

15

N,

13

C-labelled HIP2 (*HIP2) – MWobs 23778.9 ± 1.4 Da, MWcalc 23812.8
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4.2.2 Diubiquitin synthesis
A K48-linked diubiquitin chain was constructed using purified UbG76C (UbP) and
UbK48R (UbD) proteins. HIP2 was utilized in a free poly-Ub chain reaction with the
reactants UbP and UbD to yield predominantly a blocked diubiquitin species (UbP-UbD).
The formation of UbP-UbD was catalyzed by human E1 activating enzyme (UBE1)
(BostonBiochem) and HIP2 as previously described (3). Purified 15N,

13

C-labelled UbP

and UbD (*UbP and *UbD) were utilized to alternatively label diubiquitin products (*UbPUbD and UbP-*UbD). The purity of UbP-UbD, and thus the purity of each individual
ubiquitin variant, was confirmed with electrospray ionization mass spectrometry
(unlabelled UbP-UbD: MWobs 17169.2 ± 0.7, MWcalc 17169.7). The correct mass of
*UbP-UbD and UbP-*UbD was confirmed with mass spectrometry on their disulphide
complexes with HIP2 (Section 4.2.3).

4.2.3 HIP2-diubiquitin disulphide complex formation
Stock solutions of UbP, UbP-UbD and HIP2 (0.1 mM each) were reduced using
freshly made 5 mM TCEP. HIP2 was combined with a 2-fold excess of UbP or UbP-UbD
and dialyzed against several changes of 100 mM Na2HPO4/NaH2PO4, 200 mM NaCl, 10
µM CuCl2 at pH 7.4 and 4 °C.

This mild oxidation buffer drives the creation of

disulphide bonds between the active site C92 of HIP2 and C76 of UbP mimicking a
thiolester bond. The progress of the disulphide complex formation was monitored by
non-reducing SDS-PAGE and was considered complete when the reduced HIP2 was
exhausted.

The protein solution was concentrated and purified by size exclusion

chromatography on a Sephadex G-75 column with 100 mM Na2HPO4/NaH2PO4, 200 mM
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NaCl, 3 mM EDTA at pH 7.4. Fractions containing pure HIP2-UbP or HIP2-UbP-UbD
were pooled and extensively dialyzed against 100 mM Na2HPO4/NaH2PO4, 400 mM
NaCl and 3 mM EDTA buffer at pH 7.4 for NMR experiments. Complex formations
were confirmed by mass spectrometry for [15N]HIP2-UbP (MWobs 31402.9 ± 2.3 Da,
MWcalc 31402.6 Da), HIP2-UbP-*UbD (MWobs 40165.56 ± 4.6 Da, MWcalc 40184.4),
HIP2-*UbP (MWobs 31602.5 ± 0.8 Da, MWcalc 31616.6 Da) and HIP2-*UbP-UbD (MWobs
40169.1 ± 2.3 Da, MWcalc 40183.4 Da).

4.2.4 NMR sample preparation
In order to properly compare NMR spectra for variably labelled HIP2, UbP, UbD,
UbP-UbD, HIP2-UbP and HIP2-UbP-UbD complexes, all proteins were extensively
dialyzed into identical buffer conditions of 100 mM Na2HPO4/NaH2PO4, 400 mM NaCl
and 3 mM EDTA buffer at pH 7.4. The proteins HIP2, UbP and UbP-UbD include the
addition of freshly made 1 mM DTT to ensure cysteine residues remain reduced. The
400 mM NaCl was optimized to maximize solubility of the HIP2-UbP complex. All
proteins were concentrated using a 10000 MWCO Amicon spin concentrator (Millipore).
NMR samples were prepared using concentrated stock solutions of each protein by
adding 10% D2O (v/v), 1% 10 mM DSS (v/v), 0.05% NaN3 (v/v), and 0.8% Complete
MINI EDTA-free protease inhibitor tablet (Roche) solubilized with 1 mL H2O (v/v). The
final concentrations in each NMR sample were 525 µM *HIP2, 357 µM *HIP2-UbP, 550
µM *HIP2-UbP-UbD, 600 µM *UbD, 350 µM UbP-*UbD, 340 µM HIP2-UbP-*UbD, 600
µM *UbP, 600 µM *UbP-UbD, 433 µM HIP2-*UbP, and 325 µM HIP2-*UbP-UbD.
Protein concentrations of Ub were determined by weight of lyophilized proteins and UbP-
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UbD concentrations were estimated by comparison to lyophilized weights and estimating
30% loss of material in reactions.

HIP2, HIP2-UbP and HIP2-UbP-UbD protein

concentrations were determined with Bradford (BioRad) reactions performed in triplicate.

4.2.5 NMR spectroscopy
The uncomplexed proteins HIP2, UbP, UbD and UbP-UbD as well as the HIP2-UbP
and HIP2-UbP-UbD disulphide complexes were characterized by NMR spectroscopy by
isotopic labelling of only one protein component at a time. In this way *UbP, *UbD and
*HIP2 components allowed for residue specific interaction surfaces to be determined in
the larger protein complexes. All NMR data was acquired using a Varian INOVA 600
MHz spectrometer equipped with a triple resonance cold probe with z gradients
(Biomolecular NMR Facility, University of Western Ontario). Sequential assignments
for the backbone residues of *UbD, *UbP, *UbP-UbD and UbP-*UbD were performed
utilizing 1H-15N HSQC (4) and HNCA (5) experiments at 30 °C. Disulphide protein
complexes with labelled Ub (HIP2-*UbP, HIP2-*UbP-UbD and HIP2–UbP-*UbD) were
used to collect 1H-15N HSQC spectra at 30 °C and assigned by comparison to the
uncomplexed proximal or distal labeled Ub and Ub2. Protein complexes with labelled
HIP2 (*HIP2, *HIP2–UbP, and *HIP2–UbP-UbD) were used to collect 1H-15N TROSYHSQC (6) spectra at 35 °C, and assigned by comparison to HIP2 assignments from
Chapter 3. Chemical shift perturbations were calculated according to ∑Δδ = [Δδ(1H)2 +
((0.2)Δδ(15N))2]0.5, where Δδ(1H) and Δδ(15N) represent the change in chemical shift in
1

H (proton) and 15N (nitrogen) atoms within a protein backbone amide bond (7).
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4.2.6 Sedimentation equilibrium
Sedimentation equilibrium experiments were performed in a Beckman Optima
XL-A analytical ultracentrifuge with UV/VIS optics. An An-60 Ti analytical rotor was
used with a 12 mm thick six-channel equilibrium double sector Epon-charcoal
centerpiece with quartz windows. Protein samples were loaded in triplicate (100 µL
protein) with matching reference samples containing dialysis buffer (110 µL).
Absorbance measurements were collected at 280 nm in 0.002 cm radial steps and
averaged over 10 readings. Experiments were performed at 5 °C and at rotor speeds of
12, 15, 18 and 21000 rpm. A delay of 20 hours at the first speed was used to allow the
sample to reach equilibrium, and further increases in speed were allowed 8 hours to reach
equilibrium before readings were measured. At each speed two scans were performed
two hours apart and superimposed to confirm that equilibrium had been properly
achieved.

Prior to centrifugation HIP2-UbP-*UbD was dialyzed into 100 mM

Na2HPO4/NaH2PO4, 400 mM NaCl and 3 mM EDTA at pH 7.33 for 24 hours. Sample
concentrations (10.9 µM, 8.7 µM and 5.7 µM) were determined by dilution of a higher
concentration stock solution using dialysis buffer. The protein integrity was confirmed
after the experiments using electrospray mass spectrometry (MWobs 40162.2 ± 2.6 Da;
MWcalc 40184.4 Da)
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4.3 Results
4.3.1 Protein expression and purification
Ubiquitin variants UbK48R, UbG76C and HIP2C170S (henceforth referred to as HIP2)
were overexpressed as either unlabelled, or uniform 15N, or 15N, 13C-labelled proteins and
purified as described previously (Section 2.2.1, 3.2.2).

The molecular weight of

unlabelled HIP2 was confirmed using electrospray ionization mass spectrometry whereby
a major peak was observed (MWobs 22534.8 ± 0.3 Da) at the expected molecular weight
(MWcalc 22534.7). The molecular weight of

15

N,

13

C-labelled HIP2 (*HIP2) was also

confirmed with mass spectrometry to have 97.3% isotopic label incorporation with a
single major peak observed (MWobs 23778.9 ± 1.4 Da) at the expected molecular weight
(MWcalc 23812.8 Da). The correct molecular weight of ubiquitin variants was confirmed
in Ub2 complexes (Section 4.3.2).

4.3.2 Creation of lysine-48 linked diubiquitin using ubiquitin variants
The enzyme HIP2 is known to produce unanchored K48-linked poly-ubiquitin (poly-Ub)
chains in solution using only the E1 activating enzyme and free ubiquitin (Ub) molecules
as substrates (1). Utilization of the ubiquitin variants UbG76C (UbP) and UbK48R (UbD)
allows K48-linked poly-Ub chain extension to be blocked on both sides such that a Ub2
(UbP-UbD) product accumulates in solution. The predominant product from this poly-Ub
chain reaction is UbP-UbD since UbP is blocked from C-terminal chain extension by the
G76C substitution, and UbD is blocked from K48 extension by the K48R substitution.
The abbreviation UbP is used to denote the proximal Ub that can be directly attached to
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the E2 enzyme through a disulphide bond. The abbreviation UbD is used to denote the
distal Ub in Ub2 that forms a peptide bond to K48 of UbP. The formation of the
diubiquitin (UbP-UbD) species was catalyzed by the E1 activating enzyme and HIP2 and
purified using anion exchange followed by cation exchange to yield purified diubiquitin
as described previously (Fig 4.1) (3). The larger Ubn by-products are likely the result of
very low amounts of non K48-linked chains that form after all Ub K48 residues are
exhausted. Purified

15

N,

13

C-labelled UbP (*UbP) and

15

N,

13

C-labelled UbD (*UbD)

proteins were utilized in conjunction with unlabelled UbP and unlabelled UbD to produce
*UbP-UbD and UbP-*UbD.

The molecular weight of UbP-UbD was confirmed using

electrospray ionization mass spectrometry as a single major peak was observed (MWobs
17169.2 ± 0.7 Da) at the expected molecular weight (MWcalc 17169.7 Da) (Fig 4.1). The
correct molecular weight of *UbP-UbD and UbP-*UbD was confirmed with mass
spectrometry on their disulphide complexes with HIP2 (Section 4.3.3).

4.3.3 HIP2-Ub and HIP2-Ub2 disulphide complex formation
In order to examine the mechanisms of assembly of a poly-Ub chain at the active
site cysteine and/or the transfer of preassembled chains thiolester linked to the active site,
HIP2 complexes were synthesized carrying either one or two Ub molecules at the active
site. To mimic the HIP2~Ub thiolester a disulphide complex was formed between the
catalytic cysteine (C92) and ubiquitin carrying a C-terminal cysteine substitution UbG76C
(UbP). A C170S substitution in HIP2, shown to retain all activity in comparison to the
wild type protein (8), was used to provide specificity for the disulphide formation. A
single ubiquitin (UbP) or diubiquitin (UbP-UbD) was linked to the catalytic cysteine

Figure 4.1 Formation and purification of K48-linked diubiquitin (UbP-UbD). Purified UbD (lane 1) and purified UbP (lane 2) are reacted
at final concentrations of 13.6 mg / mL for each substituted Ub species, with 0.1 µM E1, 20 µM HIP2, 2.5 mM Mg/ATP solution,
0.5mM DTT and 50 mM HEPES pH 8.0 buffer containing ATP regeneration enzymes. The resulting products are predominantly Ub2
(UbP-UbD) after 16.5 hrs (lane 3) and 21 hrs (lane 4). The Ub2 is stable to reducing agent (lane 5) as 5mM DTT was added to confirm
peptide bond formation. The Ub2 product is then purified on an anion exchange column to remove E1, HIP2 and trace high molecular
weight ubiquitinated species (lane 6). Finally Ub, Ub2, and Ub3 can be separated when the products are acidified to pH 4.5 and cation
exchange column (S-column) was used with a very gradual salt elution leaving pure Ub2 (lane 7). Electrospray ionization mass
spectrometry indicates UbP-UbD is the correct mass.
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of HIP2 using mild oxidation, and the HIP2-UbP and HIP2-UbP-UbD products were
purified from other disulphide by-products using size exclusion chromatography (Fig
4.2A). This approach allowed for selective isotopic labeling (15N and/or

13

C) of each

individual protein component in HIP2-UbP (*HIP2-UbP, HIP2-*UbP) or HIP2-UbP-UbD
(*HIP2-UbP-UbD,

HIP2-*UbP-UbD,

HIP2-UbP-*UbD)

complexes

for

NMR

characterization. The creation of HIP2-*UbP and HIP2-*UbP-UbD and purification was
monitored with SDS-PAGE in Figure 4.2B. Electrospray ionization mass spectrometry
was used to confirm labelled molecular masses of protein complexes. The molecular
weight of N15, C13 labelled HIP2 (*HIP2) complexes was confirmed with mass
spectrometry to have 100% isotopic label incorporation for *HIP2-UbP (MWobs 31402.9
± 2.3 Da, MWcalc 31402.6 Da), while the correct molecular weight of *HIP2-UbP-UbD
was confirmed by mass spectrometry on the reactants *HIP2 and UbP-UbD (Section 4.3.1,
4.3.2). The molecular weight of N15, C13 labelled UbP (*UbP) complexes was confirmed
with mass spectrometry to have an isotopic incorporation of 97% for both HIP2-*UbP
(MWobs 31602.5 ± 0.8 Da, MWcalc 31616.6 Da) and HIP2-*UbP-UbD (MWobs 40169.1 ±
2.3 Da, MWcalc 40183.4 Da). The molecular weight of HIP2-UbP-*UbD was confirmed
with mass spectrometry to have an isotopic incorporation of 96% (MWobs 40165.56 ± 4.6
Da, MWcalc 40184.4).

4.3.4 Backbone resonance assignment of HIP2 and diubiquitin
In order to identify residues in HIP2 that interact with Ub or Ub2 in the disulphide linked
HIP2-Ub or HIP2-Ub2 species, the backbone resonance assignments for HIP2 were
completed using standard triple resonance experiments (Chapter 3). To maximize
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Figure 4.1 Formation and purification of K48-linked diubiquitin (Ub -Ub ).

Figure 4.2 Schematic representation of disulphide complex creation. (A) The
diagram shows the reaction mechanism used to create a disulphide bond (-S-S-)
between the E2 conjugating enzyme HIP2 and either a single UbG76C (UbP) or
diubiquitin UbG76C-UbK48R (UbP-UbD). (B) An SDS-PAGE gel was used to monitor
the specific disulphide complex formation with dual labelled proximal Ub (*UbP).
Displayed in the gel are molecular weight ladders (lane 1, 7), purified HIP2 (lane
2), purified *UbP (lane 3), purified K48-linked diubiquitin (*UbP-UbD) (lane 4),
complexation reaction for HIP2-*UbP (lane 5), complexation reaction for HIP2*UbP-UbD (lane 6). Disulphide by-products were removed from disulphide
complexes by extensive size exclusion chromatography yielding purified HIP2*UbP (lane 8), and purified HIP2-*UbP-UbD (lane 9). Molecular weights of
standards are listed to the left of the gel, and protein species are listed to the right
of the gel.
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the NMR signal-to-noise of HIP2 in these large protein complexes, collection of a high
quality 1H-15N TROSY-HSQC and HNCA spectra of HIP2 was performed at 35 °C. This
higher temperature allowed for the assignment of one additional residue, V157 (not seen
in Chapter 3), to yield assignment of 176 out of 187 (94%) non-proline 1H and 15N amide
resonances (Fig 4.3). Many of the remaining unassigned residues are located in the Nterminus (M1, N3), the loop between α1 and β1 (E20, T22), the loop between β1 and β2
(D33, E34, F36) as well as the proposed flexible linker between the catalytic core α4 and
the UBA domain α5 (S159, E161). These residues are likely in highly flexible and
solvent exposed regions, resulting in their

1

H and

15

N amide resonances being

unobservable due to fast amide exchange with water.
In order to identify the residues in the proximal and distal Ub moieties that
interact within HIP2-Ub and HIP2-Ub2 complexes the backbone chemical shift
assignments were also completed for *UbP, *UbD, *UbP-UbD and UbP-*UbD using HSQC
and HNCA experiments to compare to a previous Ub HSQC spectrum (9).

The

remaining spectra of larger HIP2 complexes (*HIP2-UbP, *HIP2-UbP-UbD, HIP2-*UbP,
HIP2-*UbP-UbD, HIP2-UbP-*UbD) were assigned by HSQC or TROSY-HSQC
comparison to the assigned smaller precursor species (*UbP, *UbD, *UbP-UbD, UbP*UbD, *HIP2).

4.3.5 HIP2 interactions with UbP within HIP2-UbP
In the HIP2-UbP disulphide, UbP is covalently linked to the active site cysteine (C92) of
HIP2. Using 1H-15N TROSY-HSQC spectra and the assigned backbone resonances for
HIP2, the position of each residue in HIP2 was assigned upon formation of HIP2-UbP to
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Figure 4.3 1 H-15N TROSY-HSQC spectrum of HIP2. Backbone amide signals are labelled with
amino acid single letter codes and sequence numbers. Signals connected by lines indicate side
chain amide resonances from Asn and Gln residues. The signals marked with (*) represent side
chain amides from Trp residues, while arrows indicate signals that are shifted further downfield
in 1H than 10ppm. The spectra was collected on a 15N, 13C-labelled HIP2 sample (525 µM) in
10% D2 O, 400 mM NaCl, 1 mM DTT, 3 mM EDTA, 100 mM Na2HPO4/NaH2PO4 pH 7.4 at 35
°C.
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determine how the Ub moiety interacts with HIP2 (Fig 4.4A).

These experiments

showed that the largest changes in chemical shift upon formation of HIP2-UbP occur in
residues found in α1 (R8, I9, R11, F13, K18), β1 (K28, V29, D30), β2 (G41, I43), β3
(K61), the loop containing the active site between β4 and α2 (F75, K78, I79, I84, S85,
S86, T88, G89, M104), α2 (L110), the loop between α2 and α3 (E121, D124) and α3
(V129) (Fig 4.4B). Other regions experiencing significant line broadening include the
loop between α1 and β1 (K24, I27), β4 (V73), the loop containing the active site between
β4 and α2 (H81, V87, I91-D98 (surrounding the active site cysteine C92), A101), α2
(T105, L106, V109), the loop between α2 and α3 (Q126, D127), and α3 (V130) (Fig
4.4B). This significant line broadening is likely due to a decrease in mobility of these
residues at the HIP2-UbP interface or due to intermediate exchange between structures
where the UbP might occupy several different locations on HIP2. The residues with the
largest changes in chemical shift and line broadening upon formation of HIP2-UbP were
mapped onto the surface of HIP2 (Fig 4.4C). The most highly affected residues straddle
the active site C92 between β4 and α2. Residues I84-G89 undergo the largest chemical
shift changes and residues I91-D98 containing a very short 310 helix structure (I95-D98 –
hence forward the ‘active site’ helix) undergo severe line broadening. Another highly
affected region near the active site includes residues in the loop between α2 and α3 and
the N-terminus of α3. Together all of these residues combine to account for the major
surface of HIP2 that is likely in direct contact with the covalently bound UbP (Fig 4.4C).
It is also evident that there are minimal chemical shift changes in the UBA domain of
HIP2 upon formation of HIP2-UbP. Although the HIP2 UBA domain has been

Figure 4.4 Identification of chemical shift changes in HIP2 upon formation of HIP2-UbP. (A) Expanded region of 600 MHz 1 H-15N TROSYHSQC spectra collected for *HIP2 (black) and *HIP2-UbP (green). Signals that undergo significant chemical shift changes (>1 S.D. above the
mean) are labelled by residue and shifts are indicated with arrows, while signals that experience significant line broadening (disappear) are
labelled without arrows. (B) Bar graph of chemical shift changes observed between *HIP2 and *HIP2-UbP spectra. The dotted line (red)
indicates the threshold for significant chemical shift changes (mean + one standard deviation). Chemical shift changes are calculated using the
equation in 4.2.5. Red asterisks indicate signals that undergo significant line broadening. (C) Ribbon and surface representation of HIP2 with
‘relaxed’ tail (Chapter 2) showing interaction with UbP and labelled according to secondary structure. Residues are coloured to indicate the
active site cysteine (orange), residues undergoing significant chemical shift changes (cyan), and residues experiencing significant line
broadening (purple).
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shown to interact non-covalently with Ub (10, 11), the results shown here indicate a UBA
interaction with the disulphide bound Ub in HIP2-UbP does not occur.

4.3.6 Intramolecular interactions within HIP2-UbP-UbD
In order to understand the effects of placing a second ubiquitin molecule on the
growing poly-Ub chain linked to the catalytic cysteine, the 1H-15N TROSY-HSQC
spectra of *HIP2-UbP-UbD was compared with that of *HIP2-UbP. A structural analysis
of HIP2-UbP-UbD could provide important insights into both the assembly and the
mechanism of transfer of prebuilt ubiquitin chains onto substrate molecules. Comparison
of *HIP2-UbP-UbD and *HIP2-UbP demonstrate large differences in chemical shift
involving residues in α1 (F13), the active site loop between β4 and α2 (I76, N83, I84,
G89, A90, A102), the loop between α2 and α3 (A119, D124, Q126), the loop between
α5 and α6 (M172, G173, F174), the N-terminus of α6 (N177), and the C-terminus of α7
(V190) (Fig 4.5A). Most of the large chemical shift changes upon diubiquitin attachment
occur on the UBA domain of HIP2 (Fig 4.5B), something that was not observed with a
single Ub thiolester mimic. Residues M172, G173, F174 and V190 form an exposed
hydrophobic interaction surface on the UBA domain in the loop connecting α5 and α6
(Fig 4.5C). Since this hydrophobic MGF patch was not affected upon attachment of UbP,
these residues must interact with the UbD molecule. This hydrophobic patch on the UBA
domain has been previously shown to bind free Ub in both HIP2 and Ubc1 (11, 12). The
same hydrophobic patch on the UBA domain is therefore used to contact both free Ub,
and UbD in HIP2-Ub2.
Several residues from the catalytic core of HIP2 are also undergoing

Figure 4.5 Identification of chemical shift changes in HIP2 caused by the addition of UbD to HIP2-UbP. (A) Expanded region of 600 MHz 1 H15
N TROSY-HSQC spectra collected for *HIP2-UbP (green) and *HIP2-UbP-UbD (magenta). Signals that undergo significant chemical shift
changes (>1 S.D. above the mean) are labelled by residue and shifts are indicated with arrows, while signals that experience significant line
broadening (disappear) are labelled without arrows. (B) Bar graph of chemical shift changes observed between *HIP2-UbP and *HIP2-UbP-UbD
spectra. The dotted line (red) indicates the threshold for significant chemical shift changes (mean + one standard deviation). Chemical shift
changes are calculated using the equation in 4.2.5. Red asterisks indicate signals that undergo significant line broadening. (C) Ribbon and
surface representation of HIP2 with ‘relaxed’ tail (Chapter 2) showing interaction with UbD and labelled according to secondary structure.
Residues are coloured to indicate the active site cysteine (orange), residues undergoing significant chemical shift changes (cyan), and residues
experiencing significant line broadening (purple).
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significant line broadening following attachment of the UbD. This includes residues in
the loop between the ‘active site helix’ and α2 (M104), in α2 (L113, A115), and in the
loop between α2 and α3 (A120, E121, D123) and α3 (A131). Chemical shift changes on
the loop between α2 and α3 (A119, D124, Q126) comprise a small but distinct surface
that is interacting with Ub2 in HIP2-UbP-UbD but not in HIP2-UbP. These chemical shift
changes measured around the active site may indicate a slight change in the position of
UbP upon addition of the second UbD. Residues I91-D98 that were significantly line
broadened in HIP2-UbP remain significantly line broadened in HIP2-UbP-UbD. This
indicates that the surface of interaction previously seen in HIP2-UbP is primarily
maintained. The loop between α2 and α3 could therefore be in contact with either a
slightly repositioned UbP that maintains most of the previous interactions or be in contact
with a small portion of UbD.

In either case, the UBA domain is predominantly

interacting with the UbD and minimal changes are noticed in the vicinity of the active site
in HIP2-Ub2.

4.3.7 HIP2-Ub2 does not significantly dimerize
The HIP2 UBA domain has been shown to preferentially bind poly-Ub chains
over mono Ub in solution (10). The structure of another UBA domain that binds K48linked Ub2 indicated that this specific UBA domain could contact the hydrophobic face
of both Ub moieties at once (13). If the HIP2 UBA domain could interact freely with an
attached Ub or Ub2 molecule on neighbouring HIP2 molecules, it is conceivable that
UBA binding could result in dimerization and/or oligomerization of HIP2-Ub2. To test
this possibility, sedimentation equilibrium studies were performed with HIP2-Ub2 (HIP2-
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UbP-*UbD) in solution at 10.9, 8.7 and 5.7 µM giving masses of 41998 ± 798, 43420 ±
387 and 42810 ± 464 Da respectively. These values range from 4.5% to 8% larger than
the expected mass of 40184.37 Da. These molecular weights are very close to the
approximate error (5%) for this technique, indicating that HIP2-Ub2 is predominantly
monomeric at these three concentrations. These results are consistent with previous
dimerization studies on HIP2 and HIP2-Ub (Chapter 2). Previous experimentation on the
UbcH5c-Ub construct has shown that oligomerization produces a completely line
broadened HSQC spectrum (14, 15).

HIP2-Ub2 does not produce a similar NMR

spectrum, therefore oligomerization at higher concentrations used in NMR studies was
not observed.

The UBA interactions observed here are therefore the result of

intramolecular interactions and not intermolecular interactions involving oligomeric
species.

4.3.8 Combined interactions of both UbP and UbD within HIP2-Ub2
As a control for the comparison of HIP2 to HIP2-Ub and HIP2-Ub to HIP2-Ub2,
the chemical position of each residue in HIP2 was evaluated in comparison to HIP2-Ub2
to determine if the combined addition of Ub2 is consistent with the individual additions of
UbP and UbD. Comparison of 1H-15N TROSY-HSQC spectra of *HIP2 with that of the
*HIP2-UbP-UbD identified residues affected by addition of UbP-UbD (Fig 4.6A).
Significant chemical changes were observed for residues in α1 (R11, F13, V16), β1
(V29), the loop between β3 and β4 (N69), the loop containing the active site between β4
and α2 (I79, N83, S85, G89, A90, A102), α2 (T108), the loop between α5 and α6
(M172, G173, F174), the N-terminus of α6 (N177), and the C-terminus of

Figure 4.6 Identification of chemical shift changes in HIP2 caused by the addition of UbP-UbD to HIP2. (A) Expanded region of 600 MHz 1 H15
N TROSY-HSQC spectra collected for *HIP2 (black) and *HIP2-UbP-UbD (magenta). Signals that undergo significant chemical shift changes
(>1 S.D. above the mean) are labelled by residue and shifts are indicated with arrows, while signals that experience significant line broadening
(disappear) are labelled without arrows. (B) Bar graph of chemical shift changes observed between *HIP2 and *HIP2-UbP-UbD spectra. The
dotted line (red) indicates the threshold for significant chemical shift changes (mean + one standard deviation). Chemical shift changes are
calculated using the equation in 4.2.5. Red asterisks indicate signals that undergo significant line broadening. (C) Ribbon and surface
representation of HIP2 with ‘relaxed’ tail (Chapter 2) showing interaction with UbP-Ub D and labelled according to secondary structure.
Residues are coloured to indicate the active site cysteine (orange), residues undergoing significant chemical shift changes (cyan), and residues
experiencing significant line broadening (purple).
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α7 (V190) (Fig 4.6B). Residues that undergo significant line broadening were identified
in the loop between α1 and β1 (K24, I27), β4 (V73), the loop containing the active site
between β4 and α2 (H81, V87, I91-D98, M104), α2 (T105, L106, V109, L113, A115),
the loop between α2 and α3 (A120, E121, D123, D127), and α3 (V130, A131) (Fig
4.6B). The chemical shift changes observed upon Ub2 attachment to HIP2 occur at the
catalytic core of HIP2 and in the UBA domain of HIP2 that contacts UbD (Fig 4.6C).
Highly affected residues are consistent with individual residue changes noticed between
*HIP2 and *HIP2-UbP combined with changes observed between *HIP2-UbP and *HIP2UbP-UbD.

4.3.9 UbD and UbP interactions within Ub2
In order to identify residues in UbP or UbD that interact with the covalently-linked
HIP2 species, the backbone resonance assignments for *UbP, *UbD, *UbP-UbD, and UbP*UbD were completed using 1H-15N HSQC and HNCA NMR spectra at 30 °C. The
assignment of UbP was 95% complete (72 / 76) for 1H and 15N amide resonances, while
the assignment of UbD was 93% complete (71 / 76) for 1H and 15N amide resonances. All
assigned residues in UbP and UbD were reassigned in *UbP-UbD and UbP-*UbD except for
G76 and R74 which broadened in UbD upon the formation of UbP-*UbD.
Comparison of *UbD and UbP-*UbD spectra indicated that large chemical shift
changes occurred in UbD for residues in β1 (T7), β2 (G10, I13), the loop between β3 and
β4 (G47), β4 (R48, L50), the loop between β4 and α2 (G53), β5 (H68, V70), and the
unstructured C-terminus (L73) (Fig 4.7A). Comparison of *UbP and *UbP-UbD spectra
demonstrated that large chemical shift changes occur in UbP for residues in β1 (T7),
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Figure 4.7 Identification of chemical shift changes between UbD and UbP within Ub2. (A)
Expanded region of 600 MHz 1H-15N HSQC spectra displayed for *UbD (black) and UbP-*UbD
(cyan). (B) Expanded region of 600 MHz 1H-15N HSQC spectra displayed for *UbP (black) and
*UbP-UbD (cyan). Signals that undergo significant chemical shift changes (mean + one standard
deviation) are labelled by residue and shifts are indicated with arrows. Chemical shift changes
are calculated using the equation in 4.2.5, and sample conditions are listed in Section 4.2.4.
Ribbon and surface representation for (C) a structure for ‘closed’ UbP-UbD (PDB: 1AAR) and (D)
a structure for ‘open’ UbP-UbD (PDB: 3AUL). The Ub structure 1UBQ was used to map the
interacting residues onto UbP and UbD. Residues are coloured to indicate residues undergoing
significant chemical shift changes (cyan) and residues experiencing significant line broadening
(purple). The secondary structure of individual Ub components are fully labelled, while ‘open’
and ‘closed’ Ub2 are only partially labelled. The ‘open’ Ub2 is missing residues 74-76 on UbP so
L73 represents the C-terminus. K48* represents the new isopeptide bond that resembles a
backbone amide resonance.
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β2 (G10, I13), the loop between β3 and β4 (A46, G47), β4 (R48, L50), the loop between
β4 and α2 (G53), β5 (H68, V70, R72), and the unstructured C-terminus (L73) (Fig 4.7B).
For both UbP and UbD, these residues are predominantly located on the same β-sheet of
Ub that makes up the classic hydrophobic patch centered on residues L8, I44, and V70.
This hydrophobic patch is the main surface utilized by most Ub-binding domains to
interact with Ub (16). Nearly identical residues in the hydrophobic patch of UbP and UbD
are utilized to interact with each other within the Ub2 complex. These chemical shift
changes are consistent with results obtained by a previous NMR analysis of Ub and Ub2
(13) as well as with the ‘closed’ Ub2 conformation observed in the Ub2 crystal structure
(Fig 4.7C) (17). This ‘closed’ conformation was shown to be in equilibrium with an
‘open’ conformation in solution since relaxation agents can interact with the residues at
the buried interface showing they are solvent accessible (13).

Very recent

experimentation has shown the ‘open’ conformation to be populated approximately 85%
of the time (Dr. Kato personal communication). These results indicate that although
there are chemical shift changes supporting the presence of a ‘closed’ Ub2 structure, this
structure is likely populated to a lesser extent than the preferred ‘open’ state. A structure
for this ‘open’ conformation has been solved in the Kato lab (PDB: 3AUL – personal
communication) where the hydrophobic faces of both UbP and UbD are exposed to
solution and point in the same direction (Fig 4.7D). Assuming there is an equilibrium
between the ‘open’ and ‘closed’ conformation of Ub2, when the ‘open’ structure is
adopted, the hydrophobic faces of UbP and UbD would be exposed and accessible for
interaction with HIP2 within HIP2-Ub2.
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4.3.10 Distal UbD interactions within HIP2-Ub2
In order to study the distal UbD in HIP2-Ub2, the NMR spectra of UbP-*UbD was
compared to that of the HIP2-UbP-*UbD complex (Fig 4.8A). Since the size of the
compared molecules increases from 17651.7 Da (UbP-*UbD) to 40184.4 Da (HIP2-UbP*UbD), line broadening of signals in the spectra was expected and observed. Comparison
of UbP-*UbD with HIP2-UbP-*UbD indicates the distal Ub experiences significant
chemical shift changes in β1 (T7), the loop between β1 and β2 (L8), β2 (I13, T14), the
loop between β4 and α2 (R54), α2 (D58), the loop between α2 and β5 (Q62), β5 (L67,
V70), and the unstructured C-terminus (L73) (Fig 4.8B). Significant line broadening was
also observed for residues in β3 (I44), β4 (R48, Q49, L50), the loop between β4 and α2
(E51), and β5 (L69, L71) (Fig 4.8B). A significant chemical shift and line broadening of
residues on the classic hydrophobic patch of UbD indicates that this surface is interacting
with HIP2 (Fig 4.8C). Previous analysis of *HIP2-Ub2 indicated that the hydrophobic
MGF patch on the UBA domain of HIP2 was responsible for this interaction. This
indicates that the MGF patch of the UBA domain binds to the classic hydrophobic patch
of UbD in HIP2-Ub2.

The significant line broadening of residues around R48 also

indicates that UBA interaction with UbD likely blocks accessibility of R48 (naturally
K48) to additional protein interactions.
A second observable effect on the distal Ub is the apparent doubling of certain
signals. This means that two signals can be observed in relatively close proximity where
there used to be a single signal. Two signals were observable for residues in β2 (T14),
β3 (L43), the loop between β4 and α2 (R54, T55), α2 (D58, Y59), the loop between α2

Figure 4.8 Identification of chemical shift changes in UbD caused by the formation of HIP2-Ub P-UbD. (A) Expanded region of 600 MHz 1H15
N HSQC spectra collected for UbP-*UbD (black) and HIP2-UbP-*UbD (red). Signals that undergo significant chemical shift changes (>1 S.D.
above the mean) are labelled by residue and shifts are indicated with arrows, signals that experience significant line broadening (disappear) are
labelled without arrows, and residues showing signal doubling are indicated with 2 lines. (B) Bar graph of chemical shift changes observed
between UbP-*UbD and HIP2-UbP-*UbD spectra. The dotted line (red) indicates the threshold for significant chemical shift changes (mean +
one standard deviation). Chemical shifts are calculated using the equation in 4.2.5. Red asterisks indicate signals that undergo significant line
broadening. Ribbon and surface representation of Ub D coloured for (C) residues undergoing significant chemical shift changes (cyan) and
residues experiencing significant line broadening (purple) or (D) coloured for the presence of signal doubling (green).
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and β5 (N60, Q62, K63) and β5 (S65). Most of these ‘dual’ signals occur with the first
signal having no change in chemical shift, and the second signal with a moderate change
in chemical shift. These ‘dual’ signals therefore likely represent an interaction in slow
exchange between the UbD moiety and a region of HIP2 in HIP2-Ub2. When mapped
onto the surface of UbD, the residues associated with the ‘dual’ signal are all located on
the N-terminal side, above the hydrophobic patch centered around α2 (Figure 4.8D).
Chemical shift changes between the each set of ‘dual’ signals were often measured to be
insignificant. Therefore, these ‘dual’ signal surfaces were considered to be a fairly weak
interaction. These ‘dual’ signals were also observed on only a small region (R54-S65) of
UbD. This region is relatively exposed to solution in both free Ub and in either the ‘open’
or ‘closed’ Ub2 structure and does not overlap with the hydrophobic face of Ub. The lack
of observable equivalent signal doubling on HIP2 means the exact complementary
interaction surface cannot be confirmed.
When analyzing the data for significant chemical shift changes, the main
interaction is clearly on the hydrophobic patch of UbD. Therefore, UbD likely contacts
the MGF hydrophobic region of the UBA domain of HIP2 in HIP2-UbP-UbD.

4.3.11 Proximal UbP Interactions within HIP2-Ub and HIP2-Ub2
The hydrophobic face of UbP was previously identified to interact with UbD in the Ub2
(*UbP-UbD) complex. In order to study the interactions of UbP within HIP2 complexes,
the spectra of *UbP and *UbP-UbD were compared to that of HIP2-*UbP and HIP2-*UbPUbD. Analysis of the labelled UbP demonstrated how HIP2 interacts with the surface of
UbP. This was first accomplished by comparing the *UbP spectrum to the HIP2-*UbP
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spectrum. In this comparison, significant chemical shift changes (>1SD) were observed
for residues in β2 (I13), β3 (L43), β4 (K48), and β5 (L67, H68) as well as significant line
broadening in the loop between β1 and β2 (L8), β3 (I44), β4 (Q49, L50), β5 (L69-R72),
and the unstructured C-terminal residues L73 and G76 (Fig 4.9A). The main conclusion
from these results is that the hydrophobic face of Ub clearly rests against the HIP2 core
domain upon attachment to the active site of HIP2 (Fig 4.9A – surface diagram). It is
interesting that residue K48 is the most highly shifted residue upon single UbP attachment
to HIP2, as this residue is the key reactive residue in acceptor Ub molecules during polyUb chain formation, only this UbP represents the donor Ub in poly-Ub chain formation.
Comparison of *UbP-UbD and HIP2-*UbP-UbD was utilized to show how UbP in
*UbP-UbD was affected through its direct attachment to HIP2. Chemical shift changes
were observed for residues in β1 (T7), β3 (R42, I44), the loop between β3 and β4 (G47),
β5 (R72), and the unstructured C-terminal L73 (Fig 4.9B).

Residues experiencing

significant line broadening were observed in β5 (V70, L71) and the unstructured Cterminal G75, G76 (Fig 4.9B). The major changes seen at the C-terminal residues were
expected as this is the main attachment point for Ub2 to the HIP2 core. It is interesting
that there are less residues affected at the hydrophobic interface upon Ub2 attachment to
HIP2 (Fig 4.9B) than following attachment of a single ubiquitin to HIP2 (Fig 4.9A). This
result indicates that the addition of UbD alters the interface between UbP and HIP2.
Comparison of HIP2-*UbP and HIP2-*UbP-UbD was utilized to show how the
attachment of UbD affects binding of the proximal UbP to the HIP2 catalytic core.
Comparison of these spectra resulted in the observation that significant chemical shift

Figure 4.9 Identification of chemical shift changes in UbP caused by interaction with HIP2 and UbD. (A) Expanded region of 600 MHz 1H-15N
HSQC spectra collected for *UbP (black) and HIP2-*UbP (blue). (B) Expanded region of 600 MHz 1 H-15 N HSQC spectra collected for *UbP-UbD
(black) and HIP2-*UbP-UbD (orange). (C) Expanded region of 600 MHz 1H-15 N HSQC spectra collected for HIP2-*UbP (blue) and HIP2-*UbPUbD (orange). Signals that undergo significant chemical shift changes (>1 S.D. above the mean) are labelled by residue and shifts are indicated
with arrows, signals that experience significant line broadening (disappear) are labelled without arrows in (A) and (B), and residues showing
signal reappearance are indicated without arrows in (C). Ribbon and surface representations of UbP are labelled according to secondary structure.
Residues are coloured to indicate significant chemical shift changes (cyan), significant line broadening (purple) and signal reappearance (green).
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changes are occurring for residues in β1 (T7), β3 (F45), β4 (K48), the loop connecting β4
and α2 (E51), and β5 (L67, H68). The large chemical shift change for K48 is expected
on UbP as this residue is the attachment site for UbD. Significant chemical shift changes
are also seen on the N-terminal region of the UbP hydrophobic face due to direct contact
with UbD (Fig 4.9C). Many signals previously line broadened when a single Ub was
attached to the HIP2 core were also observed to ‘reappear’. These ‘reappearing’ signals
were observed for residues in the loop between β1 and β2 (L8), β3 (I44), β4 (Q49, L50),
β5 (L69, R72), and the unstructured C-terminal L73 (Fig 4.9C). These residues are
located in the C-terminal region of the UbP hydrophobic face showing that this
interaction surface that was previously line broadened in HIP2-UbP spectra is now visible
in the HIP2-UbP-UbD spectra (Fig 4.9A, C). The cause for the reappearance of signals is
likely due to the disruption of protein interactions between HIP2 and UbP upon the
addition of UbD. The resulting UbP is therefore less closely associated with the HIP2
core domain.

4.4 Discussion
4.4.1 HIP2 surface involved in interaction with UbP
The surface of HIP2 utilized to contact UbP was determined by comparing the 1H15

N TROSY-HSQC spectra of *HIP2 and *HIP2-UbP. The residues highly affected in

HIP2 upon attachment of UbP are located predominantly near the active site cysteine on
the catalytic core of HIP2. It is also clear that there are minimal chemical shift changes
in the UBA domain of HIP2 upon formation of HIP2-UbP. Previous studies support this
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observation, as the Ubc1-UbP disulphide also shows no contacts between UbP and the
UBA domain (2). Although free Ub has been shown to interact with the UBA domain of
HIP2 in solution (10, 11, 18), an interaction between the UBA domain and covalently
bound Ub in HIP2-UbP does not occur (Fig 4.10A).
Models of E2-Ub have been developed for Ubc1-Ub (20), and UbcH8-Ub (19),
and structures have been presented for hUbc13-Ub (21), and UbcH5b-Ub (22, 23). The
positioning of Ub is different for each E2 enzyme. Recent experiments with Ubc13-Ub
and UbcH5b-Ub have shown the covalently attached Ub to be highly mobile, indicating
the Ub molecule likely does not adopt a single conformation on the surface of these E2
enzymes (24).

Therefore, the high-resolution models and structures of all E2-Ub

complexes may represent ‘snap shots’ showing a preferential position of an otherwise
highly mobile attached Ub that can adopt several orientations when bound to an E2. The
interaction surface for Ub on the HIP2 catalytic core seems to include residues radiating
out in all directions from the attachment point of C92. No single Ub position can account
for all of these chemical shift changes and line broadening signals. This indicates that
UbP may be sampling various bound positions on the HIP2 core (Fig 4.10A). The
missing signals from significantly line broadened residues (I91-D98) may actually
represent the strongest interaction surface between HIP2 and UbP. Signal broadening
may be the result of intermediate exchange between the bound and the unbound position
of Ub on HIP2, which could indicate that these residues at the active site and in the
‘active site helix’ represent the main contact surface between HIP2 and UbP in HIP2-UbP.
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Figure 4.10 Models of combined interaction surfaces within HIP2-UbP and HIP2-UbP-UbD. (A)
Model of *HIP2-Ub P indicating interactions on HIP2. (B) Model of HIP2-*UbP indicating
interactions on UbP. (C) Combined model of HIP2-Ub P indicating interactions between HIP2 and
UbP derived from interactions shown in (A) and (B). (D) Model of *HIP2-UbP-UbD indicating
interactions on HIP2 upon addition of Ub2. (E) Model of HIP2-Ub P-UbD indicating surfaces on
UbP and UbD that are affected by interaction with HIP2 derived from *UbP-UbD versus HIP2*UbP-UbD and UbP-*UbD versus HIP2-UbP-*UbD. (F) Combined model of HIP2-UbP-UbD
derived from interactions observed in (D) and (E). Models in (D) and (E) are depicted
simplistically, while the slightly altered model in (F) is depicted to better represent protein
positioning. The UBA domain was rotated to visualize the hydrophobic patch. Ribbon and
surface representations are based on previous structures of HIP2-Ub P (HIP2 PDB:1YLA with
altered UBA positioning and PDB:2GMI for UbP positioning to match Ubc13~Ub) and HIP2UbP-Ub D (PDB:3AUL bound manually to HIP2). Residues are coloured for the active site
cysteine (orange), significant chemical shift changes (cyan), and significant line broadening
(purple). Shaded area of simplistic models indicates interaction surfaces and two sided arrows in
ribbon models are coloured identically to indicate these interaction surfaces. The orange arrow
and circled region in (F) indicates the region of UbD that undergoes signal doubling and the
probable region of the HIP2 catalytic core that interacts with UbD.
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Previous experiments with the Ubc1Δ~Ub thiolester (no UBA) indicates Ub interacts
with Ubc1Δ α2 helix and is the basis of the ‘compact’ E2-Ub model (20). The results on
HIP2 show α2 to be less affected upon UbP attachment, indicating a HIP2-UbP structure
likely would not be identical to the previously reported structure for Ubc1-UbP.
Recent studies on Ubc1 found that residues T84 and Q122 were instrumental in
poly-Ub chain formation (25). The equivalent residues in HIP2, T88 and Q126, undergo
either a significant chemical shift (T88) or significant line broadening (Q126) upon UbP
attachment. This demonstrates that these residues are affected by the attachment of a
disulphide bound Ub at the active site. This may indicate these residues are important for
the correct positioning of the thiolester bound Ub to aid in poly-ubiquitination activity.

4.4.2 UbP surface involved in interaction with HIP2
Comparison of the 1H-15N HSQC spectra of *UbP and HIP2-*UbP indicates that
the hydrophobic patch on UbP binds to the HIP2 catalytic core domain. This interaction
was observed through the extreme line broadening of signals from residues on the
hydrophobic patch of UbP, and confirms the corresponding interaction surface observed
around the HIP2 active site (Fig 4.10B). The combined interaction surfaces between
HIP2 and UbP are depicted in Figure 4.10C whereby the HIP2-UbP structure was built by
alignment to the Ubc13-Ub structure.

This structure is consistent with SAXS data

(Chapter 2) indicating that it best represents the average position of Ub within HIP2-UbP.
It is clear that the UbP depicted in Figure 4.10C must undergo a rotation to bury its
exposed yet interacting hydrophobic patch, while retaining the same general Ub position
to agree with the average SAXS structure. Although Figure 4.10C represents a ‘snap
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shot’ of the average HIP2-UbP structure, UbP may be mobile allowing for a mixture of
elongated and compact structures. A highly mobile UbP may transiently bind to several
locations on HIP2, which may explain why the interaction surface on HIP2 is located
both above and below the UbP attachment point (Fig 4.4C). The severe line broadening
in select residues is likely due to intermediate exchange between the association and
dissociation of UbP with the catalytic core of HIP2. Intermediate exchange is consistent
with a highly mobile Ub in HIP2-UbP that could oscillate between an unbound and at
least one bound position for UbP.
The hydrophobic patch on UbP has been shown to be affected by attachment to
other E2 enzyme catalytic cores from Ubc1 (20), Ubc13 (24), Ubc2b (26), and Ube2S
(27). However, the hydrophobic surface of Ub is not always utilized in E2-Ub contacts.
For example, UbcH8 utilizes a different contact surface on UbP (19), and UbcH5c does
not seem to bind UbP (14, 15). Thus, HIP2 associates with the hydrophobic face of UbP
while some other E2 enzymes do not.

Regardless of high mobility, differences in

preferred Ub orientations in E2~Ub thiolester structures may play a role in E3 ligase and
substrate specificity by presenting alternate available interaction surfaces on various
E2~Ub structures.

4.4.3 HIP2 UBA binds UbD
The surface of HIP2 utilized to contact Ub2 was determined by comparing the 1H15

N TROSY-HSQC spectra of *HIP2 and *HIP2-UbP-UbD. Additional changes in HIP2

were observed with the addition of UbD. Some chemical shift changes were observed
around the active site, but the most significant changes occurred in residues that form a
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hydrophobic patch (M172, G173, F174 and V190) on the UBA domain of HIP2. The
importance of this MGF hydrophobic patch is demonstrated by the high conservation of
this sequence across many UBA domain alignments (28). Recent studies on HIP2 show
this hydrophobic patch (M172-F174, V190, T194, L198) on the UBA domain binds free
Ub (11, 18). This result indicates the UBA hydrophobic patch used to bind free Ub in
solution is also used to contact UbD in a covalently attached HIP2-Ub2 complex (Fig
4.10D). Ubc1 was also observed to bind free Ub through the UBA domain utilizing the
similar QGF residues in the loop between α5 and α6 as well as many residues in α7 (12).
HIP2 binding to free Ub also involved some α7 residues (T194, L198) (11). These
residues in α7 that interact with free Ub were not seen to interact with UbD of the HIP2UbP-UbD construct. The lack of full interaction of the UBA α7 residues with UbD may be
due to intramolecular steric constraints within the HIP2-Ub2 complex that allows only a
limited surface of the UBA to contact the UbD.
Previous experiments with a similar UBA2 domain from hHR23A demonstrated
UBA binding to free K48-linked Ub2 chains (13). This UBA2 binding to Ub2 utilized the
end of α2 (α6 in HIP2) and most of α3 (α7 in HIP2) to simultaneously contact both the
proximal and distal Ub (13). The HIP2 UBA domain has also been shown to bind Ub2
chains more strongly than a single Ub moiety and thus may bind Ub2 through the same
residues used with UBA2 (10). In HIP2-Ub2, however, very few chemical shift changes
in the UBA domain were observed to match the pattern of Ub2 binding identified in the
hHR23A UBA2 domain (13). These results indicate that the UBA domain does not
position itself in a similar fashion to bind both UbP and UbD in HIP2-UbP-UbD as it likely
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could with free Ub2. This is likely the result of intramolecular steric constraints that do
not allow UbP to contact the UBA domain.
Residue N177 at the beginning of α6 was also affected upon UbD attachment, but
faces the opposite direction of the hydrophobic patch. This residue was not observed in
binding to free Ub or Ub2 in the UBA2 domain of hHR23A (13), to free Ub in Ubc1 (12),
or to free Ub in the HIP2 UBA domain (11).

N177 therefore represents a novel

interaction point in the HIP2-Ub2 complex, and its shifting cannot be explained by
comparison to other UBA-Ub interactions. It is not immediately apparent what region of
the HIP2-Ub2 complex contacts UBA domain residue N177.

4.4.4 HIP2-Ub2 does not dimerize
The HIP2 UBA domain has been shown to bind Ub (11, 18), and poly-Ub chains
with even higher affinity (10). These interactions clearly allow for the possibility that
two HIP2-Ub2 thiolesters could homodimerize. However, sedimentation equilibrium
results indicated HIP2-Ub2 had very little tendency to oligomerize in solution.
Oligomerization has previously been seen with the UbcH5c-Ub complex that resulted in a
completely line broadened NMR spectrum (14, 15). The NMR spectrum of HIP2-Ub2
did not show similar line broadening of all signals indicating that oligomerization does
not occur.

The mechanism of a UBA driven dimerization is not favoured by the

observation that intramolecular contacts occlude the Ub hydrophobic patch within the
HIP2-Ub and HIP2-Ub2 complexes.

In HIP2-UbP, the hydrophobic surface of UbP

interacts with the catalytic core of HIP2 and is not easily accessible to the UBA domain
of another HIP2 enzyme. Upon formation of HIP2-UbP-UbD, the UBA domain involves

192
itself in an intramolecular interaction with the UbD. These uni-molecular interactions are
likely to be much stronger than a bi-molecular interaction and thus association between
different HIP2 molecules (dimerization) is not preferred.

Extrapolating from these

results, it is expected that the UBA domain will also bind longer chains attached to the E2
enzyme and thus UBA driven dimerization of HIP2 should not be favoured regardless of
covalently attached poly-Ub chain length.

This knowledge further supports the

conclusion that HIP2 poly-Ub chain activity functions in a monomeric fashion as was
suggested in Chapter 2. Since no E3 ligase was used in these studies, E3 assisted
dimerization of HIP2 cannot be ruled out as a possible function of this enzyme in vivo.

4.4.5 The hydrophobic face of UbD binds the HIP2 UBA domain
Analysis of the *HIP2-Ub2 complex indicated that the hydrophobic MGF patch
on the HIP2 UBA domain was significantly affected upon addition of UbD (Fig 4.10D).
Investigation of *UbD in the same HIP2-Ub2 complex identified chemical shift changes
involving residues on the classic hydrophobic patch of *UbD indicating that this surface
was reciprocally affected within this complex (Fig 4.10E). These results indicate that the
MGF patch on the HIP2 UBA domain directly interacts with the hydrophobic patch on
UbD within the HIP2-Ub2 complex (Fig 4.10F – green shaded areas and arrow). These
same interaction surfaces used between UbD and the UBA were previously identified
upon interaction of free Ub with the HIP2 UBA domain (11, 18). This indicates that UbD
is bound by the UBA in the same manner to which it would interact with free Ub.
In order to allow the UBA domain to contact UbD within the HIP2-Ub2 complex,
the hydrophobic face of UbD must be exposed. This would only be possible when Ub2
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adopts the ‘open’ structure allowing for the hydrophobic patch of both UbP and UbD to be
available for interactions with HIP2 (Fig 4.10F). Due to the complex nature of the
interactions involving numerous protein species, computational modelling of HIP2-Ub2
was not performed. However, visual depiction of the protein interaction surfaces are
detailed in Figure 4.10F by manual alignments of Figure 4.10C and the ‘open’ Ub2
structure. Figure 4.10F should be treated as a visual aid only, and rotation of these
proteins to bury the interaction surfaces indicated by double-sided arrows to form a more
globular structure likely represents the true form of the HIP2-Ub2 complex. Visual
interpretation of interaction surfaces and use of the ‘open’ Ub2 structure appears to place
UbD above the loop between α2 and α3 on the HIP2 catalytic core (Fig 4.10F). This
leaves the N-terminal ‘dual’ signal surface of UbD pointing towards the loop between α2
and α3 on HIP2 (Fig 4.10F – orange arrow), while the UBA domain would interact with
the hydrophobic face of UbD (Fig 4.10F – green arrow). The N-terminal ‘dual’ signal
region of UbD was observed to experience a slow exchange between UbD and an
unknown region of HIP2 in HIP2-Ub2. Since many residues in the loop between α2 and
α3 on HIP2 were affected upon addition of UbD, it is likely that this region contacts the
N-terminal ‘dual’ signal region of UbD, although this is only an assumption since
equivalent signal doubling was not observed in the HIP2 spectrum (Fig 4.10F – orange
arrow and circled region).
The structure of the Ub2 moiety has been shown to be in equilibrium between the
‘open’ and ‘closed’ structures. The incorporation of the ‘closed’ structure of Ub2, cannot
be fully discounted but appears unlikely. If the HIP2-Ub2 complex utilized the ‘closed’
structure of Ub2, this would leave the UBA domain to interact weakly through an on and
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off binding equilibrium to the exposed N-terminal region of UbD presumably causing
signal doubling in UbD. The chemical shift changes and line broadening observed for
residues on the buried hydrophobic patch on UbD upon attachment of Ub2 to HIP2 would
then be due to a slight rearrangement of UbD on the face of UbP. This binding mode is
unlikely as the highly affected MGF residues in the UBA domain appear significantly
shifted and contain no trace of equivalent signal doubling, as would be expected if this
region were oscillating between UbD bound and unbound states. It is therefore more
likely that the weak signal doubling involves a weak interaction between UbD and HIP2
within HIP2-Ub2. This interaction on UbD aligns quite nicely with the additional line
broadened signals observed on HIP2 within HIP2-Ub2 (Fig 4.5C, orange arrow in 4.10F).

4.4.6 UbP interaction with HIP2 is altered within HIP2-Ub2
Analysis of UbP within HIP2-Ub2 is complicated in that there are several subcomplexes to be compared to fully understand the interacting proteins. These complexes
include both UbP-UbD and HIP2-UbP compared to HIP2-UbP-UbD allowing for the
identification of individual contacts from HIP2 and UbD on UbP.

The spectral

comparison of *UbP-UbD and HIP2-*UbP-UbD indicates that only the C-terminal residues
of UbP are affected following attachment of Ub2 to HIP2. The presence of UbD has
significantly altered the interaction between HIP2 and UbP such that the full hydrophobic
patch of UbP no longer interacts with HIP2 to yield highly line broadened signals (Fig
4.10B, C versus Fig 4.10E, F – focus on UbP surface changes). The weakening of the
HIP2 interaction with UbP must be caused by either the steric strain of the UBA
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interaction with UbD, or the simple steric strain caused by the presence of UbD that
interferes with the HIP2-UbP interacting surfaces.
The spectral comparison of HIP2-*UbP and HIP2-*UbP-UbD indicates the effects
that addition of UbD will have on HIP2-UbP.

The N-terminal region of the UbP

hydrophobic face undergoes chemical shift changes due to direct contact with UbD.
Residues in the C-terminal region of the UbP hydrophobic face that were previously line
broadened in HIP2-UbP were observed to reappear in the spectrum upon addition of UbD
(Fig 4.10C versus Fig 4.10F – purple signals change to cyan). This reappearance is
significant as the size of the molecule is larger and thus increased signal decay would be
expected to cause weaker signals, not stronger signals. Increased signal intensities also
cannot be explained by differences in protein concentration, as the larger complex is less
concentrated than the smaller complex (433 µM HIP2-*UbP, 325 µM HIP2-*UbP-UbD).
These results may show that the UbP residues are no longer strongly associated with the
HIP2 catalytic core domain upon the addition of UbD, or it may show that UbP no longer
samples various bound positions against the HIP2 catalytic core within HIP2-UbP-UbD.

4.4.7 HIP2-UbP and HIP2-Ub2 model analysis
The ribbon/surface structures depicted for HIP2-UbP and HIP2-Ub2 were
developed to aid in visualizing the interaction surfaces (Figure 4.10C, F). SAXS analysis
has indicated the structure in Figure 4.10C accurately represents the general shape of
HIP2-UbP in solution (Chapter 2). This structure shows UbP to be fully exposed to
solution, but line broadening for the residues on the hydrophobic face of UbP and HIP2
indicate these residues are at least transiently interacting (Fig 4.10C). The association of
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the HIP2 catalytic core and the hydrophobic surface of UbP indicates that UbP is at least
intermittently blocked from other protein interactions.
The HIP2-Ub2 structure was constructed through manual alignment of HIP2
(PDB: 1YLA with ‘relaxed’ UBA position) and the ‘open’ structure of Ub2 (PDB:
3AUL). The position of UbP within Ub2 was aligned to that of HIP2-UbP depicted in
Figure 4.10C. This HIP2-Ub2 structure is shown only for illustrative purposes (Fig
4.10F), and the true structure likely adopts a much more compact form whereby the HIP2
UBA domain is in contact with UbD altering the position of the Ub2 to create a more
globular structure.

4.4.8 Occlusion of K48 within HIP2-UbP and HIP2-Ub2
Upon analysis of HIP2-*UbP, it is interesting that residue K48 on UbP experiences
the most significant chemical shift following attachment to HIP2. Residue R48 was
correspondingly seen to shift significantly in the E2-Ub complex of Ubc1, the yeast
homolog of HIP2 (20). This result likely indicates that the K48 residue on a thiolester
bound Ub would be buried on the surface of HIP2 and not be available to serve as an
acceptor Ub in chain elongation. Alternatively, this large chemical shift change occurs
on the edge of the interaction interface, which could indicate an increased acceptor
reactivity of residue K48. The use of HIP2~Ub as a Ub acceptor would require another
HIP2~Ub as the Ub donor.

A poly-ubiquitination reaction using HIP2-UbP as an

acceptor was observed to proceed forming HIP2-Ub2 when no other acceptors were
supplied (Chapter 2). This reaction would require a dimeric HIP2 mechanism. The
HIP2-Ub/HIP2-Ub association was measured to have a dimerization Kd >1000 µM, while
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HIP2 UBA association with Ub and Ub4 was reported to have a Kd of 400 µM and 155
µM respectively (Chapter 2) (10). These results indicate that the HIP2~Ub thiolester (Ub
donor) preferably binds free Ub or poly-Ub chains as acceptors as opposed to the HIP2Ub complex. The reason the HIP2-Ub complex makes a poor Ub acceptor may be related
to the hydrophobic surface of Ub interacting with the HIP2 catalytic core.

This

interaction would make the surface on Ub within HIP2-Ub less accessible to interact with
the UBA domain of a second HIP2~Ub thiolester (Ub donor). HIP2-Ub likely still reacts
as a Ub acceptor (Chapter 2) due to a mobile UbP that can expose its hydrophobic surface
and K48 residue. When HIP2-Ub is in its extended (exposed Ub) form the Ub can act as
a Ub acceptor by interacting with the UBA domain of another HIP2~Ub thiolester
driving poly-Ub chain extension. These results indicate that the large chemical shift in
K48 of UbP within HIP2-UbP is likely based on occlusion of the K48 residue due to it
being predominantly buried as opposed to increasing its reactivity as a Ub acceptor.
Upon analysis of HIP2-UbP-*UbD, significant line broadening of residues I44,
R48, Q49, L50 and E51 indicates that the UBA interaction with UbD involves direct
contacts of R48 (normally K48). Recent experiments examining the UBA domain of
HIP2 binding to free Ub showed residues I44, K48 and Q49 to be highly affected (11,
18), but residues L50 and E51 were minimally affected. In contrast, L50 and E51 were
completely line broadened in UBA binding to UbD within HIP2-UbP-UbD. These results
indicate that while residue K48 is on the edge of the interaction surface between free Ub
and the UBA domain, it is likely more buried on the interaction between the UBA and
UbD. The occlusion of K48 on UbD within HIP2-Ub2 would block UbD as an acceptor Ub
in chain elongation. The blockage of K48 in both HIP2~Ub and HIP2~Ub2 thiolesters
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would make these intermediates act poorly as Ub acceptors for poly-Ub chain extension.
The predominantly buried K48 residues should make HIP2~Ub and HIP2~Ub2 thiolesters
act only as Ub donors in poly-Ub chain extension. Previous experiments with the E2
enzyme Ube2g2 have shown that E3 ligase dimerization leads to proposed dimerization
of Ube2g2 responsible for active site linked poly-Ub chain formation (29). A similar E3
induced dimerization of HIP2-Ub and/or HIP2-Ub2 complexes is unlikely to aid poly-Ub
chain formation as long as the Ub K48 residues remain occluded. These results indicate
E3 assisted dimerization is unlikely for HIP2, although this possibility cannot be
completely excluded.

4.4.9 HIP2-Ub2 models can rationalize previous activity assays on Ubc1
The HIP2 UBA domain blockage of K48 residues in UbD within HIP2-Ub2 can be
used to explain previous studies investigating auto-ubiquitination of Ubc1 where UBA
removal resulted in increased poly-Ub chain length (30). In this study, poly-Ub chain
activity of wild type Ubc1 was measured through auto-ubiquitination on residue K93 that
likely forms through the direct transfer of Ub from the active site C88 to the nearby K93
residue. This auto-ubiquitinated Ubc1 likely undergoes chain extension with Ubc1-K93Ub acting as a Ub acceptor through a reactive Ub K48 residue. Experiments on full
length Ubc1 resulted in K93 attached poly-Ub chains of roughly four Ub’s in length,
while Ubc1Δ (Ubc1 with no UBA domain) produced much longer poly-Ub chains up to
12 Ub’s in length (30). On the assumption that the UBA domain in Ubc1 behaves
similarly to the UBA domain in HIP2, once Ubc1 has a chain of Ub2 or longer, the UBA
domain should interact with UbD and at least temporarily occlude K48 resulting in the

199
blocking of chain extension. Removal of the UBA domain would increase the exposure
of K48 residues making the attached poly-Ub chains better Ub acceptors and therefore
increasing the resultant chain length of auto-ubiquitination of Ubc1. The purpose of
auto-ubiquitination of Ubc1 remains unknown, and the long reaction time (16 hours) may
indicate this activity is not biologically significant, but the model for HIP2-Ub2 indicating
the K48 residue in Ub is occluded can be used to rationalize the experimental results for
Ubc1. These results show that the Ubc1 UBA domain inhibits poly-Ub chain extension
by blocking the terminal Ub. It is therefore reasonable to assume that the Ubc1 UBA
domain likely behaves in a similar manner to the HIP2 UBA domain, as both enzymes
likely block Ub K48 residues in thiolester attached poly-Ub chains.

4.4.10 Conclusions
HIP2 can produce unanchored K48-linked poly-Ub chains in solution using only
the E1 activating enzyme and ubiquitin (Ub) (1).

The biological significance of

unanchored chain building by HIP2 remains unknown, but the observation that Ub2 can
be loaded onto HIP2 just as easily as Ub indicates these chains can be used to create
HIP2~Ub and HIP2~Ub2 thiolesters and probably HIP2~Ubn thiolesters (1).

These

intermediates can form in vitro but their presence in vivo is unconfirmed.

These

observations are consistent with a poly-Ub chain preassembly mechanism for the
labelling of protein substrates. The NMR investigation of HIP2~Ub and HIP2~Ub2
thiolester mimics has led to a better understanding of the structure of these intermediates.
It has been observed that there is a significant interaction between HIP2 and Ub within
the HIP2-UbP complex. It was also observed that the UBA domain contacts UbD within
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the HIP2-UbP-UbD complex. These interactions have resulted in the Ub K48 residues
being occluded in these structures.

This indicates that HIP2~Ub and HIP2~Ub2

intermediates should act preferably as Ub donors for poly-Ub chain extension.
The intramolecular interaction of UBA/UbD within HIP2-Ub2 would make the
UBA domain less available for interaction with Ub acceptors. If the UBA domain drives
poly-Ub chain assembly by affinity to Ub acceptors, then the HIP2-Ub2 would be
resistant to continued poly-Ub chain extension since the UBA is blocked.

The

intramolecular UBA/UbD interaction also explains why HIP2-Ub2 was observed to be
predominantly monomeric, as the HIP2~Ub2 molecule would have neither the UBA
hydrophobic surface nor the UbD hydrophobic surface available for interactions with
another HIP2-Ub2.

The HIP2 N-terminal region in HIP2-Ub2 is still available for

interaction with both E1 and E3 enzymes in these structures. The available E1 and E3
interaction could allow a HIP2~Ubn intermediate to connect Ubn to a substrate through
the standard E1-E2-E3 enzyme cascade. The biological presence of E2~Ubn thiolesters is
unknown, although the ability of the HIP2 UBA domain to interact with thiolester
attached poly-Ub chains will aid in the clarification of HIP2 functional mechanisms.
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Chapter 5
Summary and Discussion

5.1 Introduction
The ubiquitin proteolysis pathway is an essential regulatory mechanism used for
the degradation of short-lived, damaged, misfolded or denatured proteins within the cell
(1).

Ubiquitination utilizes three enzymes, E1, E2 and E3 to respectively activate,

transfer and ligate ubiquitin (Ub) onto a substrate protein. The creation of K48-linked
poly-Ub chains on a substrate will target this protein to be degraded by the 26S
proteosome (1). Ubiquitination is crucial for maintaining cell homeostasis. Specific
mutations in ubiquitination enzymes and interactors can cause disruption of cell
homeostasis, leading to several diseases including cancer and neurodegenerative
disorders (2).

The E2 conjugating enzyme is the central enzyme in the ubiquitin

proteolysis pathway. Previous studies examining the structural details of E1/E2 and
E2/E3 interactions has characterized the general mechanism for Ub transfer through the
E1-E2-E3 enzyme cascade. However, how poly-Ub chains are created is much less well
understood. Several poly-Ub chain assembly mechanisms have been proposed in various
ubiquitination pathways (3). The main competing mechanisms include the sequential
addition model where poly-Ub chains are built on the substrate one at a time, and the
preassembly model where poly-Ub chains are formed prior to attachment to substrate (3).
In this thesis, HIP2 and its yeast homolog Ubc1 were investigated to determine
their mechanism of poly-Ub chain formation. These enzymes have been observed to
have poly-Ub chain activity in the absence of E3 enzymes and substrates (4, 5). These
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E2 enzymes are also unique in that they contain a C-terminal UBA domain known to
bind Ub non-covalently (6, 7). The ability of these enzymes to produce poly-Ub chains
unattached to substrates suggests poly-Ub chains may be preassembled in vivo. The
Ubc1 enzyme has recently been shown to preferably extend chains on monoubiquitinated substrates indicating it may function through a sequential addition model
(8). The HIP2 enzyme has very few identified E3 enzyme partners and substrates and
therefore has a very poorly understood biological role, although its function has been
implicated in the progression of both Huntingtin’s and Alzheimer’s disease (9-12).
Experimental investigations on both Ubc1 and HIP2 were performed to help clarify their
mechanism of poly-Ub chain formation.

5.2 Previous studies on poly-Ub chain mechanisms
The only structural evidence for the formation of poly-Ub chains comes from the
Ubc13/Mms2 E2 heterodimer that is responsible for K63-linked poly-Ub chain assembly
(13). The main discovery from this structure was that two E2 enzymes could position
two Ub molecules to be directly reacted to create a Ub-Ub connection. Many other E2
enzymes have also been implied to either homodimerize or be brought into close
proximity through E3 dimerization.

Strong evidence for E2 dimerization has been

acquired through differentially tagged Ube2g2~Ub thiolesters that can directly react with
each other to create a thiolester linked Ube2g2~Ub2 (14). This activity required its
cognate E3 enzyme that has been found to dimerize indicating poly-Ub chain assembly in
Ube2g2 may occur through E3 assisted dimerization (15). These previous experiments
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have provided strong evidence that dimerization of E2 or E3 enzymes may be very
important in the formation of poly-Ub chains within many ubiquitination pathways.
The non-covalent binding of Ub has also provided another mechanism for polyUb chain formation. This was observed on the HECT E3 KIAA10 that was found to bind
one Ub through a thiolester, and a second Ub non-covalently. The mechanism of polyUb chain assembly is presumably accomplished through the positioning of these 2 Ub
molecules in close proximity to allow the C-terminal thiolester of one Ub to react with
the lysine side chain of the other Ub (16). The ability of KIAA10 to bind two Ub
molecules indicates it may function through a monomeric mechanism.
The homologous enzymes Ubc1 and HIP2 have both been shown to have poly-Ub
chain activity without E3 enzymes, and have both been shown to bind Ub non-covalently
(4-6, 17). These results allow for the possibility that Ubc1 and HIP2 may function by
either the proposed monomeric or dimeric mechanisms used by KIAA10 and Ube2g2
respectively. This thesis has focused on using physical and structural studies as well as
activity assays to clarify the mechanism of poly-Ub chain assembly utilized by HIP2 and
Ubc1.

5.3 Dimerization of HIP2 and Ubc1 is not a major determinant for polyUb chain activity
HIP2 and Ubc1 both have K48-linked poly-Ub chain activity that is independent
of an E3 ligase or substrate (4, 5). Since E2 dimerization has been suggested to drive
poly-Ub chain formation, the Ubc1 and HIP2 enzymes were investigated for their ability
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to dimerize. The Ubc1-Ub, HIP2-Ub and HIP2-Ub2 thiolester mimic complexes were
also studied since previous work on the E2 enzyme Cdc34 indicated that formation of
thiolesters may assist dimerization (18). Sedimentation equilibrium was performed on
low concentrations of Ubc1, Ubc1-Ub, HIP2, HIP2-Ub and HIP2-Ub2 to determine
accurate molecular weights (MW). HIP2 and Ubc1 were found to be very close to their
expected monomeric molecular weight. The addition of Ub to these enzymes can result
in the reported MW to be as much as 7-11% larger than expected, while the addition of
Ub2 to HIP2 can result in the reported MW to be as much as 8% larger than expected.
These values are close to the 5% error range of this technique indicating that the proteins
are predominantly monomeric. If dimerization is occurring, a self-association model can
be used to estimate the Kd of dimerization, but since dimerization is very weak, a reliable
Kd cannot be acquired for these enzymes at low concentrations.

Therefore, higher

concentrations of Ubc1, Ubc1-Ub, HIP2, and HIP2-Ub proteins were studied with SAXS
to determine their dimerization capacity. The SAXS analysis also found these proteins to
be predominantly monomeric at concentrations up to 200 µM.

Since minimal

dimerization was observed even at these higher concentrations, only an estimation of Kd
limitations is possible through comparison to theoretical Kd curves. These calculations
indicate the Kd values for Ubc1-Ub and HIP2-Ub self-association must be >1000 µM. Kd
values of >1000 µM confirm very weak self-association of the Ubc1-Ub and HIP2-Ub
indicating thiolester formation did not greatly assist dimerization.
The HIP2 enzyme was further studied with NMR spectroscopy. NMR 1H-15N
TROSY-HSQC spectra collected on HIP2, HIP2-Ub and HIP2-Ub2 did not experience
severe line broadening of all amide protons, as was observed for UbcH5c-Ub complex
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known to oligomerize (19), indicating HIP2 and its thiolester mimics are likely
monomeric even at higher NMR concentrations of ~350-550 µM. NMR chemical shift
perturbation experiments were used to determine and characterize any protein
interactions within HIP2, HIP2-Ub and HIP2-Ub2.

These results indicate that

intramolecular interactions occur within both HIP2-Ub and HIP2-Ub2.

These

intramolecular interactions occur between the HIP2 catalytic core and UbP within HIP2UbP, and between the HIP2 UBA domain and UbD within HIP2-UbP-UbD.

These

interactions block the hydrophobic surface of UbP and UbD in HIP2-Ub and HIP2-Ub2
respectively. The presence of a UBA domain in HIP2 that binds Ub non-covalently
could theoretically bind the thiolester bound Ub of another HIP2-Ub complex to cause
dimerization. The observed intramolecular interaction within HIP2-Ub and HIP2-Ub2
limits the availability of these attached Ub and Ub2 moieties to interact with a second
HIP2 UBA domain. As a result, the intramolecular interactions within HIP2-Ub and
HIP2-Ub2 are preferred over any intermolecular interactions between HIP2-Ub and HIP2Ub2. These structural observations explain why possible UBA/Ub binding does not result
in dimerization of HIP2-Ub or HIP2-Ub2. Additionally, a dimeric mechanism would also
require reactive K48 residues on Ub in either HIP2-Ub or HIP2-Ub2, and these residues
appear buried against HIP2 making them unlikely to act as Ub acceptors (Fig 5.1A).
These combined results indicate that Ubc1 and HIP2 very likely do not function using a
dimeric mechanism for unanchored poly-Ub chain formation.
Previous experiments on Ubc1Δ resulted in the novel finding that E1 was required
for poly-Ub chain extension, suggesting it directly extends chains or may function as an
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Figure 5.1 Proposed models of HIP2 Function. Ubiquitination pathway components include the
HIP2 E2 conjugating enzyme (blue), Ub (pink), an E3 ligating enzyme (yellow), a substrate
(orange) to be ubiquitinated, and small green balls represent the reactive K48 on Ub or reactive K
residue in the substrate. (A) Model of HIP2~Ub and HIP2~Ub2 indicating blocked K48 residues
that do not preferably react with another HIP2~Ub thiolester. (B) Model of unanchored poly-Ub
chain formation driven by UBA affinity for free Ub and poly-Ub chains. Movement of the UBA
domain would bring the Ub K48 lysine into reactive distance with the thiolester bound Ub. (C)
Model demonstrating how a preassembled poly-Ub chain can be loaded onto the E1 enzyme,
transferred to HIP2 and then finally transferred to a substrate protein. (D) The sequential addition
model for HIP2 using an already mono-ubiquitinated substrate would function nearly identically
to (B) only substrate-Ub would be bound to both the E3 and the UBA domain. The E3 enzyme
contacts the HIP2 catalytic core and the substrate only.
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E2 dimerization scaffold (20). In contrast, activity assays performed in this work on
HIP2 and Ubc1 indicate that E1 enzyme removal after E2 thiolester charging did not
affect poly-Ub chain extension. This result shows the E1 enzyme does not directly assist
poly-Ub chain extension. The removal of the E1 enzyme also shows that it is not
required as an E2 dimerization scaffold. Since E3 enzymes were not studied in this work,
we cannot discount the possibility of E3 assisted E2 dimerization, although there is
currently no evidence to support E3 assisted HIP2 dimerization.

5.4 The monomeric mechanism employed by HIP2
Since HIP2 has been observed to be more active in unanchored poly-Ub chain
activity than Ubc1, and was more thoroughly investigated in this work, only its proposed
mechanism will be discussed in detail. The observation that dimerization of HIP2 is very
weak indicates these enzymes likely function in a monomeric fashion to build poly-Ub
chains without E3 enzymes.

A monomeric HIP2 enzyme most likely functions by

utilizing its ability to interact with at least two Ub molecules at once, one Ub covalently
through a thiolester linkage at the active site, and a second Ub non-covalently using the
UBA domain (17, 21). These interactions may allow HIP2 to place two Ub molecules in
close proximity to assist the formation of Ub2. This possible mechanism is supported by
SAXS data that indicates the HIP2 UBA domain is linked to the catalytic core by a
flexible linker, just like Ubc1 (6). This flexible linker may give the UBA domain the
ability to be repositioned to place the acceptor Ub’s K48 residue within range for
nucleophilic attack with the thiolester bound Ub donor (Fig 5.1B). In this reaction, the
resulting Ub2 would be unanchored and free in solution. Therefore, this is the likely
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mechanism utilized for the observed unanchored poly-Ub chains produced with only E1
enzyme, HIP2 and Ub.
The proposed monomeric HIP2 mechanism depicted in Figure 5.1B would be
driven by the UBA affinity for acceptor Ub molecules. The HIP2 UBA domain is known
to bind Ub4 with a Kd of 155 µM while a single Ub moiety binds with a weaker Kd of 400
µM (7).

These results indicate that the HIP2 UBA domain binds poly-Ub chains

preferentially, an observation that has been reported previously on other isolated UBA
domains (7). The UBA domain’s preference for binding longer poly-Ub chains may
explain previous studies on HIP2 that have shown that Ub2 acts as a better acceptor than a
single Ub (4). The UBA domain’s preference for free Ub2 chains over a single Ub
indicates that the rate of unanchored poly-Ub chain formation should increase as these
poly-Ub chains grow longer. Activity assays have demonstrated that a HIP2-Ub complex
can react with a HIP2~Ub thiolester to make a HIP2-Ub2 complex. Initially, it was
thought that this supported a dimeric mechanism for HIP2. However, the association
between HIP2-Ub/HIP2-Ub was determined to have a Kd of >1000 µM. This binding is
weaker than that for free Ub4 (155 µM) and free Ub (400 µM) indicating that HIP2-Ub is
a less preferred acceptor. Structural analysis of the HIP2-Ub complex may explain how
HIP2-Ub can react with another HIP2~Ub thiolester. SAXS experiments have shown
HIP2-Ub to be on average a rather ‘elongated’ structure, while NMR experiments have
found that there are significant contacts between HIP2 and Ub within HIP2-Ub. The
interactions between HIP2 and UbP in the HIP2-UbP complex show few large chemical
shift changes and a high number of highly broadened residues on both HIP2 and UbP.
This indicates that there may be intermediate exchange occurring between HIP2 and UbP
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as a result of at least 1 tightly bound form and 1 loosely bound form of HIP2-UbP.
Previous experimentation has shown E2~Ub structures to be highly mobile (22), which is
consistent with both the observed average ‘elongated’ structure in SAXS and the
proposed intermediate exchange between at least 2 Ub positions within HIP2-Ub in NMR
experiments. A mobile HIP2~Ub thiolester structure would result in an equilibrium
between blocked and exposed Ub. When Ub is exposed within HIP2~Ub, the Ub would
be able to interact with another HIP2~Ub thiolester’s UBA domain accounting for its
ability to act as an acceptor in activity assays. However, the HIP2-Ub complex was not
observed to be a preferred acceptor because the surface of Ub is transiently blocked when
HIP2-Ub is in its more tightly associated form. Since HIP2-Ub binds with lower affinity
than free Ub, it is likely the HIP2-Ub2 product is an artifactual by-product of not having
any available free Ub acceptor. These results are consistent with the proposed UBA
driven monomeric mechanism where longer chains bind more strongly to the UBA
domain (Fig 5.1B).

5.5 Preassembled poly-Ub chains may be used in vivo
Previous experiments have shown that Ub and Ub2 can form thiolesters on the
HIP2 enzyme with identical kinetics (4).

These results indicate that preassembled

unanchored Ub2 can then be loaded onto the E1 enzyme and then transferred to HIP2 just
as easily as a single Ub molecule.

Previous experiments have also shown that

unanchored poly-Ub chains are found in vivo, and that these chains were able to be
connected to substrates with kinetics indistinguishable from mono-ubiquitin using Ubc4
(23). The Ube2g2 E2 enzyme was also shown to be able to connect a synthesized poly-
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Ub chain directly onto a substrate (14). These combined results show that loading E2
enzymes with poly-Ub chains appears kinetically equivalent to using a single Ub moiety,
and that poly-Ub chains can be directly transferred to substrates. Therefore, preassembly
of poly-Ub chains in solution by HIP2 could be followed by the loading of these chains
onto HIP2 creating HIP2~Ubn thiolester intermediates. The study of HIP2-Ub and HIP2Ub2 complexes has shown that the Ub K48 residues are occluded indicating these
thiolester linked Ub and Ub2 moieties are likely to act predominantly as Ub donors in
poly-Ub chain extension. In this way, the UBA domain would act as an inhibitor of polyUb chain extension on HIP2-Ubn. HIP2-Ubn intermediates could then act as Ub donors
and interact with both an E3 ligase and a substrate resulting in the transfer of the Ubn
directly to a substrate in a single step (Fig 5.1C).

This mechanism describes how

preassembled poly-Ub chains could be transferred onto substrates by the HIP2 enzyme.

5.6 HIP2 poly-Ub chain preassembly in Alzheimer’s disease
HIP2 has been linked to Alzheimer’s disease through involvement with the
protein UBB+1. UBB+1 is a frameshift mutant of Ub that contains a 19 residue C-terminal
extension that cannot form a thiolester with ubiquitination enzymes (11).

Previous

experiments indicate HIP2 can poly-ubiquitinate the UBB+1 protein on its K48 residue in
vitro, and this UBB+1-Ubn resists disassembly by deubiquitinating enzymes and causes
potent proteosome inhibition (11).

HIP2 activity has also been found to increase

neurotoxicity and proteosome inhibition in vivo (12). The UBA domain of HIP2 has
recently been shown to interact with both UBB+1 and Ub in a similar manner, and in the
same study, in vivo experiments showed that HIP2 UBA domain mutations reduced
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proteosomal inhibition (17). These results indicate that HIP2 poly-ubiquitination of
UBB+1 is likely involved in the proteosomal inhibition experienced in Alzheimer’s
disease. UBB+1 is simply a normal Ub molecule with a 19-residue extension at the Cterminus meaning it can be recognized as a Ub acceptor by the UBA domain of HIP2, but
cannot form a thiolester with ubiquitination enzymes. Therefore, HIP2 likely causes
poly-ubiquitination of UBB+1 by mistakenly using this molecule as a normal Ub acceptor
in unanchored poly-Ub chain assembly (Fig 5.1B). By this mechanism, HIP2 would bind
UBB+1 with the UBA domain and react it with a thiolester connected Ub to yield UBB+1Ub. Proceeding reactions would use UBB+1-Ub as the acceptor eventually creating a
UBB+1-Ubn product.

This molecule resists disassembly and accumulates to inhibit

proteosomes. UBB+1 poly-ubiquitination and related proteosomal inhibition has also
been shown to increase aggregate formation and cell death in polyglutamine diseases
such as Huntington’s disease (9, 24, 25). The preassembly mechanism for poly-Ub
chains by the HIP2 enzyme can therefore be utilized with UBB+1 to inhibit the
ubiquitination proteolysis pathway resulting in severe pathological consequences.

5.7 The sequential addition model for Ubc1 and HIP2
Although HIP2 can preassemble poly-Ub chains in vitro, its major physiological
role may be to utilize the sequential addition mechanism where poly-Ub chains are
sequentially built on a substrate protein. This mechanism is supported by recent
experimentation on the ubiquitination of Cyclin B by the large multisubunit anaphase
promoting complex (APC – a RING E3) and the E2 enzymes Ubc4 and Ubc1 (8). In this
study, Ubc4 and Ubc1 appear to have different functions as Ubc4 was more active in

215
initial Ub attachment to substrates and Ubc1 was more active in extending chains on
substrates that already have a single attached Ub (8). HIP2 was also observed to extend
chains on substrates in combination with UbcH10, although these results showed very
low activity on the substrate Cyclin indicating this substrate may not be a preferred
substrate of HIP2 (8). Ubc1Δ (no UBA domain) was also investigated, and was found to
yield substrate attached poly-Ub chains of shorter length (8). The UBA domain of Ubc1
is therefore required for full activity in substrate poly-Ub chain extension (8). These
results are consistent with a sequential addition model whereby Ubc4 mono ubiquitinates
a substrate and Ubc1 adds Ub molecules to the growing chain. It is reasonable to assume
HIP2 may function similarly with a proper E3 enzyme and substrate. The sequential
addition mechanism may function in a similar manner to unanchored poly-Ub chain
formation (Fig 5.1B), whereby the Ub acceptor of free Ub is replaced with a substrate
bound Ub (substrate-Ub) (Fig 5.1D). If the true biological function of Ubc1 and HIP2 is
to extend poly-Ub chains on substrates, then the UBA domain may aid this activity by
directly binding to the Ub attached to a substrate (Fig 5.1D). The E2~Ub/E3/substrateUb complex depicted in Figure 5.1D would provide affinity for substrate-Ub through
both E3 binding and E2 UBA binding. The UBA domain may therefore increase the
reaction rate of this E2 enzyme by providing additional interactions for substrate-Ub
extension by directly binding the growing chain. This mechanism would suggest that the
formation of poly-Ub chains prior to attachment to substrate observed for HIP2 and Ubc1
is simply an artifactual activity caused by lack of E3 ligases and substrates, and therefore
not the major biological function of these enzymes.
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The sequential model for HIP2 and Ubc1 poly-Ub chain extension is also
supported by analysis of required reaction times. Significant unanchored poly-Ub chain
activity requires reaction times on the order of hours without an E3 ligase and substrates
(4, 5), while poly-ubiquitination of mono-ubiquitinated substrates had reaction times on
the order of minutes for Ubc1, and 90 minutes for a non-specific substrate for HIP2 (8).
These experiments indicate ubiquitination reactions occur more quickly in the presence
of E3 enzymes that place E2~Ub thiolesters in close proximity to ubiquitinated
substrates. These faster reaction rates are more biologically significant than those for
unanchored chain assembly.
Ubiquitination of mono-ubiquitinated substrates was also demonstrated for the E2
enzymes UbcH5 and Cdc34 whereby UbcH5 preferably mono-ubiquitinates substrates
and Cdc34 efficiently performs poly-Ub chain extension on these mono-ubiquitinated
substrate (26). Sequential poly-Ub chain assembly has also been strongly supported for
Cdc34 where substrates were seen to have Ub’s added one at a time through a
millisecond timescale reaction system (27). Although little is known of HIP2’s E3
enzymes and substrates, support for the sequential addition model with its yeast homolog
Ubc1 indicates that HIP2 may function in a similar manner. The biological function of
HIP2 may then be to extend chains on already mono-ubiquitinated substrate molecules
(Fig 5.1D).

5.8 Conclusions
Structural investigation of HIP2-Ub and HIP2-Ub2 has characterized the
intramolecular interactions observed within these intermediates. HIP2-Ub and HIP2-Ub2
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both have occluded Ub hydrophobic faces including the K48 residue indicating these
species are preferred Ub donors and not Ub acceptors in poly-Ub chain extension (Fig
5.1A). These results in addition to thorough dimerization studies indicate HIP2 functions
through a monomeric mechanism to build poly-Ub chains (Fig 5.1B). The purpose of
preassembling poly-Ub chains remains unknown, although previous kinetic assays
indicate these preassembled chains could be loaded onto E2 enzymes and then transferred
onto substrates (Fig 5.1C) (4, 14, 23). This model would involve the use of the UBA
domain to first aid in the construction of poly-Ub chains, followed by inhibiting chain
extension during transfer to a substrate. HIP2 may also utilize a sequential addition
mechanism where a growing poly-Ub chain is bound to a substrate. This mechanism is
supported by the observation that Ubc1 (yeast homolog of HIP2) can preferentially
extend chains on mono-ubiquitinated substrates (8). HIP2 is suspected to behave in a
similar fashion to extend poly-Ub chains on substrates, although there is currently little
evidence for such activity. This sequential addition model would utilize both the E3
interaction with substrate, and the UBA interaction with a substrate attached poly-Ub
chain (Fig 5.1D).
The monomeric UBA driven mechanism of HIP2 can explain both the
preassembly model and sequential addition model (Fig 5.1B, D). The general mechanism
of HIP2 function is identical between these two models, but the reaction rates may be
faster with the sequential addition model due to additional interaction surfaces provided
by the E3 enzyme and monoubiquitinated substrate. Although both mechanisms are
possible, the sequential addition model appears to be preferred due to the observation that
poly-Ub chain activity of Ubc1 without E3 enzymes required hours, while poly-Ub chain
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activity with E3 enzymes and substrates required only minutes (8). The mechanisms
depicted in Figure 5.1B and 5.1D would utilize the UBA domain’s interaction with Ub to
position two Ub molecules in close proximity. The affinity of UBA binding to Ub and
Ub4 has a Kd of 400 and 155 µM respectively (7). The cellular concentration of Ub is
around 10 µM (28, 29) and the cellular concentrations of E2 enzymes are likely in the
low µM (<10 µM) to nM range. With these cellular concentrations and UBA/Ub Kd
values, it is expected that unanchored poly-Ub chain activity would not proceed with
significant reaction rates in the absence of an E3 enzyme and substrate. The addition of
the E3 enzyme is likely required to greatly increase the effective concentrations of HIP2
and ubiquitinated substrate to increase the reaction rate. Additionally, the mere binding
of E3 enzymes to the E2 enzyme also has been shown to increase catalytic activity of the
E2 enzyme (30, 31). The sequential addition model is preferred over the preassembly
model since there are currently no known mechanisms in vivo that would increase the
kinetic rate of unanchored poly-Ub chain formation observed in HIP2. However, the
mechanism of unanchored chain formation appears to function in vivo with UBB+1,
which can be involved in proteosome inhibition in Alzheimer’s and Huntington’s disease
(9, 12).

5.9 Future Work
In this work, low-resolution structural details were acquired for HIP2 and HIP2Ub using SAXS. Chemical shift perturbation studies were also performed to determine
protein interaction surfaces within HIP2-Ub and HIP2-Ub2 complexes. However, a highresolution structural model of ‘compact’ HIP2-Ub and HIP2-Ub2 was not completed due
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to ambiguous constraints for computer-aided protein docking.

Additional NMR

experiments may be required to provide sufficient protein-protein interaction data to
properly dock these structures. These experiments could include hydrogen-deuterium
exchange and cross-saturation experiments both of which can provide residue specific
information of a protein-protein interface. This additional data may allow for a high
quality structural model of HIP2-Ub or HIP2-Ub2. These structures could then be used to
investigate the preferred orientation of Ub and Ub2 in HIP2-Ub and HIP2-Ub2. The
position of thiolester attached Ub and Ub2 would determine the available surfaces of
these proteins that could interact within larger protein complexes including E3 enzymes
and substrates.
Currently HIP2 has only been well studied for its unanchored chain formation
activity and very little is known of its biological function with E3 enzymes and
substrates. The best identified E3 and substrate for HIP2 may be the E3 enzyme NARF
(Nemo-like Kinase (NLK) – associated RING finger) and the transcription factors TCF
(T Cell Factor) and LEF (Lymphoid Enhancer Factor). NARF and TCF/LEF were
identified by in vivo coimmunoprecipitation experiments and ubiquitination assays. A
recent study developed an approach that allows for in depth kinetic assays on
ubiquitination in the millisecond to second timescale (27). If this approach was utilized
on HIP2 with a known E3 (NARF) and substrate (TCF/LEF), then the formation of polyUb chains can be quantitated as they form. This experiment would provide strong results
to show whether HIP2 utilizes a sequential addition model to build poly-Ub chains on the
substrate, or whether poly-Ub chains are preassembled by HIP2 and then connected to a
substrate.
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The monomeric mechanisms for HIP2 proposed in this work suggest that
UBA/Ub binding allows HIP2 the ability to place two Ub molecules in close proximity to
aid poly-Ub chain formation. It may be possible to capture these two Ub molecules in
close proximity using X-ray crystallography. The HIP2 protein has been previously
crystallized both alone and in complex with free Ub (17, 32).

These previous

crystallizations should provide details to aid in future crystallizations of HIP2.

To

determine how HIP2 can position two Ub molecules for poly-Ub chain assembly, it
should be possible to crystallize the HIP2-Ub disulphide in complex with free Ub. This
crystal structure would be expected to have a significantly altered UBA position to allow
a Ub-Ub linkage. If the UBA positions the non-covalently bound Ub in close proximity
to the thiolester, then it would be expected that this structure should be fairly compact
making it a good candidate for protein crystallization. This structure would be the first
E2 structure to mechanistically detail how K48-linked poly-Ub chains can be formed.
This structure would be immensely valuable to determining the structural and enzymatic
details for how HIP2 performs K48-linked poly-Ub chain formation.
X-ray crystallography could also be utilized to support the proposed sequential
addition model depicted in Figure 5.1D. Upon identification of an E3 enzyme and
substrate for HIP2, these proteins could be mixed with a HIP2-Ub thiolester mimic to
possibly create a tightly interacting complex. The use of a mono-ubiquitinated substrate
may increase the affinity of this complex by allowing UBA/Ub-Substrate interactions.
Structural details of such a complex would greatly aid in determining HIP2’s possible
biological role of extending poly-Ub chains on substrates through a sequential addition
model.
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